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 Abstract  
 
Ocular Mucous Membrane Pemphigoid (OcMMP) is a blinding immunobullous disease, 
characterised by auto-antibody driven conjunctival inflammation and scarring. My hypothesis 
was that progressive fibrosis in OcMMP, occurring in the apparent absence of clinical 
inflammation, was driven by underlying inflammatory processes.  
 
I observed that in OcMMP, progressive scarring did occur in the apparent absence of 
clinically identifiable inflammation and I was able to improve clinical documentation by 
developing and validating an objective Fornix Depth Measurer (FDM) for assessment of 
scarring. 
 
I optimised non-invasive Ocular Surface Impression Cytology (OSIC) combined with flow 
cytometry to characterise conjunctival leukocytes. I found that CD8αβ+ effector memory, 
cytotoxic, mucosal-homing T cells were the dominant population in health. This population 
was unaltered with age but CD4+ T cells, capable of producing IFN-γ, increased. 
 
In OcMMP, the conjunctiva was characterised by decreased CD8+ lymphocytes and an 
elevation in CD45INTCD11b+CD16+CD14- neutrophils. Although neutrophils correlated with 
clinical inflammation, they were even present in the absence of identifiable conjunctivitis. 
This elevation was associated with progression of scarring assessed by FDM, even in the 
clinically Non-inflamed eye. 
 
These findings confirmed my hypothesis and provide a platform for quantifying neutrophils as 
a biomarker of sub-clinical inflammation and their role in the scarring process. 
 
 Conjunctival Inflammation: a historical perspective 
 
“Hyperaemia of the conjunctiva may result from many causes, as the irritation produced 
by cold wind, dust, or irritating vapours, such as tobacco smoke; overwork of the eyes, 
actual or relative to their capabilities… 
 
The amount of injection varies; in the worst cases, the whole of the ocular conjunctiva 
presents a network, with very irregular meshes, formed by dilated and tortuous vessel; 
these can be moved over the surface of the eye by rubbing the lid over them, and they can 
be emptied by slight pressure; in both respects, as well as not being especially marked in 
the circumcorneal zone, differing from the dilated vessels seen in inflammation of the 
cornea or iris… 
 
In slighter cases there are very few dilated vessels, and in in some they only become 
visible after prolonged use of the eyes, or after exposure to wind, etc.” 
 
 
 
Robert Brudenell Carter and William Adams Frost.  
Affections of the eyelids, lacrymal apparatus, and conjunctiva.  
In Ophthalmic Surgery.  
London, Cassell & Co.1887 pp117-118 
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1.1 The Ocular Surface 
 
Vision is sustained by transparent ocular tissues such as the cornea and the lens and 
optically clear media within the eye including aqueous and vitreous. Nowhere is this 
threatened more than at the ocular surface, which represents the interface between 
the eyeball and its surroundings. Maintaining a clear cornea and thus optical clarity 
relies upon the ocular surface as a whole. The ocular surface (Figure 1.1) consists 
of:  
 
(i) The corneal epithelium and underlying anterior stroma 
(ii) The conjunctiva (a delicate protective mucosa that lines the back surface of the 
eyelids and the sclera) (Knop and Knop, 2007). 
 
 
 
 
 
 
 
Adapted from Yanoff and Fine. Ocular Pathology. Mosby 2002 (Yanoff and Fine, 2002). 
Figure 1.1: The Ocular Surface. Saggital representation of the eye demonstrating the important 
components of the ocular surface, underlined in panel A. Panel B shows a histological section of the 
cornea (Cor), sclera (S) and their interface - the corneoscleral limbus (L). The conjunctiva (drawn in 
blue, Con) is closely attached to the sclera 3mm posterior to the limbus and fuses with the cornea at 
the conjunctival limbus (1mm anterior to the corneoscleral limbus). Panel C demonstrates the forniceal 
conjunctiva (FC), a continuation of the bulbar (BC) and tarsal conjunctiva (TC), forming a pocket 
separating the two surfaces. 
 
 
A B C 
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Embryologically, the corneal and conjunctival epithelia are derived from surface 
ectoderm while the stroma arises from the second wave of neural crest derived 
mesenchymal cell migration (from the optic cup) by the seventh week.  Collagen 
deposition, organisation and sensory innervation continue until the 6-7th month.  
 
The avascular cornea is an imperfect sphere measuring 9-11mm vertically and 11-
12mm horizontally. Its thickness is variable, measuring 1100μm at its limbus, 650μm 
at its periphery and thinning to 520μm centrally (American Academy of 
Ophthalmology., 2006). Its central zone is a five-layered structure composed of a 5-7 
cell deep stratified, squamous non-keratinised epithelium; Bowman’s layer 
(underlying the epithelial basement membrane); stroma (with parallel bundles of 
predominantly Type I collagen arranged to optimise transparency); Descemet’s layer 
(a basement membrane) and cellular monolayer: the endothelium (Figure 1.2).  
 
 
 
 
 
 
A: Adapted from Yanoff and Fine. Ocular Pathology. Mosby 2002 (Yanoff and Fine, 2002). 
Figure 1.2: Histology of the cornea and conjunctiva. The five layers of the cornea are 
demonstrated in panel A (Ep: Epithelium; B: Bowman’s layer; S: Stroma; D: Descemet’s layer and En: 
Endothelium). The stroma occupies 90% of the thickness. The conjunctival epithelial goblet cells are 
boxed in panel B. The vascularised stroma can be seen underneath the basement membrane zone 
(BMZ). The conjunctiva consists of tarsal (palpebral) and bulbar components (lining the inner surface of 
the eyelids and globe of the eye respectively), and connected via the fornices (singular fornix) and is 
continuous with the corneal epithelium at the limbus (Figure 1.1). The lower fornix (the natural pocket 
formed between the bulbar and tarsal conjunctiva) depth is variable and appears to progressively 
shorten with age (Schwab et al., 1992). There is no detailed epidemiological data relating to the depth of 
the upper fornix. 
 
S Ep 
En 
B 
BMZ 
Ep 
S 
D 
A B 
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Due to the absence of a blood supply, nutrients are derived from tears and the 
aqueous humour. The avascularity also influences wound healing, which is achieved 
by activation of stromal fibroblasts and the laying down of fresh collagen. Corneal 
epithelial regeneration is derived from a rich stem cell niche at the limbus (Pellegrini 
et al., 1999). Destruction of the limbal epithelial stem cells has important implications 
for the maintenance of corneal clarity, as corneal epithelial cells become repopulated 
from the conjunctival stem cells, resulting in loss of corneal clarity.  
 
Mucosa or mucous membranes are mucous tissue linings composed of a specialised 
epithelium and an underlying lamina propria. The epithelial surfaces are non-
keratinised and secrete a viscous (mucous) fluid. The conjunctiva is histologically a 
mucous membrane composed of stratified epithelium, a basement membrane zone 
(divided in to a lamina lucida, lamina densa and fibro-reticularis), and an underlying 
stroma divided in to loose connective tissue (termed the lamina propria) and a 
deeper vascularised layer (overlying the episclera) (Pflugfelder et al., 2004). The 2-3 
layer stratified epithelium is squamous in its tarsal and columnar in its bulbar part and 
can be up to 7 layers. The conjunctiva contains accessory lacrimal tissue and goblet 
cells, which contribute to formation of the inner tear film layer through the production 
of mucin. Unlike corneal stem cells, conjunctival stem cells are uniformly distributed 
throughout the conjunctiva, but probably more densely populated in the fornices 
(Pellegrini et al., 1999). The tarsal and bulbar conjunctiva derives their blood supply 
from the medial and lateral palpebral arteries (from the lacrimal and ophthalmic 
arteries respectively) and the limbal conjunctiva from the anterior ciliary arteries (from 
muscular branches of the ophthalmic artery). The cornea and bulbar conjunctiva are 
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both innervated by the long ciliary nerves (branches of the nasociliary division of the 
ophthalmic nerve).  
 
The ocular surface epithelial basement membrane zone (BMZ), termed Descemet’s 
layer in the cornea, like other BMZs are composed of an extra-cellular matrix of 
proteins, which bind the epithelium to the underlying stroma. The BMZ can be divided 
in to the lamina lucida, lamina densa and underlying fibro-reticularis (Figure 1.3). 
Epithelial cells (bound to each other by desmosomes) are attached to the underlying 
lamina lucida by hemi-desmosomes. The lamina lucida and lamina densa (thought to 
be less dense in mucosa) contain extra-cellular proteins, primarily Type IV collagen 
(Type I, V and VI collagen are found in the corneal stroma), together with the cross-
shaped glycoprotein Laminin while the less densely packed lamina lucida also 
contain glycosaminoglycans such as Heparan Sulphate (Elder, 1997a, Forrester, 
2008, Challacombe et al., 2001). Integrins are hetero-dimeric receptors found within 
extra-cellular matrix and also act as signalling proteins in immune responses 
(discussed in section 1.3.2). They contain an α and a β chain e.g. α1:β1 which bind 
laminins in the BMZ. This not only contributes to the cell matrix, but also plays a role 
in trans-membrane signalling (Forrester, 2008, Humphries, 2000). The fibro-
reticularis contains collagen bundles (primarily collagen VII) called anchoring 
filaments, which attach the BMZ to sub-basal dense plates termed anchoring plaques 
(again composed of Type IV collagen and Laminin) via anchoring fibrils. 
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Adapted from Elder. Cicatrising conjunctivitis. Karger. (Elder, 1997a) 
Figure 1.3: The Basement Membrane Zone (BMZ). Epithelial (Ep) cells are held together by 
desmosomes (D) and anchored to the underlying lamina lucida (LL) of the BMZ by hemi-desmosomes 
(HD). The LL and LD are composed of Type IV collagen and Laminin, which in turn are attached to the 
underlying fibro-reticularis (FR) of the anterior stroma (St) via anchoring filaments (composed of Type 
VII collagen) to anchoring plaques (AP). 
 
1.2 The Lacrimal Functional Unit 
 
The ocular surface is protected by the ability to close the eyelids, facilitating 
lubrication and distribution of the tear film. Numerous glands found on the ocular 
surface maintain the tear film structure. Of critical importance is the lacrimal 
functional unit that comprises the lacrimal gland, conjunctiva, cornea, eyelids and 
sensory innervations, which together are essential for optical clarity (Zierhut et al., 
2002, Stern et al., 2010). The sponge-like tear film itself is a complex, broadly divided 
in to an outer lipid layer, an aqueous layer and a mucin layer.  
 
The outer lipid layer of the tear film is created by Meibomian glands (embedded in 
the tarsal plates underlying the tarsal conjunctiva) and glands of Zeiss (found in the 
eyelid margins opening in to the eyelash follicles). They help prevent evaporative 
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loss of the other components of the tear film. The principal oily components include 
wax and sterol esters which are non-polar lipids which act as a lubricant and as a 
water barrier, while polar lipids act as a base for the non-polar lipids and have 
surfactant properties, helping to spread other lipid components of the tear film 
(McCulley and Shine, 2003).  
 
The lacrimal glands are bilobed structures found in the superotemporal region of the 
orbits. They are exocrine glands, lined by acinar cells, producing a serous secretion 
draining in to the superior fornices. Supported by the accessory glands of Krause and 
Wolfring (residing in the conjunctival fornices), they form the aqueous layer of the 
tear film. This layer also contains secretory immunoglobulin A (IgA); antimicrobial 
lysozymes and lactoferrin; lipocalin (maintaining surface lipid spreading), electrolytes 
such as Na+, K+, Cl-, HCO3-, Mg2+ and Ca2+ and cytokines such as IL-1, IL-6, IL-8, IL-
10 and TNF-α (Zierhut et al., 2002, Nakamura et al., 1998, Sonoda et al., 2006, 
Tiffany, 2003). 
 
Finally, the inner mucous layer is produced by the conjunctival goblet cells, by 
producing O-glycosylated serine and threonine residue glycoproteins called mucins 
(Guzman-Aranguez and Argueso, 2010). They render the hydrophobic surface of the 
ocular tissues hydrophilic (by its surfactant properties), thereby increasing wettability 
and increased retention of the aqueous component. This glycocalyx bridges the outer 
layers to the corneal and conjunctival surfaces and therefore helps overall lubrication. 
It is thought there may be a role for ‘circulating’ mucins, which act as a debris 
removal system, the principal mucin being MUC5AC (Gipson, 2004, Tiffany, 2003). 
Mucins may also play a role in anti-adhesion, signalling and pathogen binding as well 
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as stabilising the tear film (Govindarajan and Gipson, 2010). Murine studies have 
indicated that goblet cells homeostasis is regulated by IL-13, secreted by NKT cells 
in the case of the conjunctiva (De Paiva et al., 2011).  
 
The tear film also supplies nutrients, glucose and oxygen to the cornea, maintains 
immune regulation of the ocular surface and washes away unwanted debris. Tears 
are cleared via drainage through small puncti (found in the medial limit of each eyelid 
margin) into a canalicular system, in turn draining into lacrimal sacs and out through 
nasolacrimal ducts into the nose. Disruption of any of the components of the tear film 
plays an important role in dry eye problems.  
 
Turnover of tears is regulated by the parasympathetic supply to the lacrimal glands 
(via secretomotor branches of the lacrimal nerve). Basal secretion is 1.2μl/min and 
can be massively increased by mechanical or psychological stimuli in the presence of 
a healthy lacrimal functional unit. 
 
1.3 Immunoregulation of the ocular surface 
 
Immunoregulation refers to the “tolerance and modulatory mechanisms responsible 
for tightly controlling the innate and adaptive immune response to limit bystander 
tissue damage after stress and/or microbial assaults” (Stern et al., 2010). This is 
especially true in maintaining a healthy and optically clear ocular surface. Before 
considering immunoregulation in this specialised environment, we will consider 
general principles relating to the immune system, how these have adapted in relation 
to mucosal environments and finally in the ocular surface itself. 
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1.3.1 Principles of immunity and inflammation 
 
The immune system provides an intricate means of protecting host species against 
pathogens and removing cancerous cells. Historically, immunity has been divided 
into the innate and adaptive systems. The innate system provides a rapid or non-
specific means of dealing with attack, while the adaptive immune system offers a 
specific response based on immunological memory. 
 
Innate Immunity 
 
Innate immunity includes the natural barriers of the body e.g. the skin or mucosal 
surfaces, the ability to clear microorganisms through fluids such as the tear film, and 
recruiting cells that are capable of mounting an immediate response to neutralise or 
destroy invading pathogens if epithelial surfaces are breached. These include 
granulocytic cells termed polymorphonuclear cells and include neutrophils, 
eosinophils, basophils and mast cells; macrophages and dendritic cells (DCs), 
derived from monocytes and Natural Killer (NK) cells, derived from lymphoid 
precursors.  
 
Cellular components of the innate immune system are aided by the complement 
system. This is a highly conserved organisation of plasma peptides that is able to 
recognise molecules found on the surface of pathogens such as bacteria. Three 
pathways exist including the alternative pathway (an innate response), the classical 
pathway (an adaptive response, discussed later) and the lectin pathway (Ricklin et 
al., 2010). They work by inducing a cleavage cascade by enzymatic conversion of 
one complement protein to another e.g. in the alternative pathway C3 is converted to 
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C3a, C3b or C5b by C3 convertase following recognition of pathogen. C3a can 
recruit phagocytic cells such as neutrophils and macrophages; C3b binds to 
phagocytes and promotes engulfment of micro-organisms in a process termed 
opsonisation and C5b forms a complex with C6, 7 and 8 termed the Membrane-
Attack Complex resulting in a pore-formation in the micro-organism cell wall (Sjoberg 
et al., 2009). An overview of the complement system is shown in Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Janeway’ s Immunobiology 2008. (Murphy et al.) 
Figure 1.4 The complement system. A summary diagram showing the three principle pathways of 
the complement cascade. The classical pathway can be activated by antibody while the alternative 
pathway is part of the innate immune system. The lectin pathway is initiated by recognition of foreign 
carbohydrate sequences. Phagocytic recruitment and activation including is a common end-point. 
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Neutrophils are considered primary host responder cells, capable of detecting 
pathogens and are normally recruited rapidly from peripheral blood by a number of 
mechanisms, and which serve to activate them. These include the complement 
cascade (e.g. via C3 activation of the mannose-binding lectin receptors or the 
alternative pathways), pattern recognition via Toll-like receptors (TLRs; which 
activate phagocytes by recognising peptide sequences called Pathogen-Associated 
Molecular Patterns [PAMPs] e.g. dsDNA by TLR3 or lipopolysaccharide by TLR4) or 
by cytokines and chemokines e.g. Interleukin-6 (IL-6), CXCL7 and CXCL8 produced 
by activated macrophages (Sadik et al., 2011, Williams et al., 2011).  
 
Macrophages also contribute to the innate response through phagocytosis of 
dying/dead cells, removal of opsonised cells by the compliment cascade and the 
release of cytokines such as Tumour Necrosis Factor-α (TNF- α). TNF-α helps 
contain local inflammation but together with other inflammatory cytokines produced 
such as IL-1 and IL-6, systemic release can induce an acute phase response 
resulting in elevated temperature, activate acute phase proteins (such as C-reactive 
proteins) and mobilise neutrophils from the bone marrow.  
 
Eosinophils and basophils help destroy parasitic worms by the release of proteases 
or histamine respectively in response to Immunoglobulin-E (IgE). Natural Killer (NK) 
cells have an important role in destruction of virally infected or tumour cells through 
the release of cytotoxic granules onto the infected cell surface (Caligiuri, 2008). The 
acute responses to foreign attack precede a specific immune response termed 
adaptive immunity.  
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Adaptive Immunity 
 
The major leukocytes involved in adaptive immunity are T-lymphocytes (derived form 
the thymus) and B-lymphocytes (arising in the bone marrow). The primary immune 
response in adaptive immunity relies on afferent and efferent arms and are 
characterised by antigen presentation to lymphocytes in lymphoid structures (the 
afferent response), T-lymphocyte activation and T:B cell interaction resulting in 
specific antibody production by B-cells (the efferent or humoral response). 
 
DCs have an important role in that they are able to bridge the innate and adaptive 
immune responses by phagocytosing foreign microorganisms and interacting with 
other immune cells. They are therefore termed professional antigen presenting cells. 
They can reside within the lamina propria and have projections through the basement 
membrane zone to the epithelium e.g. Langerhans cells in skin. Antigens processed 
by the engulfment and breakdown of pathogens are transferred to secondary 
lymphoid structures such as draining lymph nodes, or in the case of mucosal 
surfaces, Mucosa Associated Lymphoid Tissue (MALT) e.g. Peyer’s patches in the 
small intestine. It is here that antigen presentation to lymphocytes facilitates an 
adaptive immune response (Sheridan and Lefrancois, 2011).  
 
Professional antigen presenting cells such as DCs and macrophages, having come 
in to contact with foreign antigen, present peptides in conjunction with Major 
Histocompatability Complexes (MHCs) and signal T lymphocytes via the T-cell 
receptor (TCR - a part of the immunoglobulin family), the common leukocyte antigen 
(CD45) and co-stimulatory molecules (e.g. CD3 and CD28). MHCs (also called HLA 
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or Human Leukocyte Antigen, located on chromosome 6) are divided in to Class I 
(present on all nucleated cells) or Class II (presented on professional antigen 
presenting cells such as DCs and macrophages). MHC class I present antigen and 
stimulate CD8+ T cells via TCR, CD8 and co-stimulatory molecules while MHC class 
II signals CD4+ T cells. Following antigen exposure, T cells undergo a massive 
expansion in their numbers and the ability to recognise specific antigen, the principle 
of immunological memory (Kim and Williams, 2010, Sheridan and Lefrancois, 2011). 
 
The ability of T cells to recognise antigen presented to them as foreign is determined 
by the principle of central tolerance i.e. self-reactive T cells are removed during 
maturation in the thymus. Additional mechanisms include anergy, where the absence 
of co-stimulatory molecules during antigen presenting cell interaction with T-cells in 
the periphery results in the removal of potentially auto-reactive T cells and by T 
regulatory cells and Type b Intra-Epithelial Lymphocytes (IEL).  
 
T cell maturation is based on the type of antigen presented by antigen presenting 
cells so that precursor T cells (Th0 cells) are polarised to become a specific T cell 
subtype via the cytokine signal generated at the immunological synapse e.g. Th1 
responses, involved in cell-mediated responses by stimulating T and NK cells, are 
induced by IL-12 production by DCs in response to engulfing intra-cellular pathogens 
such as viruses and PAMPs. T cells (expressing common CD3+ marker) can be sub-
classified by the presence of CD8 or CD4, their TCR (αβ or γδ) and further classified 
by their role (effector or regulatory) based on the production of cytokines such as IL-
17 in the promotion of inflammatory responses or IL-10 in the context of regulation 
(Annunziato et al., 2007, Zhou et al., 2009).  
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CD8+ cells, conventionally cytotoxic (Tc cells), have a primary function to kill cells 
infected with viruses or having undergone malignant transformation. This is achieved 
by the production of cytolytic granules such as granzyme B and perforin and through 
Interferon- γ (IFN-γ) production (Cheroutre and Madakamutil, 2005) although there 
are unusual population that produce IL-17 termed Tc17 cells and others showing 
regulatory properties, more commonly in the mucosa. By contrast, CD4+ cells are 
broadly divided on the basis of their helper responses (Kondo et al., 2009, Koch et 
al., 2008). Th1 responses are characterised by cytokines such as Interferon- γ (IFN-γ) 
and the transcription factor T-bet and induce cell mediated responses that kill 
infected cells through activation of macrophages and NK cells; Th2 by IL-4, IL-5 and 
IL-13 (the transcription factor is GATA-3) which activate B cells; Th17 by IL-17 and 
the transcription factor RORγt that are implicated in inflammatory responses including 
anti-fungal and intercellular bacteria roles, and T-regulatory cells (TREG) by CD25+ 
and the transcription factor FoxP3+ that serve to dampen/regulate immune 
responses (Cope et al., 2011, van Wijk and Cheroutre, 2009) 
 
B cells are generated in the bone marrow and are typified by their ability to produce 
antibodies (immunoglobulins; Ig) and immature B cells producing IgM travel to 
lymphoid structures. Once Th2 (helper CD4 cells) have been activated they are able 
to form T:B cell interactions. B cells act as professional antigen presenting cells and 
engulf free antigens in draining lymph nodes, and when they come in to contact with 
cognate T cells primed by the same antigen, they are able to form a complex which 
stimulates the differentiation of the B cell when combined with co-stimulatory 
molecule CD40 (which binds to CD154) (Neron et al., 2011). Cytokines produced by 
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the Th2 cell e.g. IL-4, 5 and 6 assist this process. Activation of B cells results in 
proliferation and maturation and the formation of plasma cells.  
 
The immunoglobulins produced by B cells (and latterly plasma cells following affinity 
maturation and induction of memory) include IgG, A, M, E and D and characterise the 
adaptive immune response by neutralising virus and helping to promote rapid 
responses to known antigens through the recruitment of other immune cells – both 
from the innate and adaptive ‘efferent’ arms. The classical complement pathway can 
also be initiated by the adaptive immune response through antibody:antigen 
complexes on pathogens, which in turn convert C1q to C4 and C2 to give C4b2a and 
this becomes the C3 convertase. This occurs at the site in which it is initiated.  
 
Historical distinction between innate and adaptive responses have become blurred 
through greater understanding of cellular interactions, cell plasticity and the diversity 
of responses seen in specialist sites. Antigen-antibody complexes may also serve to 
initiate innate responses e.g. the classical complement pathway which can lead to 
the recruitment of inflammatory cells (Janeway, 2005). Neutrophils can also be 
activated by Fc receptors that can bind for example Immunoglobulin (Ig) G1 and IgA, 
and this assists target recognition.  
 
Inflammation and Autoimmunity 
 
The acute inflammatory response, initiated by foreign antigen and/or tissue damage 
results in a signalling cascade which draws innate cells rapidly, with neutrophils able 
to extravasate in to tissue spaces from the peripheral blood compartment, assisted 
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by tethering to the endothelial wall and enhanced vascular permeability. This process 
is facilitated by PECAM-1-dependent α6:β1 integrin up-regulation on transmigrating 
neutrophils (Sadik et al., 2011) and leakage of the endothelium, resulting in tissue 
swelling, redness and local temperature rise, and pain associated with the release of 
histamine – the cardinal features of inflammation described by Celsus as tumor, 
rubor, calor and dolor. This results in further recruitment of inflammatory cells 
including macrophages and NK cells that aid in the phagocytic process and 
lymphocytes which act as bystanders pending adaptive responses.  
 
Neutrophils exert their effect by engulfing pathogens and subjecting them to reactive 
oxygen species (ROS) such as H2O2 and O2- and utilising destructive azurophilic 
granules e.g. elastases and proteinases (Kessenbrock et al., 2008). These proteins 
have potential to induce severe local tissue damage as well as eradicating 
pathogens. Neutrophils may also contribute to sites of inflammation by enzymatic 
cleavage by proteinase-3 of pro-cytokines including TNF-α  (Wright et al., 2010).  
Following this acute response, their retention within tissue has historically been 
considered short lived, preceding a more chronic inflammatory response. Recent 
evidence however suggests that they may play a role in modifying adaptive 
responses by cytokine release, migration to lymph nodes or by scavenging 
inflammatory cytokines and chemokines (Mantovani et al., 2011). 
 
Chronic inflammation takes place when inadequate clearance of antigen occurs. In 
the case of infection this may result from failure to mount initial response or evasive 
mechanisms by the pathogen such as antigenic variation or drift in the case of 
influenza virus or intra-cellular localisation in the case of Mycobacteria tuberculosis. 
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Autoimmunity may also result in chronic inflammation. Autoimmunity arises due to 
the aberrant recognition of self-antigen as foreign. Numerous mechanisms can result 
in this situation and numerous diseases have an autoimmune basis including for 
example Sjögren’s Syndrome (Ramos-Casals et al., 2010a).  
 
Diseases that are antibody-mediated have been described as Type II hypersensitivity 
disorders. The mechanisms by which autoimmunity arises are diverse and include 
failure of central tolerance or anergy, failure of regulatory lymphocyte populations, 
molecular mimicry (where a pathogen produces antigen which is mistaken for self), 
polyclonal B cell direct activation of B cells by e.g. bacterial endotoxins), MHC 
mutations, superantigen activation (multiple T cell activation by e.g. Staphylococcus 
by direct binding to MHC) and bystander activation (where anergised T cells yet to be 
cleared are activated by the up regulation of co-stimulatory molecules during 
infections). They can be classified as organ specific or systemic based on the source 
of their antigens (Hoyne, 2011).  
 
1.3.2 Mucosal Immunology 
 
Mucosal surfaces, comprise the ‘wet surfaces’ of the body such as the ocular 
surface, the nasopharynx, the mouth, the respiratory and gastro-intestinal tracts 
(including the oesophagus, stomach, small and large intestines). They have adapted 
their role as a ‘first line of defence’ in order to undertake specialised roles such as 
acting as specialist transport systems e.g. gas exchange or the absorption of 
nutrients but without the additional protection afforded by keratinisation, as in the skin 
(Lawson et al., 2011).  
Chapter 1  Introduction 
 
18 
Infections pose a major challenge to the mucosal immune system and many human 
infections such as M. tuberculosis, Human Immunodeficiency Virus (HIV) and 
measles breach the immune system through mucosal surfaces. Vulnerability of the 
mucous membranes to infections is compensated for by the specially adapted MALT. 
In the gastro-intestinal tract these are termed Gut-Associated Lymphoid Tissue 
(GALT) and include tonsils and Peyer’s patches in the small intestine. The surface 
epithelium of Peyer’s patches contain microfold (M) cells and lack villi and goblet 
cells, characteristic of the surrounding epithelium. M cells are adapted to traffic 
pathogenic antigen to the underlying lymphoid structure, containing both B and T cell 
areas (Sheridan and Lefrancois, 2011). 
 
Local antibody production takes place in the mucosa by plasma cells in the lamina 
propria and MALT. Immunoglobulin A is important at mucosal sites because it is 
secretory, it has an ability to form dimers and interact with Fc receptors on 
phagocytes (Woof and Russell, 2011). There are two isotypes of secretory IgA, IgA1 
and IgA2 (with a ratio of 3:2) and class switching from naïve B cells to IgA secreting 
lymphocytes is regulated by Transforming Growth Factor-β (TGF-β) within MALT. IgA 
dimers are attached to J chains and are transported across the epithelium by 
transcytosis following binding to poly-Ig receptor at the base of the epithelium. IgA is 
the dominant secretory antibody involved in mucosal immunity and assist antigen 
presentation through microfold (M) cells in the gut lumen (van Wijk and Cheroutre, 
2009). 
 
Leukocytes within the mucosal epithelium are primarily lymphocytes and are termed 
Intra-Epithelial Lymphocytes (IEL). An abundance of IEL are found in the small bowel 
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(10-20 per 100 villus) and (unlike peripheral blood) are predominantly CD8+ cells with 
one T cell for every 10 epithelial cells (Hayday et al., 2001, MacDonald et al., 2011). 
Two subtypes have been defined in mucosal tissues (Types a and b) (Table 1.1). 
Type a IEL are ‘conventional’ TCR α:β CD8 α:β cells. Type b IEL are distinct from the 
majority of T cells found in blood (Jarry et al., 1990) and are characterised by 
expression of unusual T Cell Receptors (TCR) such as TCR γ:δ CD8 α:α and TCR 
α:β CD8 α:α subsets. TCR γ:δ CD4 CD8 ‘double-negative’ cells are also found at 
levels >10% in murine small intestine. These numbers appear to be higher in the 
large than the small intestine and may reflect a requirement in response to bacterial 
load. 
 
Type A IEL Type B IEL 
TCRαβ+CD8αβ+ TCRαβ+ CD8αα+ 
 TCRγδ+ CD8αα+ 
 TCRγδ+ Double Negative (DN) 
 
Table 1.1: Intra-Epithelial lymphocyte (IEL) subsets. Two groups have been identified including 
‘conventional’ TCRαβ+CD8αβ+ cells  (Type a IEL) and others, expressing less common TCRγδ, 
CD8αα or no CD4/CD8 markers (Type b IEL). 
 
Type a IEL bind conventional MHC class I and II are thought to have a protective role 
including protection against Cytomegalovirus and Toxoplasma (Hayday et al., 2001). 
Type b IEL are distinct in that the TCR bind to unconventional MHC class 1B 
molecules and thymus leukaemia (TL) antigen. Type b IEL are thought to represent 
an interface between the innate and adaptive immune response and are implicated in 
the repair of damaged mucosa. TCR γδ-/- mice have heightened cutaneous 
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inflammation as a result of α:β T-cell responses suggesting a protective role in 
maintaining epithelial integrity (Hayday et al., 2001, O'Brien et al., 2009). It is thought 
that they act as activated Th-1 skewed effectors cells. IEL require activation by 
additional cytokines and in their resting state a number of anti-proliferative genes are 
expressed e.g. Btg1 and 2. Therefore additional steps are required in vivo to fully 
induce activation. This has been termed ‘activated but resting’ (Hayday et al., 2001).  
 
At mucosal sites, repeated exposure to antigen may account for an altered role for 
epithelial CD8+ lymphocytes, some of which may be regulatory in nature (Koch et al., 
2008, Xystrakis et al., 2004). A population of regulatory CD8+ cells have been 
identified as expressing the CD103 (αE) integrin and these are thought have 
suppressive effects, mediated by IL-10 (Uss et al., 2006).  
 
CD4+ cells are the more dominant T cell type in the underlying lamina propria. In the 
gut these have been identified as inflammatory Th17 and Th22 cells, counteracted by 
TREGs and play an important role in the pathogenesis of inflammatory bowel diseases 
(van Wijk and Cheroutre, 2009), in particular TREGs play an important role, mediated 
by IL-10, in preventing excessive inflammation at mucosal interfaces such as the gut 
and the lung (Rubtsov et al., 2008). IL-22 secreting cells play an important role in 
mucosal barrier function and disruption has been identified in inflammatory bowel 
diseases (Sonnenberg et al., 2011). Both Th17 and T regulatory cell differentiation 
requires TGF-β (produced by epithelial cells and CD103+ DCs) and an imbalance 
between inflammation and regulation between these cell population may contribute to 
autoimmune diseases (Horwitz et al., 2003, Stockinger et al., 2007, Coombes et al., 
2007). Of interest, the mechanism may include the production of IL-17 by cells such 
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as monocytes, NK cells and γδ T-cells, which in turn promote an inflammatory 
infiltrate including neutrophils. Failure to resolve this may result in an increase in local 
TGF- β production resulting in the promotion of both Th17 an TREG populations 
(Stockinger et al., 2007). 
 
 A summary of mucosal IEL in the gut is shown in Figure 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Van Wijk Seminars in Immunology (van Wijk and Cheroutre, 2009) 
Figure 1.5. Mucosal T cell regulation and activation. In the gut microenvironment, Type a IEL help 
destroy pathogens that have breached the epithelial barriers while Type b IEL such as CD8αα+ T cells 
play a role in repair and regulation. The epithelial cells (IECs) help induce Retinoic Acid production 
(RA) by DCs, which assist in gut-homing receptor induction by CD4+ T cells when primed in the 
mesenteric lymph nodes (MNs). CD103+ DCs under the influence of IL-10 and TGF-b induce FoxP3+ 
T REGs whereas activated DCs promote inflammatory Th17 lymphocytes via IL-6. 
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Circulating T cells are recruited to mucosal tissue such as the gut by expression of 
the integrin α4:β7 (which binds to MadCam-1 on lamina propria vascular endothelium) 
and the chemokine receptor CCR9 (Figure 1.6). A switch to αE:β7 integrin expression 
on these mucosal homing T cells directs lymphocytes within the lamina propria to 
bind to E-cadherin on epithelial cells (Cepek et al., 1994). This is mediated by the 
expression of TGF-β on epithelial cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Agace 2008. Trends Immunol (Agace, 2008) 
Figure 1.6: T cell recruitment to the small intestine. Expression of the chemokine receptor CCR9 
and the integrin α4:β7 bind to vascular endothelial CCL25 and MadCam-1 respectively. Once recruited 
to the lamina propria, up regulation of αE:β7 takes place with T cell attraction to E-cadherin expressed 
on epithelial surfaces. 
 
Chapter 1  Introduction 
 
23 
A hallmark of adaptive immunity is memory, or the ability to recognise previously 
encountered foreign peptides. Antigen experience, taking place in a mucosal draining 
lymph nodes or MALT results in an alteration in cell surface marker expression 
including a switch from a high (RA) to a low molecular weight isoform (RO) of the 
CD45 common leukocyte antigen marker (Table 1.2) (Akbar et al., 1988). Effector 
memory ‘primed’ cells are able to extravasate into peripheral mucosal tissues (Gupta 
et al., 2004). CD8+ CD103+ (αE:β7) mucosal cells have also been identified as being 
CD45RA- CCR7- (CCR7 being a lymph node homing marker). Local environmental 
education in mucosal lymphoid tissue has been shown to induce the expression of 
CCR9 and α4:β7 on T cell subsets although alternative routes of immunisation can 
also induce mucosal-homing such as subcutaneous yellow-fever vaccination in 
humans (Agace, 2008, Masopust et al., 2010).  
 
 
Naïve Central Memory Effector Memory Effector Memory RA 
(Revertants) 
CD3+ 
CD45RA+ 
CD45RO- 
CD28+ 
CCR7+ 
IL-2 expression 
CD3+ 
CD45RA- 
CD45RO+ 
CD28+ 
CCR7+ 
IL-2 expression 
CD3+ 
CD45RA- 
CD45RO+ 
CD28- 
CCR7- 
IL-2, IFN-γ, IL-4 or IL-5 expression 
CD3+ 
CD45RA+ 
CD45RO- 
CD28- 
CCR7- 
IL-2 expression +/- IFN-γ  
Table 1.2: T cell memory status. T cell memory can be defined by the expression of numerous 
markers including high and low molecular weight isoforms of the Tyrosine Phosphatase CD45RO. 
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The majority of the tissue specific CD8+ populations are antigen experienced 
(CD45RO+). Our understanding of memory status is further defined by the loss of the 
lymph-node homing marker CCR7 as the cell is antigen primed and changes form a 
central to an effector memory phenotype (CCR7-CD45RA-). A significant proportion 
of CCR7-CD45RA+ ‘revertant’ CD8+ T cells are antigen experienced and are able to 
produce IFN-γ (Faint et al., 2001). This is thought to be driven by chronic viral 
infection such as Cytomegalovirus and in the periphery there is an accumulation of 
viral specific cells and CMV is described as the most immune-dominant peptide in 
humans (CMV) (Moss and Khan, 2004). Another herpes virus, Epstein Barr Virus 
(EBV) can also act as immunodominant peptide, long after the primary infection 
(Hislop et al., 2001).  
 
1.3.3 Ocular Surface Immunity 
 
Ocular surface immunity is regulated by the lacrimal functional unit and immune cells 
located on the ocular surface. Like other mucosal surfaces, the absence of a 
keratinised epithelium increases vulnerability to attack. This is particularly true of the 
optically clear cornea; even more susceptible because it is avascular (precluding 
rapid recruitment of cells as in other tissues) and has few lymphoid cells under 
normal conditions (Knop and Knop, 2007). The cornea therefore relies on 
components of the tear film and the surrounding conjunctiva for immunological 
protection (Knop and Knop, 2005b). 
 
It has become clear that like other mucosal surfaces, the ocular surface has a form of 
MALT termed Eye Associated Lymphoid Tissue (EALT) (Knop and Knop, 2003, Knop 
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and Knop, 2005a, Knop and Knop, 2005b). These are found in the lamina propria of 
the conjunctiva and like the lacrimal gland contribute to the production of IgA to the 
tear film (Knop et al., 2008). Local antibody production by plasma cells is an 
important component of the lacrimal functional unit and the maintenance of a healthy 
ocular surface. As discussed in section 1.2, the tear film also contains soluble factor 
including cytokines such as IL-1, IL-6, IL-8, TNF-α and IL-10 and growth factors such 
as TGF-β and Epidermal Growth Factor (EGF) (Zierhut et al., 2002, Nakamura et al., 
1998, Sonoda et al., 2006). TGF-β has been demonstrated in healthy tears (Gupta et 
al., 1996). Whether TGF-β is derived from the epithelium and plays a role in 
switching homing markers such as α4:β7 to αE:β7 or influences Th17 or TREG induction 
is unknown.  
 
The conjunctiva, like other mucosal surfaces, contains leukocyte populations 
including lymphoid cells called intra-epithelial lymphocytes (IEL) (Allansmith et al., 
1978, Knop and Knop, 2007, Hayday et al., 2001, Knop and Knop, 2005b). Ocular 
surface immune cells are derived from the rich conjunctival vasculature and 
components of the tear film also contribute to ocular surface immune regulation. 
 
Resident conjunctival cells identified in the normal human conjunctiva include 
abundant populations of CD3+ cells, primarily CD8+ cells in the epithelium (with a 
CD4:CD8 ratio of 0.3) and CD4+ in the lamina propria (CD4:CD8 ratio 1.3) (Sacks et 
al., 1986, Hingorani et al., 1997). The majority of epithelial T cells are CD45RO+ or 
‘antigen experienced’. Few TCRγδ cells, B or plasma cells have been identified in the 
epithelium but a population of CD20+ (B cells) and plasma cells can be found in the 
lamina propria. In non-inflammatory conditions, populations of macrophages and 
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dendritic cells are abundant in the epithelium and lamina propria. Natural Killer cells 
and neutrophils are scarce and are confined to the lamina propria (Knop and Knop, 
2007).  
 
Our knowledge of the role of IEL within the conjunctiva is currently limited. It is 
unclear which subtypes (Type a or b) exist, what their precise memory status is, what 
cytokines they produce and whether there is any indication of regulatory properties. 
Mucosal IEL CD8+ recognition of powerful immune-dominant peptides such as CMV 
in the conjunctiva is undetermined. The human conjunctiva is dominated by bacterial 
commensals such as Staphylococcus, Streptococci, Moraxella and Diphtheroids 
(Forrester, 2008). Acute bacterial conjunctivitis in adults is largely dominated by the 
same pathogens in the immunocompetent, while viral conjunctivitis largely relates to 
adenovirus, molluscum contagiosum and Herpes Simplex Type 1 (Denniston and 
Murray, 2009, Hovding, 2008). Herpes Simplex has far greater morbidity as a cause 
of keratitis rather than conjunctivitis and like other herpes viruses, CD8+ T cells play 
an important role in maintaining latency of the virus in the trigeminal ganglion (Divito 
et al., 2006).  
 
The gut has been described as having continuous low-grade inflammation 
(MacDonald et al., 2011). It may therefore be the case that the phenotype of resident 
IEL on the ocular surface are different to other mucosal sites, not least because of 
their different antigen exposure. It is known that in dry eye disease, there is an 
elevation in conjunctival IFN-γ and IL-17 producing T cells, and there appears to be a 
defective suppressor function by T regulatory cells on Th17 cells (Chauhan et al., 
2009). The effector function, memory status and antigen recognition of conjunctival T 
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cells in health, in particular the CD8+ population, therefore warrants further 
investigation.  
 
1.4 Ageing changes and the immune system 
 
The implications of ageing changes on the immune system has attracted attention as 
a greater understanding of immunosenescence is gained (Haynes and Maue, 2009). 
The immune system alters with age and an accumulation of memory cells is 
observed including an increased frequency of CD45RO+/RA- T cells (Utsuyama M, 
2009) and in keeping with the strongly immune-dominant effects of CMV discussed, 
a greater proportion of the T cell repertoire is committed to recognising this virus with 
increasing age (Khan et al., 2004). Furthermore, a process of thymic involution is 
thought to contribute to an exhaustion of naïve T cells, and this has been 
demonstrated in thymectomised young people undergoing cardiac surgery (Sauce et 
al., 2009).  
 
The innate immune system can also undergo changes with age. Neutrophils for 
example, maintain their numbers with increasing age but there is evidence of a 
diminished phagocytic capacity (Shaw et al., 2010). Natural killer cells are believed to 
have a diminished function with increasing age (Shaw et al., 2010, Panda et al., 
2009). Of interest, is the observation that the severity of ocular surface infections 
such as microbial or herpetic keratitis is clinically worse in the elderly (van der 
Meulen et al., 2008) and Mucous Membrane Pemphigoid (Foster, 1986, Chan, 2001) 
typically affect people in later life. Some studies have demonstrated an increased 
prevalence of dry eye problems with age (McCarty et al., 1998, Moss et al., 2000, 
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Stern et al., 2010). Despite this, little is known about age-related changes in the 
leukocyte populations within the ocular surface (Gwynn et al., 1993).  
 
Changes in major peripheral blood populations are demonstrated in Table 1.3. 
 
Cell population Age-related changes 
 Males Females 
Leukocytes numbers No change No change 
Lymphocytes numbers No change No change 
Monocyte numbers  No change No change 
Neutrophil numbers  No change No change 
T cell numbers  No change No change 
CD8+ numbers Decrease Decrease 
CD4+ numbers No change No change 
CD45RO+ cells Increased trend Increase 
CD4:CD8 ratio Increase Increase 
B cells Decrease Decreased trend 
NK cells Increased trend Increase 
 
Adapted from Utsuyama. Handbook of immunosenescence (Utsuyama M, 2009) 
Table 1.3 Major leukocyte population changes in peripheral blood with age. 
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1.5 Cicatricial Conjunctivitis 
 
A delicate balance of the lacrimal functional unit exists on the ocular surface that can 
be disrupted by a number of processes including dry eye states and conjunctivitis. 
Conjunctivitis (inflammation of the conjunctiva) may arise from a number of insults 
including infection, trauma (mechanical, chemical or thermal injuries), 
oculocutaneous diseases (including immunobullous disease and atopic kerato-
conjunctivitis), other systemic diseases, drug reactions and topical therapy such as 
the use of anti-glaucoma medication (Table 1.4) (Bernauer et al., 1997). These 
triggers can lead to a process of scarring termed cicatrisation.  
 
The cicatricial conjunctivitides are a group of diseases usually characterised by scar 
formation (cicatrisation) in response to conjunctival inflammation (Table 1.4). Chronic 
inflammation causes disruption to the delicate micro-environment of the ocular 
surface (Zierhut et al., 2002) (Pflugfelder and Stern, 2009). Importantly, some of 
these conditions have the capacity to progress, as the stimulus for inflammation is 
not temporary or potentially removable e.g. a chemical injury or infection. They are 
clinically important as they may contribute to progressive cicatricial conjunctivitis 
(PCC), characterised by chronic progressive scar formation (fibrosis) in response to 
conjunctival inflammation affecting the deeper layers of the conjunctiva. Some of 
these are mediated by anti-basement membrane zone (BMZ) antibodies (Bernauer et 
al., 1997).  
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+ A subset may develop autoantibody-positive progressive scarring akin to MMP 
Adapted from Wright 1986 (Wright, 1986) and Bernauer et al 1997 (Bernauer et al., 1997) 
Table 1.4: Summary table of causes of cicatrising conjunctivitis.  
 
Aetiology  Progressive 
Scarring  
Immunobullous 
Disease 
Physical:     
 Heat    
 Ionising radiation    
 Chemical   
Infection:     
 Trachoma    
 Membranous conjunctivitis (e.g. 
Streptococcus and Adenovirus)  
  
Oculocutaneous 
disorders:  
   
 Mucous Membrane Pemphigoid (MMP)  Yes Yes 
 Bullous Pemphigoid (BP)  Yes Yes 
 Linear IgA disease  Yes Yes 
 Dermatitis herpetiformis   Yes 
 Pemphigus  Yes Yes 
 Systemic Lupus Erythematosis   
 Epidermolysis bullosa (EB)  Yes Yes 
 Stevens-Johnson Syndrome (SJS) and 
Toxic Epidermal Necrolysis (TEN)  
Yes + Yes + 
 Lichen planus   
 Chronic atopic keratoconjunctivitis    
Other associated 
systemic disorders: 
   
 Rosacea    
 Sjögren’s Syndrome    
 Inflammatory bowel disease    
 Graft-versus-host disease    
 Immune complex diseases    
 Paraneoplastic syndromes  Yes  
 Drug-induced  Yes  
 Sarcoid   
 Porphyria   
Topical 
(pseudopemphigoid)  
Antiglaucoma medication    
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PCC causes severe damage to the ocular surface through destruction of the 
conjunctival goblet cells, scarring of the lacrimal and accessory glands and lid margin 
disorganisation and disruption of the oily component of the tear film. This in turn 
leads to ocular surface inflammation (Baudouin, 2001), keratinisation and limbal stem 
cell destruction. Parallel to these alterations, the conjunctival fibrosis results in 
obliteration of the conjunctival fornices and the scarring process results in entropion 
formation (eyelid deformity) and lash trauma to the ocular surface, exacerbating the 
inflammatory process (Bernauer et al., 1997, Wright, 1986). This results in ocular 
surface destruction, notably limbal stem cell loss with resultant opacification and 
neovascularisation of the optically clear corneal surface, through a process of 
conjunctivalisation and/or keratinisation. This epithelium is vulnerable to breakdown, 
which in turn leads to a higher risk of infective conjunctivitis and keratitis, promoting a 
vicious cycle resulting in eventual blindness.  
 
Dry eye is a dominant feature of cicatrising conjunctivitis. Dry eye has been 
described as a ‘multifactorial disease of the tears and ocular surface that results in 
symptoms of discomfort, visual disturbance, and tear film instability with potential 
damage to the ocular surface. It is accompanied by increased osmolarity of the tear 
film and inflammation of the ocular surface’ (2007). Although dry eye symptoms are 
relatively common, pathological causes of dry eye (synonymous with 
keratoconjunctivitis sicca) are multiple and include age-related changes discussed 
previously (2007). A relatively common cause of dry eye problems is Sjögren’s 
syndrome, an autoimmune condition characterised also by dry mouth (Ramos-Casals 
et al., 2010b). In the absence of a related autoimmune condition it is termed Primary 
Sjögren’s Syndrome (PSS), its prevalence is 0-5-3% and includes an increase risk of 
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lymphoma (Ramos-Casals et al., 2010b, Kassan and Moutsopoulos, 2004, Helmick 
et al., 2008). 
 
Although the initiating antigen is undetermined, Anti-Ro and La antibodies are 
directed against peptides within the lacrimal glands, resulting in a CD4+ T-cell and B-
cell infiltration of the gland (Stern et al., 2010, Pflugfelder et al., 2009). This causes a 
reduction of the aqueous tear component and hyperosmotic inflammatory ocular 
surface changes, with consequent conjunctival goblet cell loss and squamous 
metaplasia. Murine models of experimental dry eye, based on a desiccating stress 
environment, have revealed the importance of antigen presenting cells in initiating 
and maintaining the recruitment of auto reactive T cells (Schaumburg et al., 2011). A 
CD4+ infiltrate has been recognised in the conjunctiva of patients with PSS (Stern et 
al., 2002), and evidence points to the importance of the role of Th17 subsets in the 
pathogenesis of the disease with IL-17 detected in the tears of patients with PSS (De 
Paiva et al., 2009). 
 
Some of the diseases outlined in Table 1.4 have an underlying immunobullous 
component characterised by autoimmune mediated blistering of cutaneous surfaces 
including the conjunctiva. Although the principal ocular problems in PSS are dry eye 
there is a recognised cicatricial element. With the exception of Paraneoplastic and 
Drug-Induced causes of cicatricial conjunctivitis however, PSS is considered a slowly 
progressive cicatricial conjunctivitis (Bernauer et al., 1997), unlike many of the 
acquired ocular immunobullous diseases. 
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1.6 Acquired Ocular Immunobullous Disease 
 
Acquired immunobullous diseases that have potential ocular involvement include 
Mucous Membrane (formerly Ocular Cicatricial) Pemphigoid (MMP), Bullous 
Pemphigoid (BP), linear IgA disease, dermatitis herpetiformis, Pemphigus and 
bullous systemic lupus erythematous (Wong and Chua, 2002). Their annual 
incidence is thought to be 10.4 per million in Western populations (Bernard et al., 
1995). MMP is the most common of the true autoimmune diseases in this group with 
an incidence study in France demonstrating it was the most common to affect the 
ocular surface (Bernard et al., 1995, Wojnarowska and Briggaman, 1990). 
 
Epidermolysis bullosa is an inherited immunobullous disease. Reaction patterns, 
including exogenous triggers in the case of Stevens-Johnson Syndrome (SJS) and 
its severe immediate manifestation Toxic Epidermal Necrolysis (TEN) also have the 
potential to cause mucocutaneous blistering including PCC (Wojnarowska and 
Briggaman, 1990). Historically SJS-TEN were thought to be temporal and therefore 
failed to progress once the initial acute phase had resolved. Evidence has 
demonstrated that a significant proportion can go on to develop severe ocular 
sequelae after the systemic disease has resolved (Foster et al., 1988, De Rojas et 
al., 2007). Furthermore, this may result in the development of an MMP phenotype, 
with indistinguishable clinical and immunohistological features to MMP (Chan et al., 
1991). 
 
Although these diseases have the potential to cause PCC, with the exception of SJS-
TEN, ocular involvement is relatively uncommon. The British Ophthalmological 
Surveillance Unit (BOSU) was established to determine the incidence of rare 
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diseases in the United Kingdom (Stanford, 1997). A recent study attempted to 
determine the incidence of cicatrising conjunctivitis in the United Kingdom (Radford 
et al. The Incidence of Cicatrising Conjunctival Disorders in the UK. IOVS 2011; 52: 
E-Abstract 1136). The overall incidence was found to be 1.3 per million with Mucous 
Membrane Pemphigoid confirmed as the commonest cause of PCC (0.8/million), 
followed by SJS-TEN (0.2/million). Other causes had a combined incidence of 
0.2/million and included primarily immunobullous disorders such as Linear IgA 
disease, drug toxicity and ocular surface squamous neoplasia but also 
oculocutaneous disorders such as lichen planus and atopic conjunctivitis and other 
associated conditions including ocular rosacea, graft versus host disease, 
Adenovirus and PSS.  
 
1.7 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 
 
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are 
reaction patterns that have the potential to cause a life-threatening mucocutaneous 
blistering disease (Wojnarowska and Briggaman, 1990, Bastuji-Garin et al., 1993). 
TEN is a severe manifestation of SJS (Schopf et al., 1991, Bastuji-Garin et al., 1993) 
which can be classified systemically by scales such as the SCORTEN (Bastuji-Garin 
et al., 2000). It is a devastating disorder characterised by sloughing of epithelial 
surfaces associated with a mortality rate of up to 90% (Schopf et al., 1991) that can 
be predicted by the severity of SCORTEN (Bastuji-Garin et al., 2000). Major systemic 
problems simulate severe burns injury and include severe dehydration, renal failure 
and secondary infection. 
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The underlying aetiology is usually attributed to pharmacological agents including 
antibiotics (in particular sulphonamides but also penicillin, cephalosporins and 
tetracyclines), Non-Steroidal Anti-Inflammatories (NSAIDs) and anticonvulsants and 
less commonly to infections such as Mycoplasma, although the exact cause often 
remains unknown (Roujeau et al., 1995, French, 2006, Pereira et al., 2007). Drugs 
can activate T cells by behaving as haptens, fusing endogenous proteins following 
metabolic breakdown to form antigens, or by direct interaction with the MHC 
molecule and TCR, resulting in activation of the T cell (Pereira et al., 2007). 
 
Ocular complications include severe dry eye, ocular surface epithelial breakdown 
associated with sloughing of the muco-cutaneous junction, and infection. Long-term 
sequelae are related to conjunctival scarring and subsequent ocular surface failure 
that may persist and progress after resolution of systemic disease (Foster et al., 1988, 
De Rojas et al., 2007). While little is known about the ocular surface inflammatory 
process, keratinocyte death in cutaneous SJS-TEN is induced by blister fluid 
granulysin secreted by CD8+ cytotoxic T cells and CD56+ Natural Killer cells (Chung 
et al., 2008). There is evidence for the presence of CD8+ cytotoxic T cells in the 
cornea during the acute stages of TEN, (Williams et al., 2007) but detailed 
knowledge of the cellular profile during the acute and chronic stages of the disease in 
the conjunctival mucosa is unknown. Furthermore, how acute ocular SJS-TEN 
converts to a chronic condition in some patients remains unknown. 
 
The distinction between acute and chronic ocular disease is not clear. Although the 
systemic disease can be expected to resolve within days or weeks, there may be a 
variable ocular picture. A period of 2-6 weeks has been suggested as acute ocular 
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SJS-TEN while chronic disease has been defined as greater than 12 months (Power 
et al., 1995, Sotozono et al., 2007, Fu et al., 2010). There is no agreed definition of 
acute and chronic however and these definitions leaves a large ‘sub-acute period’ 
between 6 and 52 weeks. 
 
Predicting ocular surface outcome in disease is difficult although an estimate of 
mortality may be predicted by utilising either the scoring system SCORTEN (Bastuji-
Garin et al., 2000) or elevated serum granulysin for those with early drug-induced 
skin reactions (Fujita et al., 2011). Although conjunctival epithelial HLA-DR has been 
suggested as a biomarker for dry eye (Baudouin et al., 2002), no biomarker exists for 
the ocular surface in SJS-TEN and SCORTEN has been shown not to predict ocular 
sequelae  (Morales et al., 2010).  
 
The approach to managing systemic disease has classically been supportive and 
approaches including the use of intravenous immunoglobulin (ivIg) and systemic 
steroids have been controversial because of fears regarding systemic infection 
(Halebian and Shires, 1989), although recent data has indicated a role in improving 
visual outcome (Araki et al., 2009) and early, aggressive intervention by 
ophthalmologists may help prevent blinding sequelae of the disease (Fu et al., 2010). 
Intensive topical lubrication, steroids and autologous serum drops may all play a role 
in the management of dry eye and ocular surface inflammation, (Aragona et al., 
2002, Noble et al., 2004, Sotozono et al., 2009) but critically early use of amniotic 
membrane transplantation for acute SJS-TEN has been advocated to minimise 
ocular morbidity (John et al., 2002, Shay et al., 2010, Gregory, 2011).  
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1.8 Mucous Membrane Pemphigoid (MMP) 
 
1.8.1 Aetiology and Pathogenesis of MMP 
 
The first international consensus statement defines MMP as “a group of putative 
autoimmune, chronic inflammatory, subepithelial blistering diseases predominantly 
affecting the mucous membranes that is characterized by linear deposition of IgG, 
IgA, or C3 along the epithelial basement zone (BMZ)” (Chan et al., 2002). 
 
The aetiology of OcMMP remains unclear but it is a Type II hypersensitivity disorder. 
Genetically susceptible individuals, exposed to an unknown environmental trigger, 
develop autoantibodies that are directed against the basement membrane zone 
(BMZ). In turn this leads to the deposition of complement and an inflammatory 
infiltrate leading to fibrosis (cicatrisation) along the BMZ (Figure 1.7).  
 
 
 
 
 
 
 
 
 
Figure 1.7: Venn diagram showing the overlap between autoimmunity, inflammation and 
fibrosis (cicatrisation). 
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1.8.2 Antibodies in MMP 
 
The precipitant for anti-BMZ antibodies is currently unknown although the HLA-
DQB1*0301 allele is more common in MMP patients, and has been linked to T cell 
recognition of BMZ antigens, resulting in B cells producing BMZ-specific auto-
antibodies (Setterfield et al., 2001, Zakka et al., 2011). This association was also 
found in association with Bullous Pemphigoid (BP) (Delgado et al 1996). A linear 
deposition of anti-BMZ antibodies is seen in immunofluorescent studies (Figure 1.8). 
 
 
 
 
 
 
Figure 1.8: Immunofluorescence in MMP. Panel A is a schematic representation of the conjunctival 
epithelium (Ep); Basement Membrane Zone (BMZ) including its lamina lucida (LL) and lamina densa 
(LD); and the Stroma (St). Desmosomes (Dm) hold epithelial cells together and hemidesmosomes 
(Hd) anchor the epithelial cells to the underlying matrix. The BMZ is anchored to the underlying stroma 
by collagen fibres (Co) and anchoring filaments (Af). Panels B and C show sequential histological 
sections demonstrating subepithelial blistering (*) of the conjunctival BMZ and linear staining by anti-
BMZ antibodies (arrowed) on direct immunofluorescence (DIF). 
 
Numerous BMZ antigens have been identified as targets for immunoglobulins in 
MMP (Challacombe et al., 2001, Chan et al., 2002) (Figure 1.3, Table 1.5). The 
principal targets associated with MMP are β4 (Zakka et al., 2011) and BP180 within 
the hemidesmosomes but the major disruption has been identified as taking place in 
the lamina lucida (Challacombe et al., 2001, Wozniak and Kowalewski, 2005). The 
passive transfer of anti-mouse Laminin 5 antibodies (found in up to 5% of patients 
with MMP) raised in rabbits induces murine subepidermal blisters in the neonatal 
A B C 
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period (Lazarova et al., 1996). Furthermore, this results in increased circulating anti-
BMZ antibodies in BALB/c mice, independent of C3 complement (another hallmark of 
the disease) (Lazarova et al., 2001). The results of these studies should be 
interpreted with some caution in the context of ocular disease however, as the 
primary outcome was evidence of dermal blistering, a minor feature in human 
disease, and no clinical evidence of ocular pathology was assessed. Indeed, while 
microscopic evidence of blistering takes place this is not seen at a clinical level. 
 
 
 
 
 
 
 
 
From (Challacombe et al., 2001, Chan et al., 2002)  
Table 1.5: BMZ antigens/epitopes targeted in MMP 
 
 
A perilesional biopsy of affected tissue (e.g. conjunctiva or oral mucosa) for Direct 
Immunofluorescent (DIF) evidence of linear IgG, IgA or C3 along the BMZ supports 
clinical evidence of MMP. IgG1 and IgG4 have been identified as the dominant 
isotypes, the former associated with complement deposition (Bernard et al., 1991). 
Histological exclusion of malignancy is required specifically for similar cases before 
making the diagnosis. The Consensus statement declared that immunofluorescent 
evidence of anti-BMZ antibodies was a mandatory requirement for the diagnosis of 
Antigen/Epitope Location and Characteristic 
Epiligrin (subunit of Laminin 5) Ligand for α6β4 integrin 
Bullous Pemphigoid Antigen 1 
(BP1) or BP230  
Role in hemidesmosomal assembly and formation. 
Located in inner plate of hemidesmosomes (Hd) 
Bullous Pemphigoid Antigen 2 
(BP2) or BP180 
Transmembrane molecule and part of Hd anchoring 
filament complex 
α6 integrin Heterodimeric molecules associated with Hd 
Heterodimeric molecules associated with Hd β4 integrin 
Laminin 5 Adhesion molecule associated with anchoring 
filaments in the lamina lucida and densa 
Collagen VII Fibro-reticularis 
45kDa protein Implicated in pure ocular disease (identity unclear) 
168kDa protein Implicated in pure oral disease (identity unclear) 
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MMP. However, there is a large subset (14-40%) in whom DIF is negative (Thorne et 
al., 2004, Bernauer et al., 1994), these patients have an identical clinical disease 
phenotype and progression pattern, to those patients who are DIF positive (Saw, 
2008). Failure to recognise the existence of this subset can result in delays in 
diagnosis and treatment in those who potentially have severe blinding disease. 
Furthermore, the linear deposition along the BMZ by antibodies (Figure 1.8) is also 
seen in BP, linear IgA disease and Epidermolysis Bullosa (EB) (Chan et al., 2002) 
 
Indirect Immunofluorescence (IIF) can also be employed to detect circulating anti-
BMZ antibodies (Ab) in MMP. Although there is evidence of circulating anti-BMZ Ab 
binding to (healthy) conjunctiva correlating to conjunctival DIF in ocMMP (Leonard et 
al., 1988), difficulty in handling and lack of availability of local tissue confines 
substrate for IIF to skin or monkey oesophagus (Wojnarowska and Briggaman, 
1990). Sensitivity is increased however by exposure of antigens in the basement 
membrane by splitting skin tissue with salt (Woodley et al., 1983).  
 
Although circulating anti-BMZ Ab correlate with disease activity (Setterfield et al., 
1999), detection by IIF using salt-split skin can be insensitive and as low as 50% 
(Chan, 2001). Furthermore, the technique is not tissue specific and there is no 
correlation between circulating antibodies and prognosis (Chan et al., 2002). There 
are also some ocular patients who are IIF positive and DIF negative, indicating that a 
more sensitive IIF test could not only provide an improved diagnostic tool for MMP, 
but also inform the Consensus criteria where IIF is not an absolute requirement 
(Chan et al., 2002).   
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1.8.3 Inflammation in MMP 
 
The inflammatory process in OcMMP is manifest clinically as conjunctival 
inflammation. The detailed cellular infiltrate and inflammatory microenvironment in 
MMP, particularly in clinically involved and seemingly uninvolved mucous 
membranes is not fully understood and little progress has taken place in recent years 
(Bernauer et al., 1993a, Rice and Foster, 1990, Sacks et al., 1989). Although 
numerous in vitro and ex vivo studies have been undertaken, a major limitation is 
access to tissue due to the possibility of precipitating or aggravating disease (Chan et 
al., 2002). Material is often restricted to surplus conjunctiva from diagnostic biopsies 
and cellular phenotyping and quantification has been limited to histological sections 
with immunohistochemistry.  
 
In the presence of clinically defined minimal inflammation, there is evidence for a 
predominantly T cell infiltration of the conjunctival stroma (with a CD4:CD8 ratio of 
0.5) (Bernauer et al., 1993a, Rice and Foster, 1990). In severe conjunctival 
inflammation however there is a 3-fold increase in neutrophils and dendritic cells 
compared to controls, a 2-fold increase in macrophages and an altered CD4:CD8 
ratio to 1.0 (Bernauer et al., 1993a, Rice and Foster, 1990).  
 
Neutrophils were found to be the dominant infiltrate in the conjunctival epithelium in 
OcMMP compared to healthy controls. Furthermore, the neutrophil infiltrate 
increased with the degree of conjunctival inflammation with fewer cells seen in 
chronic, uninflamed eyes, but more than in healthy participants (Bernauer et al., 
1993a). Another smaller study also demonstrated the presence of neutrophils in 
clinically white eyes (n=5/6) (Rice and Foster, 1990).  
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As outlined in section 1.3.1, neutrophils normally exert an immediate innate 
response. Neutrophil removal relies, among other factors, on apoptosis and other 
phagocytic cells such as macrophages (Bratton and Henson, 2011). Given the short 
life span of neutrophils, a process is required to maintain turnover albeit at a lower 
level in more chronic states. In other chronic inflammatory diseases, such as the joint 
in Rheumatoid Arthritis, a persistent infiltrate with neutrophils is evident (Wright et al., 
2010). Autoantibodies are able to activate the classical complement cascade, which 
in turn recruit neutrophils.  
 
Activated neutrophils not only destroy pathogens via their azurophilic granules but 
also have the potential to cause collateral tissue damage. They also have a role in 
modulating immune response and contribute to an alteration in their own removal 
through apoptosis, but also release pro-inflammatory cytokines such as TNF-α, 
promoting an inflammatory cellular infiltrate (Witko-Sarsat et al., 2011). Like many 
auto-inflammatory and autoimmune diseases though, the trigger in OcMMP has not 
been established. It is possible that the presence of a persistent inflammatory 
infiltrate therefore contributes to the on-going damage seen in OcMMP. 
 
Our understanding of the site of production and role of inflammatory cytokines in the 
pathogenesis is also incomplete. Elevation of IL-1, Th1 cytokines such as IL-2, Th2 
cytokines such as IL-4 and IL-5, inflammatory cytokines such as TNFα and a 
reduction in IL-6 have been demonstrated (Bernauer et al., 1993b, Lee et al., 1993, 
Caproni et al., 2003, Letko et al., 2002, Saw et al., 2009a) (Figure 1.9) but data has 
been confined to circulating serum or tissue sections (Bernauer et al., 1993b, 
Razzaque et al., 2004, Razzaque et al., 2003a). Longitudinal research has therefore 
Chapter 1  Introduction 
 
43 
been extremely challenging. This has been compounded by a paucity of animal 
models.  In order to quantify inflammation in humans, alternative non- invasive tissue 
assessment is required.  
 
1.8.4 Cicatrisation in MMP 
 
Inflammation results in the deposition of sub-conjunctival matrix collagen and 
progressive cicatrisation. The mechanism underlying this process remains 
unresolved (Elder et al., 1997, Razzaque et al., 2003b). Pro-fibrotic cytokines 
involved in wound healing such as TGF-β, Connective Tissue Growth Factor (CTGF) 
and Platelet Derived Growth Factor (PDGF) are elevated in MMP (Bernauer et al., 
1993b). TGF-β’s role as a growth factor, stimulating collagen deposition by 
fibroblasts, is thought to be maximal during the acute stages of diseases. 
Furthermore TGF-β mRNA is up regulated in conjunctival fibroblasts during acute 
inflammation in MMP (Elder, 1997b).   
 
There is also an increase in Heat Shock Protein 47 (HSP 47), a cytokine implicated 
in fibrogenesis and increase in Macrophage Migration Inhibitory Factor (MIF) 
(Razzaque et al., 2003a, Razzaque et al., 2004). More recently IL-13 has been 
demonstrated as a pro-fibrotic cytokine found in the conjunctiva of individuals with 
OcMMP. Produced by T cells, it has been demonstrated to induce collagen 
contraction and the authors suggest that this cytokine may contribute to cross-talk 
with fibroblast by up-regulation of co-stimulatory molecules CD80, CD40, and CD154 
on fibroblasts in culture (Saw et al., 2009b). 
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As yet the pro-fibrotic cytokines exact role in the maintenance or resolution of the 
condition are unknown. If the scarring or fibrotic process is maximal during acute 
inflammation, it is not surprising that historically it was thought that only a small group 
of patients demonstrated progression of disease in an apparently quiescent eye 
(Elder, 1997b). Other studies have shown however that while progression can occur 
in 50% of patients in the presence of mild or moderate inflammation, 50% progressed 
without clinically apparent conjunctival inflammation (Saw et al., 2008). This has 
been termed ‘white inflammation’ (Elder, 1997b). 
 
Indeed, the cellular studies undertaken previously have shown a cellular infiltrate in 
the presence of minimal inflammation (Bernauer et al., 1993a, Sacks et al., 1989). 
Does this suggest that clinically identifiable conjunctival inflammation does not 
correlate with true underlying inflammation? There is evidence from other diseases 
that neutrophils may play a role in the fibrotic process, including pulmonary fibrosis 
and cryptogenic fibrosing alveolitis (CFA) (Chua et al., 2007, Hara et al., 2009, 
Obayashi et al., 1997).  
 
Understanding of the pathogenesis of OcMMP is currently incomplete. A summary 
diagram based on current understanding is shown in Figure 1.9. 
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Figure 1.9: Summary of understanding of the pathogenesis of ocMMP. This 
cartoon illustrates how anti-BMZ antibodies (Ab) are directed against the conjunctival 
BMZ. This leads to inflammation and chemoattraction including the recruitment of 
neutrophils (which may release proteinases and reactive oxygen species (ROS), 
macrophages, platelets, dendritic cells and lymphocytes (B cells and T cells although 
the phenotypes are poorly defined) and plasma cells. An increased expression of 
cytokines IL-1, IL-2, IL-4, IL-5 and TNFα are thought to increase the inflammatory 
response, recruit T and B lymphocytes and activate macrophages and fibroblasts. An 
elevation of pro-fibrotic Transforming Growth Factor-β (TGF-β), Connective Tissue 
Growth Factor (CTGF), IL-13 and Platelet Derived Growth Factor (PDGF) contribute 
to the deposition of extracellular matrix (ECM) collagen and scarring. Heat Shock 
Protein 47 (HSP47) and Macrophage Inhibitory Factor (MIF) have also been 
implicated in the fibrotic process, while IL-13 derived from T-cells induce collagen 
contraction and potential fibroblast-T cell cross-talk. The roles of Matrix 
Metalloproteinases (MMPs), their inhibitors (TIMPs), Vascular Endothelial Growth 
Factor (VEGF) and Fibroblast Growth Factors (FGFs) have yet to be defined. 
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1.8.5 Clinical Features and Challenges in MMP 
 
Although the skin is involved in MMP, this is primarily a disease affecting the mucous 
membranes with only a mild cutaneous phenotype. The oral mucosa is the most 
commonly affected site and the nasal, pharyngeal, anogenital, laryngeal and 
oesophageal surfaces are affected in descending order. Involvement of the 
oesophagus and airways are potentially life threatening and are therefore defined as 
‘high risk’ (Chan et al., 2002). Whereas symptoms of disease activity are common in 
oral disease, the scarring sequelae seen in other tissues are not (Higgins et al., 
2006) (Mobini et al., 1998). Development of ocular disease in those with pure oral 
involvement can occur at a later date and in one series 37% of patients developed 
both ocular and oral disease (Higgins et al., 2006). 
 
The ocular (conjunctival) surface is the second most common site to be involved. The 
ocular phenotype of MMP (OcMMP) is a bilateral sight-threatening disorder 
characterised by clinical conjunctival inflammation, progressive conjunctival fibrosis 
(cicatrisation, manifest in part as adhesions called symblephara) and eventual 
surface failure sequelae including corneal vascularisation and scarring. This process 
leads to destruction of goblet cells resulting in severe dry eyes and cicatricial 
entropion causing mechanical abrasion of the cornea. Ocular features are therefore 
regarded as “high risk” (Chan et al., 2002). 
 
MMP usually presents between 30 and 90 years of age, with a peak age of onset 
after 70 years (Foster, 1986, Mondino and Brown, 1981, Chan et al., 2002) with 
disease progression being more aggressive in younger patients (Rauz et al., 2005a). 
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The disease is also associated with other autoimmune diseases such as Rheumatoid 
Arthritis. Symptoms of disease in the early stages are those of non-specific chronic 
conjunctivitis and may include conjunctival irritation, hyperaemia and discharge 
(Wright, 1986). The course of ocular disease is variable and determining disease 
activity and progression represents a major challenge (Mondino and Brown, 1983). 
Patients are often diagnosed at an advanced stage of disease when signs are 
abundant (Miserocchi et al., 2002, Rogers et al., 1982) but the duration of symptoms 
at presentation is variable, ranging from 1 month to 25 years (Rauz et al., 2005a, 
Thorne et al., 2004, Thorne et al., 2008, Saw et al., 2008). There is also evidence 
that disease progression is more rapid in the context of manifest conjunctival 
inflammation (Mondino et al., 1979). 
 
In the United Kingdom (UK) streams of referral are to tertiary services specialising in 
the management of OcMMP from other ophthalmologists, other specialists caring for 
patients with MMP or directly from the primary care service such as general (family) 
practitioners and optometrists. There is limited information regarding the differences 
in duration of symptoms, disease activity, stage and progression in those who 
present to specialised services.  
 
As in SJS-TEN, the distinction between acute and chronic disease has not been fully 
established. Bernauer and colleagues suggested that acute disease was less than 12 
months duration (Bernauer et al., 1993a) although the actual duration of symptoms 
before medical intervention may actually be far longer than this, not least because of 
the non-specific nature of symptoms. 
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1.8.6 Clinical Assessment of Disease Activity in OcMMP 
 
At present, disease activity is based upon the extent of clinically identifiable 
conjunctival inflammation (1) absent, (2) mild, (3) moderate, (4) severe (which 
includes inflammation in all 4 quadrants, limbitis and conjunctival ulceration) (Elder, 
1997c) (Figure 1.10). Limbitis is associated with a greater risk of progression (Elder 
et al., 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Clinical disease activity in OcMMP. This is determined by clinically identifiable 
conjunctival inflammation. The picture denoting severe clinical inflammation also demonstrates 
limbitis, associated with a greater risk of progression. 
 
 
 
 
 
 
 
 
Absent Moderate 
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1.8.7 Clinical Assessment of Disease Damage in OcMMP 
 
Fibrotic damage is based either on the extent of conjunctival scarring or the presence 
of symblephara. Different staging systems have been described including the ocular 
staging described by Mondino and Brown ([I] 0%-25%, [II] 25%-50%, [III] 50%-75%; 
[IV] 75%-100% loss of inferior fornix) (Mondino and Brown, 1981) and Foster ([I] 
subconjunctival scarring and fibrosis, [II] fornix foreshortening of any degree, [III] 
presence of any degree of symblepharon [IV] end-stage cicatricial pemphigoid) 
(Foster, 1986). Conjunctival blisters are rarely seen in ocular disease (Saw et al., 
2009b).  
 
Sequential documentation of forniceal foreshortening is important in assessing stage 
and progression of disease (defined as increase in either Mondino or Foster stage) 
(Tauber et al., 1992, Mondino and Brown, 1981, Foster, 1986). Clinical 
documentation presents challenges including reliance on the subjective evaluation of 
subepithelial fibrosis, extent of symblepharon formation and grading of percentage 
shrinkage of the lower fornix (Foster, 1986, Mondino and Brown, 1983). A 
modification encompassing both systems, was described by Tauber and colleagues, 
who proposed that counting the number of and percentage horizontal obliteration of 
the lower fornix by symblepharon could potentially improve detection of disease 
progression (Figure 1.11).  (Tauber et al., 1992). This scale, while limited by its lack 
of a numerical score, has the advantage of detecting more subtle changes compared 
to the 4-point ordinal scales described by Mondino and Foster in isolation. In order 
for the scales, in particular the proposed staging described by Tauber, to be effective 
then accurate documentation in the clinical setting is vital. 
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Lower fornix shortening is frequently documented either subjectively or semi-
objectively by utilising a slit-light beam; whereas the degree of upper forniceal 
obliteration is seldom quantified. Measurement of the fornices using devices such as 
the ‘fornicometer’ have been described, but their current design limits upper fornix 
measurement (Schwab et al., 1992, Kawakita et al., 2008). Specifically, the depth 
and curvature of the upper fornix dictates the requirement of a FDM that is sufficiently 
long and curved to enable comfortable assessment of the upper fornix. An FDM 
however offers the possibility of measuring fornix shrinkage in mm, allowing greater 
flexibility in determining progression compared to categorising change by order (0-
25%, 25-50% etc.) and potential to measure symblephara. 
 
Other problems associated with current documentation strategies relate to confining 
activity and damage indices to the conjunctiva when many of the problems relate to 
dry eye, entropion formation, limitation of ocular movements and the final, potentially 
blinding outcome of reduction in clarity or destruction of the optically clear cornea.  
 
Quantification of corneal damage has been attempted in the context of SJS-TEN. A 
scoring system for chronic SJS-TEN (defined as >12 months since disease onset) 
was developed by Sotozono and colleagues (Sotozono et al., 2007). This took the 
form of a 39-point scale, assessing criteria involving the eyelid, conjunctiva, tear film 
and cornea. In particular the assessment of damage to the cornea including 
neovascularisation (by extent and central encroachment) and evidence of corneal 
opacification (scarring, conjunctivalisation and keratinisation) was considered. This 
study has shown how enumerating corneal damage is possible in the context of 
PCC.  
Figure 1.11: Disease damage according to Tauber’s proposed staging systems 
(Tauber et al 1992). This incorporates the staging systems of Mondino and Foster and 
quantifies the percentage horizontal involvement by and number of symblephara.  
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Staging Characteristics Description 
I Subconjunctival 
scarring & fibrosis 
II Fornix 
foreshortening 
% loss of inferior vertical 
fornix depth 
a 0-25% 
b 25-50% 
c 50-75% 
d 75-100% 
III Presence of 
symblephara 
% horizontal involvement 
of inferior fornix 
a 0-25% 
b 25-50% 
c 50-75% 
d 75-100% 
IV Ankyloblepharon,  
frozen globe 
Symblephara  
Stage 3 d   
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1.8.8 Therapeutic Intervention in OcMMP 
 
The aim of therapy in OcMMP is to remove correctable factors that cause ocular 
surface inflammation (including tear substitution for dry eyes, prevention of keratitis, 
surgical correction of trichiasis and cicatricial entropion) and initiation of systemic 
immunosuppression to control inflammation secondary to disease and leading to 
fibrosis; prophylaxis of corneal exposure and ulceration; improvement in vision 
(through contact lens use, cataract surgery, corneal transplantation, ocular surface 
reconstruction and keratoprosthesis) (Saw and Dart, 2008).  
 
Although topical corticosteroids can improve comfort they do not prevent cicatrisation 
(Foster, 1986). Therefore, in all but mild disease, 75% of patients require 
immunosuppression to control inflammation, limit disease progression and facilitate 
surgery (Elder et al., 1996). Without systemic immunosuppression, the disease 
progresses to conjunctival scarring and blindness (Miserocchi et al., 2002). 
Progression by Mondino staging occurred in 40-50% of stage I, 62-75% stage II and 
73-77% stage III disease in the absence of systemic immunosuppression in one 
study (Mondino and Brown, 1983, Mondino, 1990).  
 
The approach to systemic immunosuppression can be summarised by a stepladder 
approach, dependent on disease severity, outlined in Figure 1.12 (Rauz et al., 
2005a, Saw et al., 2008). Although systemic immunosuppression can limit 
progression, halting the disease completely can be a challenge. Disease progression 
can occur despite systemic immunosuppression in 25-75% of patients (by Mondino 
staging) (Mondino and Brown, 1983, Mondino, 1990, Elder et al., 1996, Saw et al., 
2008) and 10-20% (according to Foster staging) (Miserocchi et al., 2002, Thorne et 
Chapter 1  Introduction 
 
53 
al., 2008). Control of clinically identifiable conjunctival inflammation is achieved in 70-
90% patients (Miserocchi et al., 2002, Thorne et al., 2008) but unfortunately, there is 
also a disease subset that either is completely refractory to conventional immuno- 
suppression or relapses despite initial success (Thorne et al., 2008).  
 
Alternatively the primary use of the alkylating agent Cyclophosphamide has been 
advocated (Thorne et al., 2008) with good success but the use of Cyclophosphamide 
is limited because of the risk of haemorrhagic cystitis and neoplastic changes in the 
bladder (Jabs et al., 2000). A few isolated case reports indicate that ‘biological’ 
agents, such as rituximab (anti-CD20) or infliximab (anti-TNFα), may be beneficial in 
some of these patients, but as randomised trials are lacking, funding for such 
treatment in the United Kingdom prohibits regular use (Segura et al., 2007, 
Canizares et al., 2006, Heffernan and Bentley, 2006, John et al., 2007, Taverna et 
al., 2007, Ross et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Immunosuppressive Strategies for OcMMP (based on Rauz et al 
Ophthalmology 2005). Step-up treatment with agents having the fewest side effects 
were used for ocular mucous membrane pemphigoid. Disease activity (mild, 
moderate or severe) is used to guide therapy. Dapsone (25-50mg twice a day), 
Sulphapyridine (500mg twice a day) was used for mild inflammation; Azathioprine 
(1-2.5mg/kg/per day) or Mycophenolate mofetil (500-1000mg twice a day if 
intolerant to Azathioprine) were added or substituted for recalcitrant disease. Severe 
inflammatory disease was treated with Cyclophosphamide (1-2mg/kg/per day) and 
adjuvant Prednisolone (1mg/kg/per day with or without a maximum of 3 
supplementary loading doses of 1g intravenous Methylprednisolone preceding oral 
therapy) for up to 3 months until the optimal effects of Cyclophosphamide had taken 
effect.  Refractory disease is managed through intravenous immunoglobulin or 
biologics e.g. anti-CD 20 (Rituximab) or anti TNF-α therapy. 
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1.9 Detecting Cellular Changes in the Ocular Surface  
 
Gaining access to mucosal tissue in non-ocular or oral sites present challenges 
because of the need to employ endoscopic techniques in order to lavage fluid or 
biopsy. This is clearly evident in the case of the gastro-intestinal and respiratory 
tracts. For human translational work, surplus diagnostic tissue has therefore been an 
invaluable source of material. Despite the clear advantage of tissue access however, 
as in OcMMP, repeated sampling is precluded because of the risk of precipitating 
further scarring. This has certainly limited our ability to take samples for research 
purposes. Two developments have offered a potential means of non-invasively 
determining human cell populations in both health and disease – ocular surface 
impression cytology (OSIC) and multi-colour flow cytometry. 
 
OSIC is a technique that has been available since the late 1970s. First described by 
Egbert et al, the ability to use cellulose acetate filters to collect bulbar conjunctival 
surface cells allowed fixation, staining and examination under a microscope (Egbert 
et al., 1977), and it has been employed since for studying ocular surface disease 
(Nelson, 1988).  
 
OSIC is a technique that facilitates the removal of 2-3 layers of superficial cells 
although visualisation of the basal epithelium through multiple impression of the 
same area can be achieved (Singh et al., 2005). Conjunctival OSIC has been used 
for monitoring ocular surface health in contact lens wearers and evaluating ocular 
surface neoplasia (Knop and Brewitt, 1992, Nolan et al., 1994, Tole et al., 2001). 
Perhaps its widest application is the use of the technique for the quantification of dry 
eye severity through determination of goblet cell density and changes to the epithelial 
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cell morphology (Nelson, 1988, Tseng, 1985, Adams et al., 1988). OSIC has also 
been used to determine analysis of the inflammatory microenvironment in related 
conditions such as Sjögren’s syndrome and other dry eye states (Baudouin et al., 
2002).  
 
Flow cytometry is a technique that allows the quantification and characterisation of 
cell populations based on their size and granularity and by employing fluorochrome-
conjugated monoclonal antibodies to cell-surface or intra-cellular peptides. It utilises 
a high-speed cell analyser and lasers: (e.g. 488nm, 635nm and 405 nm wavelengths) 
which in turn excite cells passing through the column of a fluidic system at high 
speed. As cells pass through a sheath flow, lasers excite the fluorochromes 
conjugated to the labelled cells and the light emitted are detected by photomultiplier 
tubes. Cells can be detected by either their size or granularity (termed forward and 
side scatter) and/or by the emission of the cellular fluorochromes (Loken and Stall, 
1982, Maftah et al., 1993). 
 
Baudouin and colleagues pioneered the use of flow cytometry on conjunctival 
epithelial cells recovered by OSIC (Baudouin et al., 1997). The superior unexposed 
bulbar conjunctiva has been advocated as the most suitable location for conjunctival 
OSIC, in particular because of variation in inflammation in exposed areas of the 
ocular surface (Brignole-Baudouin et al., 2004). They describe a simple means of 
recovering cells from the impression membrane by using a pipette tip to gently 
agitate cells from membranes stored in preservative.  
 
Chapter 1  Introduction 
 
57 
Flow cytometry technology has evolved rapidly in the last 15 years and multi-colour 
panels can be designed to accommodate numerous cell surface markers (Perfetto et 
al., 2004). This allows a more detailed phenotype to be explored both in terms of cell 
surface marking and also intra-cellular staining for cytokines and other proteins.  
 
By combining multiple markers, T cells for example, can be discriminated not only by 
the presence of CD3, CD4 and CD8 but according to the T cell receptor subtype e.g. 
TCRαβ or TCRγδ, the presence or absence of common markers through CD56 (NKT 
cells express CD3 and CD56) and whether they are antigen experienced by the 
presence of CD45RO.  
 
Innate cell markers such as CD14 (LPS receptor present on myelomonocytic cells 
such as macrophages), CD16 (FcγRIII receptor present on neutrophils, macrophages 
and Natural Killer (NK) cells) can be combined with additional markers e.g. CD11b 
(present on myeloid cells and NK cells) in discriminating granulocytes such as 
neutrophils from e.g. basophils and eosinophils (Gopinath and Nutman, 1997). The 
pan-leukocyte marker CD45, can also be used to discriminate lymphocytes, 
monocytes and eosinophils by the presence of CD45HIGH expression compared to 
CD45INTERMEDIATE (INT) expression seen on neutrophils (Stelzer et al., 1993, Kern et al., 
2000). This affords greater flexibility and accuracy in characterising the conjunctival 
epithelial leukocyte populations – in both health and disease. 
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1.10 My hypothesis and its context 
 
The most common acquired ocular immunobullous disease is OcMMP. The binding 
of autoantibodies to the BMZ and the deposition of complement, with associated 
inflammatory infiltration is recognised, but there is no means of non-invasively 
detecting this process. Clinicians currently rely upon subjective clinical assessment of 
disease activity to monitor clinically identifiable inflammation and to guide 
immunosuppressive therapy. These issues are compounded by the further lack of 
understanding of healthy ocular surface immune regulation and the ability to 
accurately quantify the conjunctival scarring process. Unfortunately the disease may 
progress in the absence of conjunctivitis leaving the clinician in an invidious position 
and wondering whether a self-perpetuating fibrotic process occurs, or in fact that sub-
clinical inflammation does take place and results in conjunctival fibrosis.  
 
My hypothesis therefore is that progressive fibrosis in OcMMP, occurring in the 
apparent absence of clinical inflammation, is driven by underlying inflammatory 
processes. 
 
1.11 Aims of the thesis 
 
The aim of my thesis is to determine the detailed cellular profile in OcMMP by non-
invasive conjunctival OSIC and multi-colour flow cytometry by undertaking (i) cross-
sectional and (ii) longitudinal comparisons with healthy volunteers and those with 
other PCC and determine the relationship between clinical parameters and cellular 
profiles, in particular the inflammatory profile in a clinically quiescent eye. 
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1.12 Objectives for the thesis 
 
In order to address my hypothesis I have sought to undertake three principle 
objectives during my thesis: 
 
Part 1: Measuring clinical parameters in acquired ocular immunobullous 
disease  
1. Defining the clinical phenotype of patients with OcMMP  
2. Determining an objective method for recording the conjunctival cicatricial process 
3. Determining an optimal system for accurately phenotyping disease 
 
Part 2: Characterising the healthy conjunctival epithelial leukocyte population 
1. Optimisation of mucous membrane cellular profiles detection by OSIC 
2. Defining resident conjunctival leukocyte populations 
3. Age-related changes in the healthy human conjunctival epithelium 
4. Effector function of the dominant conjunctival epithelial CD8+ T cell population 
 
Part 3: Characterising the conjunctival epithelial leukocyte population in 
acquired ocular immunobullous disease 
 
Determine whether inflammatory cellular profiles differ in 
1. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) 
2. Ocular Mucous Membrane Pemphigoid (OcMMP) in clinically inflamed and 
uninflamed eyes 
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2.1 Clinical Studies 
 
Details of the recruitment of patients with PCC such as MMP, SJS-TEN and PSS and 
healthy participants are outlined in this chapter. Study-specific details are outlined in 
the relevant chapters (3, 4 and 5). 
 
2.1.2 Ethical Approval 
 
Clinical data collection and patient sampling were undertaken following ethical 
approval in accordance with the Declaration of Helsinki (London MREC: National 
Survey Of Cicatrising Conjunctivitis and Stevens−Johnson Syndrome/Toxic 
Epidermal Necrolysis In The UK 07/MRE02/41 and Birmingham East, North and 
Solihull Ethics Committee: Inflammation in Ocular Surface Disease IOSD 
08/H1206/165 (UKCRN number 7448).  
 
2.1.3 Study Recruitment 
 
Patients with disease (MMP, SJS-TEN or PSS) were identified either at first 
presentation to the ocular surface disease (OSD) clinic (Birmingham and Midland 
Eye Centre - BMEC) or from existing cohorts (BMEC; University Hospital Birmingham 
– UHB and Moorfields Eye Hospital – MEH) utilising electronic medical databases.  
 
Diagnosis of OcMMP was based on clinical findings characteristic for the disease, 
namely progressive conjunctival cicatrisation in the absence of other causes of 
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conjunctival scarring. If patients did not have a previous positive tissue biopsy, a 
confirmatory perilesional conjunctival and/or oral mucosal biopsy for direct 
immunofluorescence was undertaken. A positive result was defined as linear 
deposition of IgG, A or complement (C3) along the basement membrane zone (Chan 
et al., 2002). If typical clinical characteristics were evident, a negative result did not 
exclude the diagnosis (Saw et al., 2008, Ahmed et al., 2004, Bernauer et al., 1994, 
Tauber, 2008) because of the recognition of a subgroup of ocular patients who have 
ocular features consistent with OcMMP but have a negative biopsy (Bernauer et al., 
1994, Thorne et al., 2004). In accordance with the first international consensus, a 
positive indirect immunofluorescence was not an essential requirement for diagnosis 
(Chan et al., 2002). 
 
Diagnosis of SJS and TEN was based on the criteria described by Bastuji-Garin and 
made by a consultant dermatologist. Patients were classified as having SJS if the 
maximal percentage of denuded skin was below 10%; SJS/TEN overlap syndrome 
between 10 and 30%; and TEN above 30% (Bastuji-Garin et al., 1993). 
 
Diagnosis of PSS was based on the revised American–European Consensus Group 
(AECG) criteria (Vitali et al., 2002). Briefly, this included a requirement to fulfil 4 out 
of 6 criteria if items IV or VI were positive or the presence of any 3 of the 4 objective 
criteria items (III, IV, V, VI) where I: Ocular symptoms, II: Oral symptoms, III: ocular 
signs, IV: Histopathology, V: Salivary gland involvement and VI: presence of serum 
Anti Ro (SSA) or La (SSB) antibodies. Ocular symptoms included (i) Daily, persistent, 
troublesome dry eyes for more than 3 months (ii) Recurrent sensation of sand or 
gravel in the eyes (iii) Use of tear substitutes more than 3 times a day. Ocular signs 
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included objective evidence of ocular involvement defined as a positive result for at 
least one of the following two tests: (i) Schirmer’s I test, performed without 
anaesthesia (<5 mm in 5 minutes) or  (ii) Corneal Rose Bengal/Lissamine Green 
staining. 
 
Healthy volunteers were defined as those with no history or clinical evidence of 
ocular, systemic inflammatory or autoimmune disease (including dry eye) (Behrens et 
al., 2006, 2007), contact-lens wear, previous ocular surgery, cataract surgery within 3 
months (unless stated - see section 5.2.1) or use of topical ophthalmic medication.  
 
2.1.4 Clinical Documentation 
 
The details of the clinical parameters recorded are outlined in Chapters 3 and 5. 
Where clinical examination took place, routine and validated assessments took place. 
Specific scoring systems are outlined within individual chapters. LogMAR visual 
acuity was assessed and tables converted to Snellen. Visual acuity (VA) was 
classified as good (6/6–6/18), or in accordance with the WHO definitions of ‘visual 
impairment’ (6/18–6/60), ‘severe visual impairment’ (6/60) and ‘blind’ (3/60). Details 
of the development of the Clinical Record Form (CRF) employed are outlined in 
Chapter 3. 
 
2.1.5 Databases 
 
A bespoke Filemaker Pro database was created (GPW and PJT) in order to store 
clinical linked-anonymised data in an electronic case record form (eCRF) (Filemaker 
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Pro v9.0, Santa Clara, California). At the time of recruitment, patient details and 
samples were given a linked-anonymised code. Details of patient research codes 
were stored on a database on the N3 secure Sandwell and West Birmingham NHS 
Trust SAN server. The anonymised eCRF data is stored on the University of 
Birmingham Active Directory Server.  Only anonymised data was shared between the 
two databases and only members of the clinical care had access to codes relating to 
the patients. 
 
2.1.6 Clinical Sampling 
 
Collection of conjunctival cells was undertaken with autoclaved synthetic membranes 
divided in two semi-circles (measuring 13 x 6.5mm2 each) (Brignole-Baudouin et al., 
2004). Millipore isopore polycarbonate (0.4µm membranes) (Fisher, Leicester, UK) or 
Supor 200 polyethersulfone filters (0.2µm membranes) (VWR, Lutterworth, UK) were 
applied following instillation of 0.4% Oxybuprocaine (as a topical anaesthetic).  
Conjunctival Ocular Surface Impression Cytology (OSIC) was performed with up to 
four semi-circle membranes per eye (equivalent to 2 full impressions) from the 
superior unexposed bulbar conjunctiva for 5-10 seconds using a sterile technique 
(Brignole-Baudouin et al., 2004, Brignole et al., 2000) and before the application of 
topical fluorescein drops for clinical assessment. Membranes were removed and 
placed in 1.5ml of RPMI 1640 (Sigma-Aldrich, Dorset, UK) with 10% Heat Inactivated 
Foetal Calf Serum (Sigma-Aldrich) in a sterile 5ml universal container.  
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2.2 Ex vivo experimentation 
 
General details of experimentation techniques are described in this chapter. Specific 
adaptations are described in the relevant results chapters. 
 
2.2.1 Haematoxylin and Eosin staining of OSIC membranes 
 
Identification of cells retained on impression cytology membranes were undertaken 
by Haematoxylin and Eosin staining. Briefly, membranes were fixed for 1 minute in 
95% methanol/5% glacial acetic acid and then rinsed in tap water. Staining with 
haematoxylin for 30 seconds followed by rinsing in tap water, incubation in tap water 
for 1 minute followed by a further rinse in tap water. Counterstaining with 1% 
aqueous Eosin for 5 seconds preceded dehydration through 2 stages of alcohol (70% 
for 30 seconds and 100% for 30 seconds). Membranes were cleared through 2 
changes of Histoclear (National Diagnostics, Hessle, UK) for 1 minute each and 
mounted face up with neutral mounting medium (DPX) (Clin-Tech Ltd., Surrey, UK) 
and a coverslip. 
 
Photography was undertaken with an Olympus BH1 light microscope and captured 
with PictureFrame 2.1 software (Optronics, California, USA 2004). 
 
2.2.2 Cell Recovery from OSIC 
 
Conjunctival epithelial cells collected by OSIC were recovered by gentle agitation 
with a sterile 1ml P1000 Gilson pipette tip for 1 minute unless stated. Cell 
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suspensions were transferred to a 1.5ml Eppendorf tube and centrifuged (400g for 5 
minutes). The supernatant was discarded, leaving 10 µl, which was re-suspended in 
a further 90 µl RPMI:10% HIFCS (to a total 100 µl) unless stated. Cells were placed 
in 96 well plates for flow-cytometric analysis. 
 
2.2.3 Preparation of Lysed Peripheral Blood 
 
Peripheral blood was collected in EDTA tubes and aliquoted at a volume of 1ml, 
centrifuged and re-suspended in 1:10 dilution of filter-sterilised red cell lysis buffer 
(8.29g NH4Cl (Sigma-Aldrich), 1g KHCO3 (Sigma-Aldrich) and 37.2 mg EDTA 
(Sigma-Aldrich) per litre dH20). After 5 minutes at room temperature, the suspension 
was diluted with up to 15ml RPMI to block further lysis. Following centrifugation, the 
pellet was re-suspended in Phosphate Buffered Solution (PBS; Oxoid, Cambridge, 
UK) at a concentration of 1x107 cells/ml and aliquoted at a volume of 100μl in to 
individual wells. 
 
2.2.4 Flow Cytometry 
 
Flow cytometry was undertaken with a Dako Cyan ADP High Performance flow 
cytometer (Beckman Coulter, High Wycombe, UK). Multi-colour cytometry 
compensation was performed using cells or compensation beads individually stained 
with each fluorochrome conjugated-antibody. Compensation circumvents spectral 
overlap by adjusting for false positives from other fluorochromes. This is achieved by 
setting compensation levels for one fluorochrome at a level commensurate with the 
background fluorescence of another e.g. PE-Cy7 anti-CD56 vs. PerCP Cy5.5 anti-
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CD4, the fluorescence intensity for the positive population of CD56 stained 
beads/cells is adjusted so that it is at the same median fluorescence as background 
(for the PerCP Cy5.5 channel).  
 
2.2.5 Antibody Cell Surface Marker Staining 
 
To characterise the cellular profile of the ocular surface, multi-colour flow cytometry 
panels were developed. These were titrated to determine the optimal concentrations. 
Each panel was applied to cells recovered from conjunctival impression cytology or 
from peripheral blood.  
 
100μl of cells were placed in to 96-well plates (with a cell count per well ranging from 
2x105—1x106 for PBMCs) or 20μl of positive and negative compensation beads. 
Cells were centrifuged for 4 minutes at 400g at 4°C, the supernatant removed and 
the 96-well plate gently vortexed. Cells were stained with surface marker antibodies 
(made up in 50μl at appropriate dilutions) and incubated on ice in the dark for 20 
minutes. 100μl of FACS buffer (PBS and 0.5% Bovine Serum Albumin (BSA; Sigma-
Aldrich) was added to each well prior to further centrifugation and removal of 
supernatant. Cells were re-suspended in 295μl of FACS buffer and 5μl counting 
beads (CALTAG/Invitrogen, Paisley, UK) (1002 beads/ μl) buffer prior to analysis. For 
dead cell exclusion, 30μl Sytox blue (Invitrogen, Paisley, UK) was added at a dilution 
of 1/800 to the FACS tubes and incubated for 5 minutes prior to running on the flow 
cytometer.   
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For healthy volunteers and patients with disease (Chapters 4 and 5) cell-surface 
fluorochrome-labelled monoclonal antibodies were employed in two panels; Panel 1 
mouse anti-human CD45RO (FITC), γδTCR (Phycoerythrin, PE), CD4 (PerCP Cy5.5), 
CD45 (Allophycocyanin, APC), CD3 (AlexaFluor 780) (Ebioscience, Hatfield, UK); 
CD8α (Pacific Orange) (Invitrogen, Paisley, UK); CD8β (PE Texas Red) (Beckman 
Coulter); CD56 (PE Cy7) (Biolegend, Cambridge, UK) and Panel 2 mouse anti-
human CD16 (FITC), CD45 (Allophycocyanin), CD14 (AlexaFluor 780)  
(Ebioscience); CD20 (Pacific Orange), CD19 (PE Texas Red) (Invitrogen); CD138 
(PerCP Cy5.5) (BD, Oxford, UK) and CD11b (PE Cy7) (Biolegend). These were 
titrated to determine the optimal concentrations.  
 
Appropriate panels were applied to cells recovered from conjunctival OSIC or 
peripheral blood.   
 
2.2.6 Intracellular Cytokine and Cytolytic Protein Staining  
 
For cytokine assays, conjunctival and lysed peripheral blood cells were stimulated 
with phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) and Ionomycin (Sigma-
Aldrich). Briefly, cells were incubated in 200μl containing PMA (250ng/ml), Ionomycin 
(250ng/ml) and Brefeldin A (Sigma-Aldrich) 2ug/ml for 3 hours at 37°C, 5% CO2. For 
cytolytic proteins 
 
A Live Dead fixable yellow dye (Invitrogen) was used to discriminate dead cells. Cells 
were suspended 100μl of 1:1000 Dye:DMSO for 30 minutes on ice in the dark.  
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For cytokine assays and cytolytic protein studies, surface marker antibodies in this 
panel were suspended in Fixation medium A (Fix & Perm, Invitrogen) under the same 
conditions as described for Antibody Cell Surface Marker Staining (Section 2.2.5).  
Intracellular antibodies and cytolytic protein antibodies were suspended in 
Permeabalisation medium B (Fix & Perm, Invitrogen) on ice in the dark for 20 
minutes before centrifugation and re-suspension as described.  
 
2.2.7 Transcription Factor Staining 
 
For the transcription factor FoxP3 cell surface marker staining was as described in 
2.2.5. An eBioscience staining buffer kit was employed for intra-cellular staining. 
Briefly, cells were suspended in Fix buffer on ice in the dark for 30 minutes before 
washing in PBS, fixing in Perm buffer and staining with rat serum and anti-FoxP3 
antibody. 
 
2.2.8 Viral peptide MHC-I Tetramer Staining 
 
Conjunctival and matched peripheral blood cells were incubated with pooled CMV or 
EBV peptide-MHC-Class I tetramers conjugated to APC as previously described by 
Khan et al (Khan et al., 2004). For donors of known CMV/EBV response and HLA 
type, the following HLA restriction/peptide sequence were employed: CMV - HLA-A1 
VTE, HLA-A1 YSE, HLA-A2 NLV, HLA-B7 RPH, HLA-B8 ELK, HLA-B8 QIK and EBV 
- HLA-A2 GLC, HLA-A2 YVL, HLA-B8 RAK and HLA-B8 FLR). A full table is listed in 
Table 2.1. Briefly, cells were incubated at room temperature for 20 minutes with 
pooled CMV or EBV tetramers prior to cell surface staining with anti-CD45 
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(Allophycocyanin), CD3 (AlexaFluor 780), CD8β (PE Texas Red) and CD56 (PE Cy7) 
(Biolegend) as described above (2.2.5).  
 
 
Viral Antigen HLA restriction Peptide Sequence Sequence location 
CMV 
IE-1 B8 QIKVRVDMV  88 –96  
B8 ELKRKMIYM 199 –207  
pp50 A1 VTEHDTLLY 245–253 
A1 YSEHPTFTSQY  363–373  
pp65 A2  NLVPMVATV  495–503  
B7 RPHERNGFTVL  265–275  
EBV lytic cycle 
BMFL1 A2  GLCTLVAML  280 –288  
BMRF1 A2  YVLDHLIVV  109 –117  
BZLF1 B8  RAKFKQLL  190 –197  
EBV latent cycle 
EBNA3A B8 FLRGRAYGL  325–333  
 
Adapted from Khan et al 2004 (Khan et al., 2004) 
Table 2.1 Table of MHC Class 1 restricted peptides used. 
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2.3 Statistical Analysis 
 
Statistical analysis was undertaken using SPSS 16.0, 18.0 for Macintosh and 14.0, 
19.0 for Windows (SPSS, Chicago, Illinois 2006, 2010), Excel for Macintosh 
(Microsoft, Washington 2010) and Prism version 5.0 for Macintosh (GraphPad 
Software, California 2008). 
 
Non-parametric continuous comparisons were undertaken with the Mann Whitney U 
test for two groups, Kruskal-Wallis test and Dunn’s multiple comparison for multiple 
groups, Wilcoxon signed rank method (for paired analysis) and correlations by 
Spearman’s correlation. Discrete variable were compared by Fishers exact test, 
McNemar’s test (for paired analysis), Jonckheere-Terpstra test and Kendall’s Tau b 
for rank correlations. Generalised Estimating Equations were employed where linear 
correlations were unknown. Agreement was determined by the Bland-Altman test. 
 
Statistical guidance was sought from Dr Peter Nightingale, Statistician, Wellcome 
Trust Clinical Research Facility, Queen Elizabeth Hospital, University Hospitals 
Birmingham NHS Foundation Trust, Birmingham, B15 2TT. 
Chapter 3  Measuring Clinical Parameters 
 
72 
 
 
 
Chapter 3 
 
Measuring Clinical Parameters in  
Acquired Ocular Immunobullous Disease  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Measuring Clinical Parameters 
 
73 
3.1 Introduction 
 
The challenge in acquired ocular immunobullous diseases such as OcMMP and SJS-
TEN is not only to manage multiple problems arising from ocular surface 
inflammation, but to correctly identify individuals who are at risk of accelerating 
disease activity and progression. For this reason, OcMMP has been referred to as an 
‘‘evil curse’’ (Hossain, 2011). Elder et al coined the term “white inflammation” which 
referred to an occult fibrotic process in OcMMP driven by inflammation in the 
absence of clinical manifest aspects of inflammation (Elder, 1997b). In addition, the 
constellation of clinical signs affecting the eyelid, ocular surface and tear film can 
potentially overwhelm the clinician resulting in documentation in which key features 
indicative of progression may be overlooked.  
 
In this chapter, I have sought to define the clinical phenotype of patients with OcMMP 
presenting to tertiary centres in the UK, determine an optimal means of measuring 
disease damage objectively and a system for accurately recording disease 
phenotype in the clinical setting.  
 
3.1.1 Defining the clinical phenotype of patients with OcMMP  
 
In the UK, streams of hospital referral are primarily to tertiary care services 
specialising in the management of ocular surface disease and OcMMP and originate 
chiefly from ophthalmologists practicing in secondary care. The duration of symptoms 
is variable at presentation (Rauz et al., 2005a, Thorne et al., 2004, Thorne et al., 
2008, Saw et al., 2008). The literature offers a confusing picture related to disease 
duration, with disease progression believed to be more rapid in the context of 
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manifest conjunctival inflammation (Mondino et al., 1979) yet patients are often 
diagnosed at an advanced stage of disease when signs are abundant (Miserocchi et 
al., 2002, Rogers et al., 1982). Although the possibility of a referral bias of patients 
with a more severe phenotype is recognised (Thorne et al., 2008), there is limited 
information regarding the clinical features of patients with early or established 
disease who present to specialised services, whether these patients require 
continued tertiary care, or are discharged back to their referring unit.  
 
The demographic profile and duration of symptoms at presentation including extra-
ocular features and immunohistological profile of disease, current levels of clinical 
documentation, disease activity, damage and progression rates and clinical 
intervention at tertiary referral centres was undertaken. 
 
3.1.2 Determining an objective method for recording the conjunctival cicatricial 
process  
 
Forniceal measurement by measurer Fornix Depth Measurers (FDM), have been 
previously outlined, but their design restricts accurate upper fornix measurements 
(Schwab et al., 1992, Kawakita et al., 2008).  Specifically, the depth and curvature of 
the upper fornix dictates the requirement that the ideal FDM is sufficiently long and 
curved to enable comfortable and accurate assessment of the upper fornix. A 
modification of the Schwab FDM was designed at MEH, for the purpose of a clinical 
trial. However this FDM was made ‘in-house’ and a re-design was required in order 
to develop a bespoke comfortable prototype that could provide an accurate tool for 
improving forniceal sac and horizontal fibrosis documentation in the outpatient clinic 
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setting, and for the purposes of clinical evaluation during my thesis, with potential to 
enable consistent and comparable assessment of disease stage.  
 
3.1.3 Determining an optimal system for accurately phenotyping disease 
 
In BMEC, like other tertiary centres, the ‘proposed’ scoring system described by 
Tauber (Tauber et al., 1992) has not routinely been documented, precluded because 
of an absence of an objective method for scoring and measuring disease damage. 
The ‘proposed’ system incorporates the Mondino (Mondino and Brown, 1981) and 
Foster (Foster, 1986) systems. The advantage of combining both systems is that the 
scale allows for a simpler, and it is argued, a more sensitive system of recording 
damage (Tauber et al., 1992), but this scale requires documentation of both the 
number and involvement of symblephara. The mechanism for objectively 
enumerating these parameters were not described in the original system however 
(Tauber et al., 1992).  
 
While conjunctival fibrotic changes, as discussed in Chapter 1.7.3, could historically 
be considered primary outcome measures of disease damage, they are not the 
terminal event as far as vision is concerned. Corneal scarring including 
vascularisation ultimately results in the sight-threatening manifestations of disease 
(Elder, 1997c, Saw and Dart, 2008). Therefore, a means of recording corneal 
changes systematically in the clinic setting was required. The process for creating a 
clinical record form (CRF) for this purpose is described. 
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3.2 Methods 
3.2.1 Defining the clinical phenotype of patients with OcMMP  
Study population 
 
Retrospective case note review involved two individuals (GPW and CR) with transfer 
of linked-anonymised data to secure databases (Chapter 2). Fifty-four consecutive 
patients with a documented history of OcMMP referred to dedicated ocular surface 
disease (OSD) clinics at MEH and BMEC (Cohort 1), were identified from electronic 
databases and followed for 24 months.   
 
Patients were stratified according to duration of symptoms, where symptoms were 
defined as redness, tearing, burning, decreased vision or foreign body sensation 
(Ahmed et al., 2004). The frequency distribution of the duration of disease defined 
two groups straddling either side of the median (1460 days (4 years)) (Figure 3.1). 
Group1 (n=26, 51 eyes) consisted of patients with <1095 days (<3 years) history and 
was termed the “early-onset” disease (EOD) group, whereas Group 2 (n=24, 48 
eyes) comprised patients with > 1825 days (>5 years) history and was termed the 
“established” disease (EstD) group. Four patients had duration of symptoms that fell 
on the median (4 years), and these patients were excluded from further analysis.   
 
 
 
 
 
 
 
 

	

Figure 3.1: Symptom duration of patients presenting with OcMMP. The frequency 
distribution of the 54 patients referred to our specialist tertiary hospitals according to 
duration of ocular symptoms of MMP (days) at presentation to the specialist centres. 
Two groups are apparent: those with a duration of symptoms clustering under the 
median duration of symptoms of 1460 days termed the early onset of disease (EOD) 
group, and those with a duration of symptoms >1460 days indicating more 
established disease (EstD). The 4 patients symptomatic for 1460 days were excluded 
from further analysis. 
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Study Design 
 
Data were captured at presentation, immediately following first consultation, and at 
12 months and 24 months after first presentation. Visual acuity categories were as 
described in 2.1.4. Disease activity was based upon the degree of conjunctival 
inflammation: absent, mild, moderate or severe (including inflammation in all 4 
quadrants, limbitis and/or conjunctival ulceration) (Figure 1.10) (Elder, 1997c).  
 
Stage of disease and progression was determined by utilising the staging systems 
described by Mondino and Brown ([I] 0%-25%, [II] 25%-50%, [III] 50%-75%; [IV] 
75%-100% loss of inferior fornix) (Mondino and Brown, 1981) and Foster ([I] 
subconjunctival scarring and fibrosis, [II] fornix foreshortening of any degree, [III] 
presence of any degree of symblepharon [IV] end-stage cicatricial pemphigoid) 
(Foster, 1986). Progression was defined as an advance in either Mondino or Foster 
staging criteria.  Immunosuppression strategies employed a ‘step-ladder’ approach 
as previously described (Figure 1.6) (Rauz et al., 2005a, Saw et al., 2008). 
Information regarding surgical intervention was also recorded. 
 
Statistical Analysis 
 
Statistical analysis was by SPSS 16.0 for Macintosh and 14.0 for Windows (SPSS, 
Chicago, Illinois 2006), and Prism version 5.0 for Macintosh (GraphPad Software, 
California 2008) using Fishers Exact test, McNemar’s test, and Kendall’s Tau b for 
rank correlations. Continuous variables were analysed by nonparametric tests 
(Mann-Whitney U test).  Data were collected on all eyes and comparisons were 
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undertaken between the worst affected eye for cross-sectional analysis of 
inflammation/fibrosis and the better-seeing eye for visual acuity. When determining 
disease progression, comparisons were undertaken between patients (either one or 
both eyes). In order to determine if changes seen at differing time points were 
significant rather than as a result of a change in the cohort (e.g. due to patients being 
discharged back to the referring hospital or missing data), longitudinal analysis of the 
same eye was undertaken. Due to the referral of patients back to the originating 
physician, the sample sizes at the three time points differ and percentages rather 
than absolute counts are therefore reported. 
 
3.2.2 Determining an objective method for recording the conjunctival cicatricial 
process 
 
3.2.2.1 Design of a bespoke Fornix Depth Measurer (FDM; BMEC Version 1) 
 
A polymethylmethacrylate (PMMA) FDM (BMEC Version 1) was designed using 
industry-standard jewellery computer software (GPW/SR/SE/PC) (CAD v5, 3Design, 
Brussieu, France 2007). The virtual model was then exported as an .STL file into a 
program to set the cutting parameters for the milling machine (Modela Player v4, 
Roland DG, Shizuoka, Japan 2002) (Figure 3.2a).  The virtual model was cut with a 
machine to a precision of 2μm/step, and increments expressed at 2mm intervals. The 
BMEC v1 FDM measured 25mm x 5mm and was biconcave to ensure ease of 
insertion and comfort (Figure 3.2b).  
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Patients  
 
An ethically approved evaluation of the bespoke FDM (BMEC v1) was undertaken 
through a prospective, masked, independent assessment of central lower fornix 
depth by two observers (GPW, TS). The validation of the FDM (BMEC v1) was 
conducted on a heterogeneous group of patients comprising of clinically normal and 
abnormal conjunctival fornices presenting to BMEC. This heterogeneity enabled a 
wide range of fornix depths to be tested with the bespoke FDM.  
 
The cohort consisted of 51 eyes of 26 patients with a median age of 64 years (range 
42-100 years) of whom 65% (17/26) of patients (33/51 eyes) had an identifiable 
cause of cicatrising conjunctivitis (OcMMP, 10; Dry Eyes, 5  (including 3 with 
Sjögren’s syndrome); Stevens-Johnson Syndrome (SJS), 2) and 35% (18/51) had no 
evidence of conjunctival scarring (Age-Related Macular Degeneration (ARMD), 4; 
Uveitis, 3; Peripheral Ulcerative Sclero-keratitis, 2) (Cohort 2).  
 
Following instillation of one drop of 0.4% Oxybuprocaine hydrochloride, patients were 
asked to look in the opposite direction to the placement of the FDM (BMEC v1) 
(upper fornix, downgaze; lower fornix, upgaze) and the central conjunctival fornix was 
measured to the eyelid margin, defined as the posterior lip of the meibomian gland 
orifice (Figure 3.2c). All FDM (BMEC v1) readings were in triplicate with the first 
measurement taken used for inter-observer comparison. A subjective estimation of 
lower fornix conjunctival shrinkage was also performed (NB a subjective assessment 
of the upper fornix is not possible). Patients were also asked about their tolerance to 
the FDM.  
C
  
B
  
A
  
Figure 3.2: FDM (BMEC v1) Construction. A PMMA FDM was constructed using 
industry-standard jewellery software and machinery. A screenshot of the 3design 
prototype is shown in the top panel (panel A). The final prototype is illustrated in the 
left panel (panel B). Increments are expressed at 2mm intervals to a precision of 2μm/
step and the FDM was heat moulded to a biconcave shape for comfort. The FDM 
(BMEC v1) was applied following instillation of one drop of 0.4% Oxybuprocaine 
hydrochloride (panel C). Patients were asked to look in the opposite direction to the 
placement of the FDM and the central conjunctival fornix was measured to the eyelid 
margin, defined as the posterior lip of the meibomian gland orifice.  
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Calculations and Statistical Analyses 
 
The percentage loss of lower fornix for both methods of measurement (subjective 
and objective) was calculated using the equation: 
 
(Fornix Depth (FD) age – FDM measurement)/FD age x 100=% loss of fornix 
 
 A correction factor for age was implemented as the lower forniceal depth is known to 
progressively shorten with age (Schwab et al., 1992). The “FD age” values were 
derived from published age-specific lower fornix depths in normal eyes detailed in 
Table 3.1 (Schwab et al., 1992).  For example, for a patient aged 80 years with a 
lower fornix measured at 6mm, the calculated percentage shrinkage is as follows:  
(10.2-6)/10.2 x 100=41.2% 
  
Age Mean Depth of normal lower 
fornix in mm (‘100%’) 
10% of normal 
lower fornix in mm 
40-49 11.9 1.19
50-59 11.3 1.13
60-69 11.0 1.10
70-79 10.6 1.06
80+ 10.2 1.02
  
Adapted from Schwab et al Ophthalmology 1992 (Schwab et al., 1992) 
Table 3.1: Age specific normal values for the conjunctival lower fornix. 
 
Intra- and inter-observer agreement was assessed using Bland-Altman plots of 
differences in measurements versus mean measurements using Excel for Macintosh 
(Microsoft Office 2008) (Bland and Altman, 1986, Bunce, 2009). The mean difference 
in observations and the 95% limits of agreement (the mean difference ±2 standard 
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deviations) (Bland and Altman, 1986) were calculated using SPSS v 16.0 for 
Macintosh (SPSS, Chicago, Illinois 2007). A continuity correction was applied to the 
95% limits of agreement, to take account of the fact that Bland and Altman plots 
assume that the variables measured are continuous. 
 
A 10% threshold or ‘tolerance’ was chosen as an allowance for intra-observer 
variation. Agreement was also evaluated by determining the percentage of 
observations that agreed to within the 10% ‘allowance’ for both observers.  
 
3.2.2.2 Enhancement of the FDM for enumerating symblephara (FDM; BMEC 
Version 2) 
 
A further adaptation of the FDM was undertaken (BMEC Version 2). This was to 
facilitate enumeration of the number and extent of symblephara (Tauber et al., 1992). 
In order to consistently measure the number and extent of symblephara we elected 
to re-design the FDM in order to measure the distance from medial to lateral canthus 
inferiorly and superiorly (Figure 3.3A and B).  
 
It was anticipated that the BMEC v1 FDM could be adapted to facilitate fornix 
measurement and allow inter-canthal measurement, without the requirement for two 
separate FDMs. The 20mm ‘handle’ (Figure 3.2A,B) from BMEC v1 FDM was 
therefore incorporated in to a new FDM (BMEC v2) with a longer 50mm inter-canthal 
measurer (Figure 3.3C and D). The precise inter-canthal distance is unknown but 
two considerations were taken in to account during the re-design (i) curvature of the 
globe and (ii) length. The natural curvature of the eye means that assessing the 
presence of symblephara could not be achieved with a straight-line measurement 
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(Figure 3.3A and B). We therefore utilised the curvatures employed to fit scleral 
contact lenses employed at BMEC and MEH (recommended by scleral contact lens 
practitioners Paul Cottrell (PC) and Ken Pullum; 2008 personal communications; 
Innovative Sclerals Scleral Lens Fitting Manual, 2008).  
 
The elongated FDM was re-designed as described in 3.2.2.1 (GPW/SR/SE/PC) but 
narrowed to 5mm diameter for comfort and to aid measurement. The longer 
measurer was moulded around a cylinder measuring 13.5mm in diameter, giving a 
bi-concave shape with a shorter handle identical to the original FDM, validated as 
outlined above (Figure 3.3C and D). This allowed measurement from medial to 
lateral canthi along the eyelid margin of the lower and upper fornix (Figure 3.3E and 
F). 
 
40 eyes of 20 individuals were assessed by two independent observers (IK and AG, 
observers 3 and 4 respectively) in a cohort of healthy volunteers (median age 42 
[range 20-78 years]; 9 females; 20 Asian) for the purpose of determining intra- and 
inter-observer variability in objective measurement of the inter-canthal curved 
distances as described in 3.2.2.1. 
 
 
 
 
 
 
 
A B
C D
E F
Figure 3.3: Development of BMEC FDM v2. Measurement of symblephara extent 
and number depends on the ability to enumerate objectively (A). Currently, no 
accepted system exists for this purpose. We therefore chose to measure the curved 
distance from canthus to canthus inferiorly (lower) and superiorly (upper), thereby 
circumventing an under-estimation taken with a straight-line measurement (A and B) 
using an enhanced FDM (BMEC v2). The symblephara can be measured and 
subtracted from the total inter-canthal distance. Figures C and D illustrate the short 
(conventional FDM for lower and upper fornix measurement) and the curved, 
extended arm for inter-canthal measurement, demonstrated in E and F. Pictures 
courtesy of Jonas Brane, Sandwell and West Birmingham Hospitals NHS Trust. 
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3.2.3 Determining an optimal system for accurately phenotyping disease 
 
In order to calculate primary outcome measures of conjunctival fibrosis, based upon 
the proposed system described by Tauber, measurement of upper and lower fornix 
depth, number and extent of symblephara between the medial and lateral canthi and 
the inter-canthal distance were incorporated in to a Clinical Record Form (CRF) 
(Tauber et al., 1992, Mondino and Brown, 1981, Foster, 1986).  
 
In the absence of validated secondary measurements of disease damage to the 
cornea, a literature search was undertaken to determine alternative scales employed 
for PCC using PubMed by GPW/SR/PT. The scoring system described by Sotozono 
and colleagues was identified as the most relevant system that could be adapted for 
this purpose (see Chapter 1.7.3).  Individual relevant scales were trialled at the OSD 
clinic at BMEC. The following ordinal scales are employed in the Sotozono system 
for SJS-TEN: 
 
(i) Corneal neovascularisation is quantified by extent as none, to the periphery, to the 
pupil margin or involvement of central cornea 
(ii) Corneal opacification is quantified as none, partial obscuration of iris details, iris 
details poorly seen with pupil margins just visible and complete obscuration of iris & 
pupil details. 
(iii) Corneal conjunctivalisation as none, < ¼, ¼ to ½, > ½  
(iv) Corneal keratinisation as none, < ¼, ¼ to ½, > ½  
 
The captured data also included currently used and accepted scoring system for 
clinical conjunctival inflammation in OcMMP described by Elder et al (Elder, 1997c). 
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The division of conjunctival and limbal hyperaemia in to quadrants was agreed in 
collaboration with Prof. John Dart (Consultant Ophthalmologist at MEH) in order to 
achieve consistency between BMEC and MEH and provide a platform for future 
validation studies. Although not considered primary or secondary outcome 
measurements during subsequent longitudinal assessment undertaken during this 
thesis (see Chapter 5), indices relevant to the tear film, eyelids, conjunctiva and 
sclera were also considered for completion including those described in the Delphi 
report on dry eyes; eyelid and corneal changes described for the chronic ocular 
manifestations of SJS and scleritis using standardised criteria for punctal involvement, 
(Sotozono et al., 2007, Behrens et al., 2006, 2007, Denniston and Murray, 2009). 
The presence of additional scales for filaments, lid margin disease, peripheral 
ulcerative keratitis (PUK), conjunctival mucous, keratinisation and corneal ulceration 
were defined arbitrarily and are subject to on-going validation.  
 
Symptoms and legends used for clinical drawings were based on the scales used at 
MEH (Elder, 1997c) and BMEC (unpublished). Oral involvement was based on the 
scale described by Setterfield et al (Setterfield et al., 1998). This was used as 
platform for improving documentation of oral disease and referral/liaison with oral 
medicine colleagues specialising in MMP and agreed with Mr John Hamburger (JH), 
Senior Lecturer and Consultant Oral Physician at the University of Birmingham 
School of Dentistry. The CRF incorporated demographic (age, gender, race), 
therapeutic and clinical information outlined in the ‘Consensus’ statement (Chan et al., 
2002) to aid general clinical documentation.  
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3.3 Results 
 
3.3.1 Defining the clinical phenotype of patients with OcMMP  
The patterns of referral to tertiary centres and duration of symptoms  
 
The geographical origin of our patient cohort is illustrated in Figure 3.4 and illustrates 
the distribution of patients presenting to BMEC and MEH (Cohort 1). 
 
The EOD group was younger than the EstD group (62(32-82) versus 69(39-91) years 
(median, range) (p=0.02)). 19 patients (37 eyes) EOD and 16 EstD patients (32 
eyes) were followed for 24 months. Of the 15 patients not reviewed at 24 months, 1 
patient in the EstD group died before 12 months follow up and 14 (28%) were 
referred back to the referring hospital.  Of these, 11 had no clinically detectable 
inflammation at their last visit before discharge from the tertiary centre, two had mild 
inflammation which continued to be monitored and treated at the local referring 
hospital and one patient repeatedly failed to attend for follow up despite recall. The 
remaining cohort (EOD 19; EstD 16) consisted of patients with more severe ocular 
disease. 
 
 
 
 
 
 
 
 
B 
L 
Figure 3.4: Geographical distribution of referrals for OcMMP. Map containing 
Ordnance Survey data (© Crown copyright and database right 2010) showing the 
combined geographical distribution of referrals (▼) to the two tertiary referral 
hospitals: Moorfields Eye Hospital, London, UK (circled, L) and the Birmingham and 
Midland Eye Centre, Birmingham, UK (circled, B). The furthest referral was for 
Newquay, Cornwall to Moorfields (238 miles).  
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Extra-ocular features and histological profile of disease  
 
Extra-ocular Features 
Extra-ocular mucocutaneous involvement was present in 52% (26/50) of patients at 
presentation (62% (16/26) of the EOD group; 42% (10/24) of EstD group; p=0.257; 
Table 3.2). A total of 18% (9/50) patients had a history of skin involvement and this 
was more frequently reported in the EstD group (29.2% (7/24)) than the EOD group 
(7.7% (2/26)). Conversely, oral involvement was more common in the EOD group 
(57.7% (15/26)) compared with 20.8% (5/24) in the EstD group (p=0.01).  
 
Biopsies  
A total of 87.2% (34/39) of patients who underwent a biopsy, were direct 
immunofluorescence (DIF) positive. By contrast, indirect immunofluorescence studies 
were positive in only 34.8% (8/23) of tested individuals, all of whom were also DIF 
positive (Table 3.2). Although five (12.8%) patients were biopsy negative, these 
patients had clinical features consistent with OcMMP in the absence of other causes 
of progressive conjunctival scarring. Ten patients in total did not undergo a 
conjunctival biopsy: seven patients were of advanced age (> 80 years) with co-
morbidities where systemic immunosuppression was contraindicated; and the 
remaining three patients had end-stage disease (defined as Mondino/Foster stage 4) 
where the sensitivity of a positive DIF conjunctival biopsy is low due to physical 
destruction of the basement membrane zone architecture (Bernauer et al., 1994). 
 
 
 
Chapter 3  Measuring Clinical Parameters 
 
91 
 
 All patients Early-onset 
disease 
Established 
disease 
p 
value 
Total no. of patients  50 26 24 - 
Total no. of eyes  99 51  48  - 
Male: Female (% Female) 23:27 (54) 11:15 (58) 12:12 (50) - 
Median age (yrs) [Range] 67 (32-91) 62 (32-82) 69 (39-91)  p=0.02 
Median duration of  
symptoms (yrs) [Range] 
 
3 (0-41) 
 
1.5 (0-3) 
 
14 (5-41)  
 
p<0.001 
Patient follow-up (eyes) 
12 months 
24 months 
 
43 (85) 
35 (69) 
 
23 (45) 
19 (37) 
 
20 (40) 
16 (32) 
 
- 
- 
No of patients discharged back to 
referring hospital ¶ 
    
Total number discharged 14 7 7 - 
12 months follow-up 4 1 3 - 
24 months follow-up 10 6 4 - 
Biopsy * 
DIF +ve 
IIF  +ve † 
 
87.2% (34/39) 
34.8% (8/23) 
 
92% (23/25)  
42.9 % (6/14)  
 
78.6% (11/14) 
22.2% (2/9) 
 
p=0.33 
p=0.4 
Extraocular mucocutaneous 
involvement 
All mucocutaneous tissues 
Skin 
Oral  
 
 
52% (26/50) 
18% (9/50) 
40% (20/50)  
 
 
62% (16/26) 
7.7% (2/26) 
57.7% (15/26)  
 
 
42% (10/24) 
29.2% (7/24) 
20.8% (5/24)  
 
 
p=0.26 
- 
p=0.01 
Visual Acuity ‡       
Normal: 6/6 ->6/18 80.6% (29/36) 95.2% (20/21) 60% (9/15) 
p<0.01 
Visual impairment: <6/18- 6/60 8.3% (3/36) 4.8% (1/21) 13.3% (2/15)  
Severe visual impairment:  6/60-3/60 0% (0/36) 0% (0/21) 0%  (0/15)  
Blind: <3/60 11.1% (4/36) 0% (0/21) 26.7% (4/15)  
‡Excluded due to other causes 28% (14/50) 19% (5/26) 38% (9/24)  
     
Table 3.2: Patient demographics and characteristics in OcMMP. The Early-Onset Disease (EOD) 
group consisted of a younger cohort of patients with increased frequency of oral MMP. Direct 
immunofluorescence (DIF) and Indirect immunofluorescence (IIF) refer to the proportion of patients 
who demonstrated the linear deposition of immunoglobulin G, A or complement (C3) along the 
basement membrane zone (BMZ) or had measurable titres of immunoglobulin in the serum 
respectively.  
¶ Follow-up: one patient from the Established Disease (EstD) group died before 12 months FU, 
and one from the EstD group failed to attend between 12 and 24 months and was referred back to 
their local hospital for continuing care. 
* Ten patients in total did not undergo a conjunctival biopsy (7 patients with advanced age (> 80 
years) and immunosuppression was systemically contraindicated and the remaining 3 patients had 
end stage disease (defined as Mondino/Foster stage 4)). Data were missing for one individual and this 
patient was excluded from analysis. 
† All patients who were IIF were also DIF positive. There were no patients who were IIF positive 
in the absence of positive DIF studies.  
‡   VA represents a comparison of visual acuity in the better-seeing eye, after exclusion of other 
causes of reduced vision such as cataract, glaucoma, age-related macular degeneration and diabetic 
retinopathy (n=14, EOD 5; EstD 9). 
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Disease activity, damage and progression 
 
Disease Activity 
 
Information regarding conjunctival inflammation was documented in 95.0% (94/99) 
eyes at presentation, 90.6% (77/85) eyes by 12 months and 97.1% (67/69) at 24 
months follow up. 
 
At presentation, 53% (50/94) of all eyes had clinical evidence of conjunctival 
inflammation where the majority (76% (38/50 eyes)) were in the EOD group 
(p<0.001) when comparing the worst affected eye (Figure 3.5A).  Patients with 
moderate / severe inflammation were also more likely to have EOD. By 12 months 
follow up (Figure 3.5A), inflammation had resolved in 78% (60/77) of all eyes 
(EOD=83% (35/42) versus EstD=71% (25/35), p=0.917) and there were no patients 
with residual severe conjunctival inflammation. These data were endorsed by 
McNemar’s longitudinal analysis, showing a significant reduction in inflammation in 
the EOD (p<0.001) compared to the EstD group (p=1.0). 
 
A recalcitrant group of patients with persistent inflammation not responsive or only 
partially responsive to treatment was identified in 29.9% (20/67) of eyes examined at 
24 months. Interestingly, the persistence of inflammation was independent of group 
phenotype (EOD=27% (10/37) versus EstD=33.3% (10/30), p=0.967; Figure 3.3A).  
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Figure 3.5: Cross-sectional analysis of clinically detected conjunctival 
inflammation (A) and ocular staging using Mondino (B) and Foster (C) systems 
in the worst eye at presentation, 12 months and 24 months follow-up in the EOD 
() and EstD groups (). Differences in the extent of conjunctival inflammation and 
stage of disease were compared between the two groups by rank correlation using 
Kendal’s tau b. At 12 months follow-up, inflammation had resolved in the majority of 
eyes within both groups, and there were no patients with severe inflammation. By 24 
months, 30% of the remaining patients at the tertiary centres had residual 
inflammation not responsive to treatment.  Note that patients in the EstD had more 
advanced stage of disease compared with the EOD throughout the follow-up period, 
but there was no difference in the progression rate (worsening of clinical stage of 
disease) between the two groups. NB 14 patients had been referred back to their 
original hospital by 24 months and 1 had died. These patients have been excluded 
from the analysis thereby accounting for the apparent increase in the percentage of 
patients at stage 1 and decrease in the percentage of patients at stage 4 disease 
during the 12 and 24 months according to the Mondino staging system 
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Disease Damage 
 
Foster staging of conjunctival fibrosis was more consistently documented at 
presentation, 12 and 24 months follow up compared with the Mondino staging 
system. Foster stage was documented in 98.0% (97/99); 90.6% (77/85 eyes) and 
87.0% (60/69) eyes versus Mondino stage in 83.4% (83/99); 60% (51/85) and 72.5% 
(50/69) eyes at presentation, 12 and 24 months respectively. Assessment of the 
staging system described by Tauber was not possible because of the absence of 
information regarding the extent of symblephara involvement. 
 
Eyes in the EstD group had more severe conjunctival fibrosis at presentation (Figure 
3.3B and 3.3C) gauged by staging systems described by both Mondino (Stage IV: 
EOD=5%(2/40) versus EstD=39.5%(17/45), p<0.001) and Foster (Stage IV: 
EOD=3.9%(2/51) versus EstD=13%(16/46), p<0.035). At 12 months, the EstD group 
demonstrated significantly advanced stage of disease, irrespective of staging system 
used (Figure 3.5B and C), despite a total of 20.8% of all eyes having progressed 
according to both Mondino and Foster systems. By 24 months, there was no 
significant difference in the stage of disease in both groups according to either 
staging systems (Figure 3.5B and C).  
 
There was no significant difference when comparing progression (defined by 
worsening of clinical stage of disease in at least one eye) amongst patients in both 
groups neither between presentation and 12 months (Mondino: EOD=33.3%(4/12) 
versus EstD=23.1%(3/13), p=0.67; Foster: EOD=18.2% (4/22) versus EstD=38.9% 
(7/18) p=0.173), nor during the subsequent 12 to 24 months follow-up period 
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(Mondino: EOD=53.8%(4/22) versus EstD=16.7%(2/12), p=0.10; Foster: 
EOD=23.5% (4/17) versus EstD=28.6% (4/14) p=1.0) (Fishers exact test). 
 
Disease Progression and the Presence of Conjunctival Inflammation 
 
Differences in the rates of progression (defined by an advance in Mondino or Foster 
staging) were stratified according to the presence or absence of clinically identifiable 
conjunctival inflammation in at least one eye. There was no significant difference 
observed between the first and second 12 months follow-up periods (data not shown). 
Moreover, despite the absence of clinically detectable inflammation, progression of 
disease occurred in 42% of patients according to the Mondino system (Figure 3.6A, 
left panel), and 16% and 38% of patients according to the Foster (Figure 3.6A, right 
panel) system for each of the 12 months follow-up periods, respectively. 
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Figure 3.6: Progression rates and immunosuppression. Progression rates, 
defined by worsening of either Mondino or Foster clinical staging of MMP, in the 
presence or absence of clinically detectable conjunctival inflammation are shown in 
the upper composite Panel A. Note there was no significant difference in progression 
between eyes with clinically detectable inflammation or those that were seemingly 
uninflamed (Fishers exact test). The percentage of patients requiring 
immunosuppression at presentation, following the first follow up (FU) clinic visit, 12 
months and 24 months follow-up time points are shown in the lower panels B and C. 
Immunosuppression strategies were ranked according to the hierarchy described by 
Rauz et al (Ophthalmology 2005). Overall, a significant initiation or escalation in 
‘strategic-step’ was required at the first FU visit (Panel B; McNemar’s test), but this did 
not significantly differ when  the Early Onset (EoD) and Established Disease (EstD) 
groups were compared (Panel C; Kendal’s tau b). By 12 months follow-up, 5 patients 
stabilised on immunosuppression and were discharged back to their originating 
hospitals, and similarly a further 10 between the 12 and 24 months follow-up. 
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Therapeutic Intervention at tertiary referral centre 
Surgical Intervention 
 
At initial presentation to the specialist units, 32% (16/50) of patients had previously 
undergone eyelid or fornix reconstructive surgery by the referring hospital with the 
majority of cases being performed in the EstD group (p<0.01) (Table 3.3). Although 
both groups required oculoplastic surgical intervention at the tertiary hospitals, this 
did not differ between the two groups, nor during the first and second 12 months 
follow-up periods. 
 
 
Surgical intervention Total  Early-onset 
disease 
Established 
disease 
p value 
Presentation 
Eyelid/fornix surgery 32% (16/50) 11.5% (3/26) 54.2% (13/24) p<0.01 
Corneal intervention 2% (1/50) 0% (0/26) 4.2% (1/24) NS (p=0.480) 
Cataract surgery 20% (10/50) 23.1% (6/26) 16.7% (4/24) NS (p=0.728) 
Glaucoma surgery 4% (2/50) 7.7% (2/26) 0% (0/24) NS (p=0.491) 
0 to 12 months 
Eyelid/fornix surgery 27.9% (12/43) 34.8% (8/23) 20% (4/20) NS (p=0.327) 
Corneal intervention 7% (3/43) 4.3% (1/23) 10% (2/20) NS (p=0.590) 
Cataract surgery 7% (3/43) 0% (0/23) 15% (3/20) NS (p=0.092) 
Glaucoma surgery 2.3% (1/43) 0% (0/23) 5% (1/20) NS (p=0.465) 
12 to 24 months 
Eyelid/fornix surgery 25.7% (9/35) 31.6% (6/19) 18.8% (3/16) NS (p=0.460) 
Corneal intervention 5.7% (2/35) 5.3% (1/19) 6.3% (1/16) NS (p=1.0) 
Cataract surgery 11.4% (4/35) 5.3% (1/19) 18.8% (3/16) NS (p=0.312) 
Glaucoma surgery 0% (0/35) 0% (0/19) 0% (0/16) - 
 
Table 3.3 Surgical intervention in OcMMP. Figures in both groups at presentation, between 
presentation and 12 months and between 12 and 24 months follow up periods are shown. Differences 
were compared by the Fishers exact test. 
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Immunosuppression Strategies 
 
40% (20/50) of all patients were on immunosuppression at the time of referral. After 
first consultation, 36% (18/50) required initiation and 12% (6/50) a switch to a more 
potent immuno-modulatory treatment representing a significant overall ‘step-up’ on 
the step ladder approach (p=0.001) (Figure 3.6B). During the first 12 months follow-
up period, a further 30% (13/43) of patients required 'step-up' treatment (p=0.215) 
(Figure 3.4B) equating to a total of 88% (38/43) of patients requiring initiation or 
changes in immunosuppression at presentation or during the first year of follow-up. 
By 24 months, immunosuppression could be withdrawn in only one patient but no 
further escalation in therapy was required. 28% patients had stabilised and were 
discharged to the referring unit for immunosuppression monitoring (Table 3.2). There 
was no statistical difference between the requirement for immunosuppression for 
each of the patient groups at each of the time points (Figure 3.6C). 
 
The most commonly used drug by the referring unit was Dapsone (26% (n=13)) 
followed by either Azathioprine or Mycophenolate (8% (n=4)) with only one patient on 
Cyclophosphamide (2% (n=1)). The majority of these patients were commenced on 
Azathioprine or Mycophenolate 10% (n=5) or switched to these drugs from Dapsone 
10% (n=5). Two further patients required oral Cyclophosphamide to control 
inflammation. By 12 months, an additional seven patients had initiated 
Cyclophosphamide therapy and this was either because of the presence of 
exuberant inflammation (n=3) not adequately responding to less potent agents (Two 
requiring i.v. Methylprednisolone) or there was a requirement for an increase in 
immuno-modulation prior to ocular or eyelid reconstructive surgery. Resolution of 
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inflammation occurred in two patients who were “stepped-down” to less potent 
agents. By 24 months, oral Cyclophosphamide was withdrawn in three patients (due 
to completing the maximum safe duration of therapy of approximately 14 months i.e. 
a cumulative dose (oral or i.v.) of <20g. The majority (40%) of patients were 
maintained on either Mycophenolate or Azathioprine.  There was no statistical 
difference in the immunosuppressive agents used between the EOD and EstD 
groups. Intravenous immunoglobulin or biological agents were not administered 
during the course of this study. 
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3.3.2 Optimising a system for objectively measuring the cicatricial process 
 
3.3.2.1 FDM (BMEC Version 1) 
Fornix Depth 
A cohort of 51 eyes of 26 patients were evaluated (Cohort 2). 100% of patients had 
>1 assessments of their fornices.  
 
Lower Fornix Assessment 
Intra-observer variation 
 
Triplicate measurements of FDM (BMEC v1) readings of the same anatomical 
position by each observer (central lower fornix) demonstrated exact agreement of 
86% (42/49) and 89% (41/46) of measurements within observer 1 and observer 2 
respectively. When allowing for 1mm ‘tolerance’ (approximating to 10% of the normal 
lower fornix, see Table 3.1), 100% of intra-observer observations fell within 1mm for 
both observers.  
 
Inter-observer variation 
 
Inter-observer variation between the subjective and objective measurements of the 
central lower fornix by the two observers was also assessed. Assessment of the 
lower fornix shrinkage was expressed as a percentage for both subjective and 
objective estimations, the latter using the age correction factor described in the 
methods (Schwab et al., 1992). 
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The mean difference in calculated percentage fornix depth using measurements 
obtained from the FDM (BMEC v1) by observer 1 and 2 was 1.19% and with a 
continuity correction, the 95% limits of agreement (±2SD) were narrower for inter-
observer objective (FDM) measurements versus those obtained subjectively (-15 and 
+ 20%) (Figure 3.7). The inter-observer agreement within the 10% allowance (i.e. 
approx. ±1mm) of total lower fornix depth was 86% (44/51) (Figure 3.8).  
 
In contrast, the inter-observer mean difference in subjective estimation of percentage 
fornix depth was -1.86% and with a continuity correction, the 95% limits of 
agreements (±2 Standard Deviations, SD) were between -30 and +25% (Figure 3.7). 
Only 63% (32/51) of the subjective measurements taken by the two observers 
agreed to within a 10% allowance of total lower fornix depth (Figure 3.8). 
 
These data highlight that the FDM (BMEC v1) afforded greater consistency in fornix 
depth measurement by each observer (intra-observer variation), and between 
observers (inter-observer variation). 
 
Upper Fornix Assessment 
Intra-observer variation 
 
Triplicate measurements (to assess intra-observer variation) of FDM (BMEC v1) 
readings of the same anatomical position of the central upper fornix by each observer 
demonstrated minimal variation (i.e. identical objective measurements) in 88% 
(45/51) and 70% (33/47) of measurements by observer 1 and observer 2 respectively. 
There are no data regarding normal upper fornix depth in the published literature, 
Chapter 3  Measuring Clinical Parameters 
 
102 
precluding calculations for age-based corrections and percentage fornix depth 
foreshortening and tolerance threshold.  
 
Inter-observer variation 
 
Inter-observer variation of the upper fornix showed a mean difference in fornix depth 
measurement using the FDM (BMEC v1) for observer 1 and 2 of 0.57mm with 95% 
agreement (± 2SD) of -2 and + 3mm (Figure 3.9). The absence of normal upper 
fornix values precludes evaluation of the 10% allowance, however 84.3% (43/51) of 
upper fornix measurements were within 1SD of the mean difference of 0.57mm (+2 
to -1mm of the mean with a continuity correction). 
 
Patient comfort and tolerance 
 
The FDM (BMEC v1) was well tolerated by patients with only a few patients (3) 
experiencing mild discomfort with upper fornix measurement, despite repeated 
measurements. None of these patients reported prolonged discomfort or pain.  
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Figure 3.7: Lower fornix assessment using an FDM. Bland-Altman plots showing 
inter observer variation in lower fornix assessment (left panels; A objective and C 
subjective). Some data points are identical and therefore overlay each other on the 
figures. The % difference in assessment between observer 1 and 2 is plotted against 
the mean % loss of fornix for each eye using the BMEC FDM v1. If there was a 
completely normal fornix this is represented as 0% loss of fornix on the x axis. Note 
the increase in the 95% limits of agreement (±2SD) for subjective assessment 
(arrowed), demonstrated also by the histograms (right panels, B and D).  
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Figure 3.8: Difference in objective (FDM) and subjective assessment of lower 
fornix. The histograms demonstrate the difference in objective and subjective lower 
fornix assessment between observer 1 and 2 using the BMEC FDM v1. The number 
of individuals which agree to within a 10% ‘allowance’ are boxed and are higher for 
objective measurements A 86% (44/51), compared to subjective measurement, B, 
63% (32/51).  
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Figure 3.9: The FDM as a tool for assessing the upper fornix. The Bland-Altman 
plot (left upper panel, A) shows inter observer variation in upper fornix assessment. As 
there are no defined limits for the upper fornix, the calculations are in mm. The mm 
difference in assessment between observer 1 and 2 is plotted against mean mm 
measurement for each patient using the BMEC FDM v1.  The 95% limits of 
agreement are vertically arrowed and represented also by the histogram (right upper 
panel B). The lower histogram (panel C) demonstrates the difference in upper fornix 
assessment between observer 1 and 2; the 10% allowance cannot be calculated in 
the absence of normal upper fornix values but 71% (36/51) of measurements were 
within 1mm and 92% (47/51) of observations were within 2mm of each other.  
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3.3.2.2 FDM (BMEC Version 2) 
 
Triplicate measurements (to assess intra-observer variation) of FDM (BMEC v2) 
readings of the lower inter-canthal distance same location by each observer 
demonstrated no variation (i.e. identical objective measurement) in 53% (21/40) and 
73% (29/40) of measurements by observer 3 and observer 4 respectively. Intra-
observer variation of upper inter-canthal distance demonstrated no variation (i.e. 
identical objective measurement) in 63% (25/40) and 80% (32/40) of measurements 
by observer 3 and observer 4 respectively. If allowing for 1mm difference (‘tolerance’), 
100% of intra-observer readings were within 1mm. Like upper fornix depth, there are 
no data regarding inter-canthal distances in the literature, preventing calculations for 
age-based corrections.  
 
Inter-observer variation of the lower inter-canthal distance showed a mean difference 
in fornix depth measurement using the BEMC v2 FDM for observer 3 and 4 of -
1.6mm. The 95% limits of agreement (±2SD) were between -3.5 and + 0mm (Figure 
3.10A). 88% (35/40) of lower fornix measurements were within 1SD of the mean 
difference of -1.6 mm (-3 to -1 mm of the mean with a continuity correction). Inter-
observer variation of the upper inter-canthal distance showed a mean difference in 
fornix depth measurement using the BMEC v2 FDM for observer 3 and 4 of -1.3mm. 
The 95% limits of agreement (±2SD) were between -3 and + 1mm (Figure 3.10B). 
100% (40/40) of upper fornix measurements were within 1SD of the mean difference 
of -1.3 mm (-2 to 0 mm of the mean with a continuity correction). 
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Figure 3.10: Inter-canthal agreement using an adapted FDM. The Bland-Altman 
plot (upper panel, A) shows inter observer variation in lower inter-canthal assessment 
using BMEC v2 FDM. The mm difference in assessment between observer 1 and 2 is 
plotted against mean mm measurement for each patient. The 95% limits of agreement 
are vertically arrowed. The lower Bland-Altman plot (lower Panel B) represents the 
upper inter-canthal assessment.  
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3.3.3 Optimisation of clinical documentation and assessment 
 
A summary of the parameters agreed for the CRF are shown in Table 3.4 and the full 
CRF can be found in Appendix 7.1. The CRFs were initially trialled in the OSD clinic 
at BMEC by experienced anterior segment specialists (SR/TS). In particular, the 
Sotozono scales were scrutinised to determine their practicality for quantifying the 
extent of corneal neovascularisation opacification, conjunctivalisation and 
keratinisation. 
 
The development of the CRF, combined with the FDM outlined in 3.3.2 allowed the 
Tauber scale for the lower fornix to be calculated by the percentage of lower fornix 
shrinkage (3.2.2.1), percentage lower canthal involvement by symblephara 
(mm)/inter-canthal distance (mm) (denoted by horizontal arrows in the CRF) and 
number of symblephara. 
 
During initial trialling of the secondary outcome measures (corneal 
neovascularisation, opacification, conjunctivalisation and keratinisation) it was 
determined that the neovascularisation should be expanded to reflect the degrees of 
involvement by clock hours e.g. to order to reflect early but extensive peripheral 
vascularisation in some individuals or a single central blood vessel. Furthermore, 
conjunctivalisation and keratinisation were changed from none, < ¼, ¼ to ½, > ½ to 
none, <⅓, ⅓-⅔, >⅔ as this was deemed to be a more incremental ordinal scale. 
Opacification was also changed to reflect this scale. The format of the CRF was also 
developed so that a consistent scale in a ’checklist’ format of clinical parameters 
could be transferred to the linked-anonymised database. Full-scale validation, 
requiring internationally agreed consensus, was beyond the scope of this thesis. 
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Table 3.4: Examination assessment scores developed for the Clinical Record From (CRF). 
Primary Outcome Measures for OcMMP were derived from the ability to determine forniceal fornix 
depth, symblephara number and mm of involvement (primary outcome measures) and corneal 
neovascularisation, opacification, conjunctivalisation and keratinisation (secondary outcome 
measures)  
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3.4 Discussion 
 
3.4.1 Defining the clinical phenotype of patients with OcMMP  
 
In the retrospective study undertaken at BMEC and MEH, two disease phenotypes of 
OcMMP were statistically defined: (i) those with early onset disease (EOD) who were 
characterised as having less advanced disease stage but significantly greater 
conjunctival inflammation, and (ii) those patients with established disease (EstD) who 
had less clinically identifiable inflammation but more advanced stage of disease. 
Although 40% of the patient cohort were on existing systemic immunosuppression, 
the majority of patents required initiation or escalation in systemic 
immunosuppression following either their first clinic visit, or during the first year of 
follow up in order to control inflammation, facilitate corrective eyelid surgery or 
prevent further progression in already advanced disease states. Despite these 
measures, 20.8% of eyes demonstrated disease progression during the first 12 
months and another 20.8% between 12 and 24 months; and this progression was 
independent of the EOD or EstD clinical phenotypes.  
 
Could the advanced stages seen in the established group therefore be explained 
simply by longer duration of disease? For the patients to have progressed, the 
working hypothesis outlined (Section 1.9) is that the disease may have been driven 
by underlying inflammatory processes, even if this was not clinically detectable. 
These results reinforce the observation that OcMMP may progress at any stage of 
disease (Mondino and Brown, 1981, Elder et al., 1996) and more importantly, 
progression rates amongst eyes that are clinically inflamed and those that are not, do 
not differ.  These data endorse previously reported literature (Mondino and Brown, 
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1983, Saw et al., 2008, Elder, 1997b) and possibly signify a molecular, fibrotic 
process independent of inflammation which can be seen clinically.  
 
Accurately documenting progression presents difficulties, not least because of the 
sensitivity of the currently employed staging systems. The increased sensitivity of the 
Mondino staging system (Elder et al., 1996, Saw et al., 2008) may reflect the ability 
to discriminate the stage of disease in both groups at presentation and 12 month, but 
documentation was superior for Foster staging system. The staging systems 
currently employed also rely upon subjective assessment of conjunctival fibrosis and 
obliteration, indicating that judgment of progression is open to individual 
interpretation. This was reflected in a patient documented as stage 4 at 12 months 
being documented at stage 2 at 24 months. Information regarding horizontal 
obliteration of the fornix by symblephara was also not routinely documented, 
precluding employment of the proposed staging system described by Tauber (Tauber 
et al., 1992). There is also no standardised method of documenting disease 
progression by percentage obliteration in the upper fornix, although the disease is 
clearly not confined to the inferior conjunctival surface.  
 
The difficulty lies not only in identifying early disease and determining which patients 
may progress, but also recognising when this is happening. ‘Activity’ and ‘damage’ 
indices have been validated and accepted for a number of autoimmune conditions 
including Systemic Lupus Erythematosis (SLE) and Primary Sjögren’s Syndrome 
(PSS) (Yee et al., 2007, Gladman et al., 2000, Bowman et al., 2007, Barry et al., 
2008). These indices facilitate not only comparison of clinical cohorts worldwide, but 
also inform clinical trials specifically those targeting therapeutic intervention. As such, 
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clearer strategies for discriminating MMP disease ‘activity’ and ‘damage’ are 
necessary to afford a uniform language and understanding when describing OcMMP 
phenotypes, before molecular targeting and evaluation of novel therapeutic 
approaches through randomised controlled trials can be considered. The 
employment of an agreed CRF as described in Section 3.3.3 may help make these 
distinctions. 
 
These difficulties in determining activity and progression highlight the challenge in 
directing appropriate therapy. The issue of suboptimal therapeutic immuno-
modulation of disease course has been widely described (Foster et al., 1982, 
Mondino and Brown, 1983, Saw et al., 2008, Thorne et al., 2008, Tauber et al., 1991, 
Miserocchi et al., 2002). A recalcitrant group of patients with persistent mild or 
moderate inflammation is highlighted, in keeping with the findings of others (Saw et 
al., 2008, Thorne et al., 2008, Rauz et al., 2005a). Unfortunately, there is also a 
disease subset that either is completely refractory to conventional 
immunosuppression or relapses despite initial success (Thorne et al., 2008). A few 
isolated case reports indicate that ‘biologic’ agents such as rituximab (anti-CD20) or 
infliximab (anti-TNFα) may be beneficial in some of these patients, but as 
randomised trials are lacking, funding for such treatment in the UK prohibits regular 
use (Segura et al., 2007, Canizares et al., 2006, Heffernan and Bentley, 2006, John 
et al., 2007, Taverna et al., 2007, Ross et al., 2009). These data re-emphasise the 
fact that the pathogenesis of OcMMP is not resolved and strengthen the case for 
further study of clinically involved and seemingly uninvolved mucous membranes 
(Bernauer et al., 1993a, Rice and Foster, 1990, Sacks et al., 1989). 
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The reasons for a delay in presentation in the EstD group are not clear. It is possible 
that the clinical features or the severity of the disease may not have been recognised 
until late, as early symptoms may have been insidious and non-specific (Foster et al., 
1982, Bernauer, 1997). A variable duration of disease and course have been 
described by others (Thorne et al., 2008), but the true definition of early disease in 
the context of OcMMP is not known. This may well lie under the 3 year duration of 
symptoms statistically defined in our cohort, and this is particularly relevant if disease 
activity or progression is initially either subtle or sub-clinical. Experience in other 
more common autoimmune diseases such as Rheumatoid Arthritis, point to the 
clinician actively pursuing identification of early disease to enable early therapeutic 
intervention, in order to limit tissue damage (Sheppard et al., 2008). In the light of the 
potential for disease progression in both early or late onset OcMMP disease forms, 
irrespective of whether inflammation is clinically detected or not, it may be prudent for 
ophthalmologists to take precedence from the rheumatological concepts for capturing 
early disease, and adopt a similar approach. 
 
Many of our patients travelled long distances to our centres and this may represent a 
barrier to early tertiary-care of this rare disease, resulting in initiation of suboptimal 
immunomodulation and/or surgery. Stringent efforts to identify features characteristic 
of OcMMP are necessary in order to avoid missing an early diagnosis. Where local 
diagnosis or management is not possible, or where the identification of high risk 
features including severe/ refractory inflammation or evidence of progression is 
manifest, prompt referral of cases with OcMMP to specialised tertiary centres is 
essential for optimisation of immunosuppression aimed at limiting long-term tissue 
damage.  
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Whilst this study is limited by its retrospective nature and bias in the study population 
towards a more severe clinical phenotype, a high proportion (48%) of patients 
required initiation or a switch to more potent immunosuppression following referral to 
our tertiary centres. Additionally, 28% of patients were eventually returned to their 
local referring unit for monitoring after stabilisation of disease.  Most importantly 
however, up to 42% of patients (irrespective of disease phenotype, early or late) 
continued to demonstrate progressive conjunctival scarring in the absence of 
clinically detectable inflammation. A greater understanding of disease pathology is 
required to facilitate earlier recognition of disease, improved activity and damage 
scores, and more accurate therapeutic targeting, specifically for patients recalcitrant 
to existing immunomodulatory therapy.  
 
3.1.2 Determining an objective method for recording the conjunctival cicatricial 
process  
 
Determining progression of disease in PCC is a challenging aspect of patient 
management, as demonstrated in the retrospective analysis of patients at BMEC and 
MEH. As outlined, this relies upon accurate documentation of disease, in particular 
conjunctiva shrinkage of the fornices. Subjective assessment of fornix foreshortening 
is inconsistent and variable, which led to the development of the FDM to enable 
objective FD measurement in our clinic. The use of such devices have been 
previously described for the assessment of scarring in cicatrising conjunctivitis, 
(Schwab et al., 1992, Barabino et al., 2003, Kawakita et al., 2008), but are not 
commercially available.  
 
Chapter 3  Measuring Clinical Parameters 
 
115 
It was apparent that there was a need to design a custom-made FDM that was 
comfortable, accurate and demonstrated low intra- and inter-observer variability. Both 
v1 and v2 of the FDMs were designed and made using industry-standard software 
and machinery taking in to account the curvature of the globe, whilst assessing the 
upper fornix depth. The BMEC v1 and v2 FDMs demonstrated low intra- and inter-
observer variability enabling repeatable and reproducible measurements of both 
upper and lower fornix depths and inter-canthal distance. This represents an 
important advantage in facilitating both accurate documentation and ensuring robust 
clinical documentation of disease stage takes place.  
 
The FDM has the potential to measure upper fornix depth, currently not routinely 
employed in clinical assessment, nor taken into account during ocular staging 
systems which calculate percentage obliteration of the fornix (Mondino and Brown, 
1981, Tauber et al., 1992). The cicatricial process is not confined to the lower fornix 
and the sight threatening sequelae including subtarsal fibrosis, upper lid entropion 
with subsequent lash trauma are clinically apparent. Certainly this is reflected in the 
staging system described by Foster, where fornix shortening or symblepharon of any 
degree is taken in to account (Foster, 1986). The potential for decreased sensitivity in 
relying on this system alone have been discussed and illustrate an obvious 
advantage of using the FDM. 
 
The larger depth of the upper fornix and difficulty of access explains the omission of 
detailed upper fornix pathology in currently recognised scoring systems (Tauber et al., 
1992, Mondino and Brown, 1981). Perhaps not surprisingly therefore, there appears 
to be little data in the ophthalmic literature regarding the anthropology and normal 
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depth of the upper fornix. Kawakita and colleagues have recently discussed the use 
of a non-curved 150mm x 2mm FDM in Japanese patients with Stevens-Johnson 
syndrome and healthy volunteers (Kawakita et al., 2008). They found that the mean 
supero-temporal and supero-nasal upper fornix depths were 14.1mm ±2.5mm in 
normal Japanese individuals. My findings demonstrate a median central upper fornix 
depth of 16mm, even in the presence of recognised causes of cicatricial conjunctivitis. 
Direct comparison is not possible due to the central location of measurement in this 
study, the inclusion of different ethnic groups and the small numbers employed in 
both studies. However, the central upper fornix depth in other healthy populations 
(Caucasian, Afro-Caribbean etc.) may be smaller or larger and clearly illustrates the 
need for a population-based study of the normal age-based upper fornix depths to 
facilitate percentage shrinkage calculations in cicatricial conjunctivitides. This has 
been highlighted in the context of other diseases affecting the size of the upper fornix 
such as the giant fornix syndrome (Rose, 2005). These pieces of data illustrate the 
need for population-based studies of the normal age-based upper fornix depths to 
facilitate percentage shrinkage calculations in conjunctival scarring diseases; and 
these are is currently being undertaken at BMEC and MEH.  
 
The custom-designed FDM is well tolerated by patients with only 3 patients 
experiencing mild discomfort during assessment of the upper fornix. The FDM 
demonstrates low intra- and inter-observer variability enabling repeatable and 
reproducible measurements of lower fornix depths. The custom-design of an FDM 
using industry-standard jewellery software and machinery and curved to fit for the 
globe provides an accurate and comfortable means of assessing lower fornix depth. 
Furthermore, it has potential to measure upper fornix depth, currently not routinely 
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employed in clinical practice. By adapting the longer ‘arm’ of the FDM, allowing for 
the natural curvature of the globe, the FDM could be utilised to measure the inter-
canthal distance. This has the advantage of facilitating assessment of the degree and 
number of symblephara, currently not documented in our clinics. The use of an 
objective mm scale allows a simpler assessment at baseline and follow-up of lower 
and upper fornix depth and the degree of symblephara. 
 
3.4.3 Determining an optimal system for accurately phenotyping disease 
 
In the retrospective series evaluated, current clinical practices of documentation were 
evaluated. Documentation of clinical activity (conjunctival inflammation) was 95% at 
presentation and damage according to the Foster staging 98% indicating that these 
scales were documented consistently in the outpatient setting. Unfortunately the 
Mondino staging system was documented only 84% in the retrospective analysis 
undertaken. Furthermore, Tauber staging was not possible because of the absence 
of information relating to symblephara extent.  
 
The CRF takes the form of a clinical ‘free text’ sheet with accompanying checklist for 
parameters relating to the tear film, the eyelids, the conjunctiva, the fornices, the 
cornea and the sclera. It has been designed to facilitate documentation and is 
complimented by objective assessment by the use of the FDM. It is hoped that it will 
enable a robust, consistent means of documenting damage scales that have been 
validated in the context of OcMMP such as those described by Mondino, Foster and 
Tauber, but also offer the potential for further elucidation of sight-threatening corneal 
damage (Mondino and Brown, 1981, Foster, 1986, Tauber et al., 1992).  
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As stated, a full validation of corneal and indeed other damage indices was beyond 
the scope of this thesis. In order to undertake this, an internationally agreed 
consensus would be required, incorporating an expert panel to oversee an agreed list 
of clinical parameters, followed by validation and determination of inter-observer 
agreement. Whereas the complexity of this task has been highlighted in the case of 
the internationally agreed uveitis classification (Jabs et al., 2005, Kempen et al., 2008, 
Deschenes et al., 2008), our group is currently establishing a platform to allow the 
next stage of developing this tool for PCC. These data have helped inform the nature 
of the clinical phenotype, confirmed the presence of ‘white inflammation’ amongst our 
cohort, and facilitated a better system for measuring and documenting the scarring 
process in OcMMP and other causes of PCC. 
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4.1 Introduction 
 
In order to understand the inflammatory changes on the ocular surface during 
immune-mediated disease, a detailed knowledge of the healthy human conjunctival 
epithelial leukocyte compartment is required. Our current understanding is based on 
conjunctival sections combined with immunohistochemical analysis, the major 
leukocyte populations being predominantly T lymphocytes (Hingorani et al., 1997).  
 
Flow cytometry has been employed widely and contributed to our understanding of 
immune processes, not least in the immunology of the gut both in animal models and 
human tissue (Agace, 2008). OSIC combined with flow cytometric analysis has been 
undertaken in the context of the conjunctiva, employing two-colour flow cytometry in 
dry eye disease on cells transferred in fixative (Baudouin et al., 1992, Baudouin et al., 
1997). Ex vivo analyses of the healthy ocular surface cell populations through flow 
cytometry including the exploitation of multi-colour panels has not previously been 
undertaken however. This chapter outlines how this approach was optimised and 
utilised to determine leukocytes in health, ageing and how dominant T cells behave. 
 
4.1.1 Optimisation of mucous membrane cellular profiles detection by OSIC 
 
Before characterising healthy conjunctival epithelial leukocyte populations the 
following practicalities were considered: 
1. How could conjunctival leukocytes be collected? 
2. How they were transported and recovered? 
3. How leukocytes were discriminated from other cells e.g. epithelial cells? 
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Of the two membranes commonly used for OSIC, the isopore polycarbonate 
membrane (Millipore) is attractive because of its commercial availability in a pre-
sterilised form (mounted on a transparent cylinder), facilitating easy use in the clinical 
environment. By contrast, circular polyethersulfone membranes (Supor) (13mm 
diameter) are available in unsterilised packages that require division and autoclaving 
for application with forceps. However, more efficient cell recovery has been reported 
with the Supor filter combined with transport in fixative and recovery with gentle 
agitation using a pipette tip (Brignole-Baudouin et al., 2004).  
 
When undertaking OSIC of the conjunctiva, all cell types are recovered including 
epithelium, goblet cells and intra-epithelial leukocytes (Brignole-Baudouin et al., 
2004). In order to discriminate leukocytes a pan-leukocyte marker such as CD45 can 
be employed (Baudouin et al., 1997). It was important to determine the brightest 
signal that would allow accurate distinction of leukocytes from other cells e.g. 
neutrophils, which have a less bright expression of CD45 than lymphocytes and 
monocytes (Stelzer et al., 1993). 
 
4.1.2 Defining resident conjunctival leukocyte populations 
 
As outlined in Chapter 1, the precise composition of leukocytes in the healthy 
conjunctiva has not been undertaken. Multi-colour flow cytometry offers an 
opportunity to discriminate cell populations by using multiple markers e.g. CD3 and 
CD56 for T cells, NK and NKT cells or T cells based on TCR subtype e.g. TCRαβ or 
γδ. In this chapter resident conjunctival epithelial leukocyte populations were defined. 
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4.1.3 Age-related changes in the healthy human conjunctival epithelium 
 
Little is known about age-related changes in the leukocyte populations within the 
ocular surface (Gwynn et al., 1993). This study utilised OSIC in combination with 
multi-colour flow cytometry not only to provide a detailed characterisation of the 
frequency of leukocyte subsets in the healthy human conjunctival epithelium, but 
whether these altered with age. This has the potential to offer clues about natural 
ageing changes and vulnerability to age-related diseases affecting the ocular surface. 
 
4.1.4 Effector Function of the dominant conjunctival epithelial CD8+ T cells 
 
The effector function of dominant conjunctival epithelial T cells is unknown. Antigen 
experienced (CD45RO+) cells have been identified in the conjunctiva, but precise 
memory status of CD8+ population is unknown. At mucosal sites, effector function of 
CD8+ T cells may differ from a conventional cytotoxic phenotype and repeated 
exposure to antigen may account for an altered role for epithelial CD8+ lymphocytes, 
some of which may be regulatory in nature (Koch et al., 2008, Xystrakis et al., 2004). 
CD8+ T cells play an important role in regulating chronic viral infection such as CMV 
and the use of MHC restricted tetramers in HLA-typed individuals has demonstrated 
that 1-2% of CD8+ T cells recognise viral antigens such as pp65 and IE-1 and the 
aggregate response could account for 50% of the total CD8+ repertoire (Moss and 
Khan, 2004, Faint et al., 2001). Before phenotyping conjunctival epithelial leukocytes 
in MMP and how these may alter with disease activity or progression, it is important 
therefore to establish if and how the CD8+ T cells dominate the conjunctiva in health 
before characterising any potential change in the context of disease.  
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4.2 Methods 
4.2.1 Optimisation of mucous membrane cellular profiles detection 
Determining an optimal OSIC membrane 
 
Cell recovery comparisons were undertaken as described in section 2.1.6. 
Application of an OSIC membrane on a healthy participant is shown in Figure 4.1. 
 
Cells were collected from healthy volunteers (n=5) (median age 70 [30-88]; 3 male; 4 
White European, 1 Asian) (Cohort 4) to establish whether events could be detected 
with both filters. Cells were recovered by agitation with a pipette tip for 30 minutes as 
described in section 2.2.2. Unlabelled cells were run through a flow cytometer as 
described in 2.2.4. Where low events were detected by flow cytometry, haematoxylin 
and eosin staining of the membrane was undertaken as described in 2.2.1 to 
determine if there were residual cells on the membrane. 
 
 
 
 
 
 
 
 
Figure 4.1 Application of an OSIC membrane. Colour photograph demonstrating the application of a 
Supor membrane to the healthy ocular surface of the superior bulbar conjunctiva. 
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Identification of leukocyte populations by CD45+ pan-leukocyte marker 
 
Cells recovered by OSIC were stained with anti-CD45+ pan leukocyte markers in 
order to discriminate leukocyte populations. Two commercially available anti-CD45 
antibodies were compared; Phycoerythrin (PE) anti-CD45 and Allophycocyanin 
(APC) anti-CD45 (Ebioscience). Staining procedures were as described in 2.2.5. 
 
Increasing the efficiency of cellular recovery 
 
In order to determine whether cellular recovery by pipette tip agitation could be 
expedited, agitation of cells recovered with a pipette were compared at conventional 
(30 minute) and rapid (1 minute) time frames.  
 
4.2.2 Defining resident conjunctival leukocyte populations and age-related 
changes in the healthy human conjunctival epithelium 
 
Study Subjects. Two separate cohorts were evaluated: 
 
Cohort 5 (Figures 5.5-5.7): OSIC of right and left eyes of 30 healthy participants 
(median age 61 years [21- 83]) together with matched peripheral blood were 
collected. 20/30 individuals were White (European) and 10/30 were Asian (defined 
according to the ethnic demographic categories employed in the UK census 2011). 
Fifteen were male and fifteen were female.  
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Cohort 6 (Figure 5.8): OSIC of right and left eyes were collected and pooled for each 
of 10 healthy volunteers (5 young; median age 24 [23-33] and 5 older; median age 
66 [65-83], p=0.01) in order to evaluate conjunctival T cell cytokine production.  All 
were White (European) with five males and five females. Samples were pooled in this 
cohort in order to maximize the yield of cells for cytokine staining. 
 
Sample collection and recovery 
 
OSIC sampling and cellular recovery were as described in section 2.1.6. OSIC with 
sterile Supor filters were used to collect superficial conjunctival cells. Following cyto-
centrifuge, the majority of the supernatant was discarded, which was re-suspended in 
RPMI:10% HIFCS to a total volume of 200µl (Cohort 5) or 100µl (Cohort 6). 100µl of 
cells were placed into each well of a 96-well plate for flow-cytometric analysis. 
Peripheral blood was centrifuged and re-suspended in 1:10 dilution of filter-sterilised 
red cell lysis buffer (8.29g NH4Cl, 1g KHCO3 and 37.2 mg EDTA per litre dH20) as 
described in in section 2.2.3. 
 
Flow cytometry was undertaken as described in section 2.2.4.  
 
To characterise the cellular profile of the conjunctival ocular surface, nine colour flow 
cytometry panels were employed as described in 2.2.5.   
 
Procedures for intracellular cytokine assays (Cohort 6) were as described in 2.2.7. 
An additional panel was utilised to determine cytokine expression by T cell subsets: 
mouse anti-human IFN-γ (efluor 450) (Ebioscience), IL-17 (FITC) (Ebioscience) and 
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rat anti-human IL-10 (Phycoerythrin) (Biolegend) combined with cell surface marker 
antibodies to CD4 (PerCP Cy5.5), CD45 (Allophycocyanin), CD3 (AlexaFluor 780) 
(Ebioscience), CD8β (PE Texas Red) (Beckman Coulter) and CD56 (PE Cy7) 
(Biolegend).  
 
4.2.3 Effector Function of the dominant conjunctival epithelial CD8+ T cells 
 
Study Subjects. Two separate cohorts were evaluated:  
 
Cohort 7 (Figure 5.9-5.10): OSIC of right and left eyes were collected and pooled for 
each of 17 healthy participants (median age 32 [21-81]; 10 males; 16 White 
European, 1 Asian) in order to evaluate memory and homing status and phenotypic 
markers of conjunctival epithelial CD8+ T cells.  
 
Cohort 8 (Figure 5.11): OSIC of right and left eyes were collected and pooled for 
each of 10 healthy volunteers (median age 33 [25-52]; 6 male; 10 White European) 
of known HLA typed individuals in order to evaluate viral MHC class tetramer staining.  
 
Samples were pooled in both cohorts in order to maximise the yield of cells for 
cytokine staining. The right and left eye samples together with matched peripheral 
blood were collected.  
 
Sample collection was as described in 2.2.3.  
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The majority of the supernatant was discarded, which was re-suspended in 
RPMI:10% HIFCS to a total volume of 100µl. Cells were placed into each well of a 
96-well plate for flow-cytometric analysis as previously described. 
 
The protocol for flow cytometric analysis was as described in 2.2.4.   
 
Surface staining was as described in section 2.2.5. For determination of homing and 
memory markers (Cohort 7), a re-configured panel was designed and included 
mouse anti-human leukocyte markers CD45 (Allophycocyanin or Phycoerythrin), 
CD3 (AlexaFluor 780) (Ebioscience, Hatfield, UK); CD8α (Pacific Orange) (Invitrogen, 
Paisley, UK) or CD8β (PE Texas Red) (Beckman Coulter); CD56 (PE Cy7) 
(Biolegend, Cambridge, UK); Memory markers including CD45RO (FITC), CD45RA 
(PE Texas Red) (Beckman Coulter, UK), CCR7 (FITC) (R & D Systems, UK) and the 
homing markers αE (CD103) (FITC) (DAKO, UK) and β7 (PE Cy5) (BD, UK). These 
were titrated to determine the optimal concentrations.  
 
Intracellular Cytokine Staining, Cytolytic Proteins and Transcription Factors 
 
Procedures were as described in 2.2.6 and 2.2.7, including the use of a Live Dead 
fixable yellow dye (Invitrogen) Cytokine expression was determined by a panel 
including mouse anti-human IFN-γ (efluor 450) (Ebioscience), IL-17 (FITC) 
(Ebioscience), and rat anti-human IL-10 (Phycoerythrin) (Biolegend) or IL-22 
(Ebioscience). These were combined with surface marker antibodies anti-CD45 
(Allophycocyanin or Phycoerythrin), CD3 (AlexaFluor 780), CD8β (PE Texas Red) 
and CD56 (PE Cy7) (Biolegend) following stimulation of cells.  
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Mouse anti-human Granzyme B (PE) (BD, UK) or Perforin (PE) (Ancell, Bingham, 
UK) were combined with anti-CD45 (Allophycocyanin), CD3 (AlexaFluor 780), CD8β 
(PE Texas Red) and CD56 (PE Cy7) (Biolegend) without stimulation of cells.  
 
Rat anti-human FoxP3 (PE) (Ebioscience) was combined with anti-CD45 
(Allophycocyanin), CD3 (AlexaFluor 780), CD8β (PE Texas Red) and CD56 (PE Cy7) 
(Biolegend) without stimulation of cells. 
 
Details of viral peptide MHC-I tetramer staining is described in 2.2.8. Tetramers were 
prepared in advance and donated as a gift by AP and HL. CMV or EBV tetramers 
were pooled in order to maximise T-cell interaction in conjunctival OSIC or peripheral 
blood cells with known viral antigens derived from HLA typed individuals, known to 
respond to antigens outlined in Table 2.1. 
 
Statistical Analysis 
 
Non-parametric comparisons were undertaken with the Mann Whitney U test, 
Wilcoxon signed rank test and correlations by Spearman’s correlation using Prism 
version 5.0 for Macintosh (GraphPad Software, California 2008). 
Chapter 4  Characterising the healthy conjunctiva 
129 
4.3 Results 
4.3.1 Optimisation of mucous membrane cellular profiles detection 
Conjunctival OSIC and Cellular Recovery 
 
Cell recovery using the Supor filter detected a median of 5 x 104 [range 100-100,000] 
events/filter paper (n=5). By contrast, cell recovery with Millipore filters following 
collection, suspension and agitation yielded no cells (n=4) or 1 x 103 events/filter 
paper (n=1). Few cells were identifiable by H & E staining of the residual membrane 
following agitation, indicating that the Millipore collection yield was poor (Figure 4.2).  
 
 
 
 
 
 
Figure 4.2: Haematoxylin & Eosin staining of Millipore filter. Representative H & E section (10x 
magnification) of a Millipore filter following conjunctival impression, suspension in RPMI and agitation 
of cells with a capillary tip. Note the scanty residual cells (1 demonstrated in this section) on the 
membrane despite agitation. The poor yield from agitation implies that initial collection of cells with this 
filter is poor, limiting its value in cell collection for the purpose of flow cytometric analysis. 
 
Identification of tissue leukocyte populations by flow cytometry 
 
In order to discriminate leukocyte populations from epithelial cells in conjunctival 
OSIC specimens using Supor filters, a pan-CD45 leukocyte marker was employed. 
Figure 4.3 demonstrates surface marker staining of whole blood and conjunctival 
impressions taken from a healthy volunteer ‘spiked’ with 5μl of whole blood 
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(1x107cells/ml) in order to replicate the presence of neutrophils (which would not be 
expected in healthy human conjunctival epithelium). Two antibodies were compared 
to determine the brightness of surface staining and ability to discriminate subsets of 
cells (PE anti CD45 and APC CD45). Granulocytes (including neutrophils) have a 
high side scatter (SS) and when using the APC anti-CD45 antibody, the brightness of 
this antibody was greater than for PE (Regions R5 and R6 respectively), seen on the 
x-axis of the whole blood staining. This presents a problem for the ‘spiked’ 
impression as CD45LOW cells (predominantly epithelial cells from the conjunctival 
OSIC), cannot easily be discriminated from CD45INT (neutrophils) when using the PE 
anti-CD45 antibody. Back gating these populations (R5 and R6) on to a forward 
scatter (FS) and SS profile demonstrate a higher proportion of cells with a high SS, 
consistent with neutrophils, when using the APC-anti CD45 antibody. This was the 
antibody used for comparisons between healthy volunteers and patients with disease 
where the presence of neutrophils was anticipated. 
 
A period of 30 minutes of agitation of cells from the impression filter has previously 
been described (Brignole-Baudouin et al., 2004). Figure 4.4 demonstrates that the 
number of lymphocytes derived from 1 minute of agitation were greater than for re-
suspension of the impression filter and agitation for 30 minutes after running both 
samples until completion. The forward and side scatter profile was also different for 
30-minute agitation those observed for 1 minute. It is possible that prolonged 
agitation disrupts the filter membrane itself, contributing to the events detected by the 
flow cytometer.  
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Figure 4.3: Determination of efficacy of Phycoerythrin (PE) and Allophycocyanin 
(APC) anti-CD45 labelling of leukocyte populations. The side scatter (SS) and 
staining intensity of CD45  leukocytes can be compared between the two 
fluorochromes (regions R4 and R1 respectively for PE [Panel A] and APC [Panel B]).  
The SS and fluorescence profiles of conjunctival Ocular Surface Impression Cytology 
(OSIC) spiked with 5υl whole blood (as a ‘positive’ control’) allow comparison of cells 
that have a SS profile consistent with neutrophils (regions R5 and R6). Back-gating 
for CD45+ high cells (regions R4 and R1) allows discrimination of epithelial cells 
which are not masked by CD45  (intermediate) cells (demonstrated in R5 for PE). 
These cells had a scatter profile consistent with neutrophils, seen on regions R43 and 
R7 respectively. 
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Figure 4.4: Demonstration of cellular recovery from conjunctival Ocular Surface 
Impression Cytology (OSIC) at 1 minute agitation (left panels) versus 30 
minutes agitation (right panels). Cells were recovered from media following 1 
minute agitation, centrifuged and re-suspended in 100ul of media prior to antibody 
labelling. The residual impression filters were then re-suspended and agitated for 30 
minutes before processing (Panel B). Upper Panels A show the unlabelled forward 
(FS) and side scatter (SS). Back gating of live cells (blue boxed, panel C) on to a FS v 
SS profile are shown in Panel C. Note the abnormal scatter profile following 30 minute 
agitation and diminished yield of lymphocytes from the 30 minute agitation. 
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4.3.2 Defining resident conjunctival leukocyte populations 
Conjunctival OSIC and matched peripheral blood samples taken from healthy 
subjects (Cohort 5) demonstrated that while the light scatter profile for peripheral 
blood clearly delineated each leukocyte population (Figure 4.5A), it was not possible 
to make this discrimination from OSIC (Figure 4.5D). This was overcome by gating 
on APC labelled CD45+ live cells, which permitted demonstration of lymphocytes as 
the dominant leukocyte population in the conjunctival epithelium (Figure 4.5E,F). 
This approach also clarified the identity of the leukocyte populations found in 
peripheral blood (Figure 4.5B,C). 
 
Leukocyte populations were therefore defined as being live CD45+ve cells derived 
from conjunctival impressions specimens from the superior bulbar conjunctiva, 
transferred immediately to RPMI:HIFCS and agitated for 1 minute before preparation 
and staining. 
 
There were no differences in the number of leukocytes between the right and left 
eyes (p=0.23; Wilcoxon signed rank test) and right and left eye leukocyte numbers 
were highly correlated (r=0.72; p <0.0001). Therefore, the mean of right and left eyes 
for each subject was calculated (i.e. right and left eyes per individual subject were 
considered to be experimental duplicates).  CD45+ live cells accounted for a median 
834 [range 60-17635] of total events. Of the cohort of 30 subjects (median age 61 
years [21-83]), the dominant conjunctival leukocyte population were lymphocytes 
(median 89% of the total lymphocyte, monocyte and neutrophil counts [32-99]) as 
defined by their forward and side scatter profiles; 9% [0-34] were monocytes and 
<1% [0-66] were neutrophils. This compared to 52%[18-75], 5%[3-28] and 42%[19-
76] respectively in matched peripheral blood.  
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Figure 4.5: Lymphocytes are the dominant conjunctival epithelial leukocyte 
population. Representative plots of a subject demonstrating the gating strategy used 
to identify conjunctival leukocytes. Panels A and D show the forward and side scatter 
profiles for peripheral blood and conjunctival Ocular Surface Impression Cytology 
(OSIC) respectively. Live leukocytes were identified by gating for CD45+ cells that 
were negative for the dead cell exclusion dye Sytox blue (lower right box in panel B 
and E) and back-gated to show the forward and side scatter profiles of the CD45+ live 
cells (panels C and F). Percentages are shown for the representative subjects 
(Granulocytes 45% and <1%; Monocytes 5 and 7%; Lymphocytes 45 and 79% 
respectively). 
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T and NK cell subsets were defined by the expression of CD3 and CD56 (Figure 4.6). 
T cells (CD3+CD56-) dominated in both conjunctival OSIC (69% [47-90]) and in 
matched peripheral blood (74% [57-84]), and these were >98% TCRγδ-(TCRαβ+) in 
both (Figure 4.6A,B). T cells were further characterised by the expression of the 
CD4, CD8α and CD8β cell surface co-receptors (Figure 4.6A,B). Unlike in the 
peripheral blood where the dominant T cell population was CD4+ (Figure 4.6D; 69% 
[45-91]), the dominant population from the conjunctival impression was CD8αβ+ 
(Figure 4.4C: 80% [37-100]). The majority of CD4+ and CD8αβ+ T cells were 
CD45RO+ in the conjunctival epithelium (100%[0-100] and 94%[55-100] 
respectively), higher than the proportion of antigen experienced populations in blood 
(61%[0-90] and 56%[20-86] respectively). CD4-CD8αβ- (DN) T cells accounted for 
only 7.3% [0.7-22] and 3.5% [0.4-26] of conjunctival and peripheral blood T cells, 
respectively (Figure 4.6E). Whilst CD8αα+ cells formed the minority of T cells, these 
were significantly higher in the conjunctiva than in peripheral blood (Figure 4.6F; 
2.6% [0-12.5] versus 1.4% [0.1-4.4] (p<0.001)).  
 
NK cells represented 7%[0-20] of conjunctival epithelial lymphocytes compared with 
9%[0-22] in peripheral blood. There was also a greater proportion of NKT 
(CD3+CD56+) cells (conjunctiva 6%[0-17] versus peripheral blood 2%[0-6]  (p>0.05)) 
but fewer CD19+CD20+ B cells (3%[1-45] versus 9%[3-23], respectively, (p<0.0001)).  
 
 
 
 
Figure 4.6: TCRαβ+ CD8αβ+ T cells are the dominant population of lymphocytes 
in the conjunctival epithelium. Representative scatter profile of leukocyte 
populations derived from matched peripheral blood and conjunctival ocular surface 
impression cytology (OSIC) from a healthy subject. Data is shown for a representative 
subject, gated on CD45+ live cells for peripheral blood (A) and conjunctival OSIC (B). 
CD45RO staining is shown for CD3+CD56-TCRgd- gated CD4+CD8b- (top panel) 
and CD8ab+ (bottom panel) cells. Percentages of CD3+CD56- lymphocytes are 
shown for the representative subject (n=30). Statistical comparisons between 
peripheral blood and conjunctival impression populations of CD8αβ+, CD4+, CD8αα+ 
and TCRαβ+CD4-CD8αβ- (double negative; DN) T cells (C-F) were undertaken by the 
Mann-Whitney U test (NS: Not significant [p>0.05], **P < 0.01, ***P < 0.001). 
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4.3.3 Age Related Changes In Leukocyte Populations In The Healthy Human 
Conjunctival Epithelium 
 
Having determined the normal leukocyte populations in Cohort 5, the age spectrum 
within this cohort allowed us to determine if age-related changes occurred in these 
leukocyte populations (Table 4.1). Analysis of peripheral blood monocyte, neutrophil 
and lymphocyte frequencies showed that the only change was a decrease with age 
in lymphocytes calculated as a percentage of total leukocytes (Table 4.1).  This was 
not observed in cells recovered from the conjunctival epithelium. By contrast, 
conjunctival cells showed an increase in the numbers of lymphocytes and monocytes 
(but not neutrophils), resulting in a significant increase in the total number of 
leukocytes (Table 4.1). This demonstrates that the primary observation of 
lymphocytes being the dominant population is maintained with age, but alterations in 
the composition of the lymphocytes occurred. 
 
Within the conjunctival epithelial lymphocyte population there was an age-related 
decrease in the proportion of T cells (Figure 4.7A; Table 4.2), compensated for by 
an increase in the percentage of NK cells (Table 4.2). The dominant CD8αβ+ cell 
population remained unchanged in the conjunctival epithelium with age but 
decreased in peripheral blood (Figure 4.7B, Table 4.2). Conversely, the absolute 
number of CD4+ cells significantly increased in the conjunctiva but remained 
unchanged in peripheral blood (Figure 4.7E, Table 4.2). This resulted in proportional 
changes in CD8αβ+ and CD4+ lymphocytes (Figure 4.7C and F Table 2) with a 
consequent increase in the CD4:CD8 ratio with age (Table 4.2). In addition, the 
CD45RO+ memory population increased in the peripheral blood with age, a change 
that was not seen in conjunctival OSIC (Figure 4.7D and G, Table 4.2), reflecting the 
Chapter 4  Characterising the healthy conjunctiva 
138 
high proportion of antigen experienced CD8+ (93%) and CD4+ cells (100%) present 
in the conjunctival epithelium from a young age. 
 
Cell population Age correlation r value (p value1) 
 Peripheral Blood Conjunctival 
OSIC 
Peripheral Blood Conjunctival 
OSIC 
Leukocytes numbers No change Increase 0.05 (NS) 0.43 (0.02) 
Lymphocytes numbers No change Increase -0.23 (0.03) 0.38 (0.04) 
Lymphocytes  
(% of leukocytes) 
Decrease No change -0.4 (0.03) -0.08 (NS) 
Monocyte numbers  No change Increase 0.01 (NS) 0.45 (0.01) 
Monocytes 
(% of leukocytes) 
No change No change -0.01 (NS) 0.34 (NS) 
Neutrophil numbers  No change No change 0.20 (NS) 0.33 (NS) 
Neutrophils 
(% of leukocytes) 
No change No change 0.34 (NS) -0.09 (NS) 
 
1Spearman’s correlation: NS: Not significant [p>0.05], 
 
Table 4.1. Ageing changes in leukocyte populations in peripheral blood and conjunctiva.  
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Cell population Age correlation r value (p value1) 
 Peripheral Blood Conjunctival 
OSIC 
Peripheral Blood Conjunctival 
OSIC 
T cells  
(% of lymphocytes) 
No change Decrease -0.18 (NS) -0.45 (0.01) 
CD8αβ+ numbers Decrease No change -0.5 (<0.01) 0.3 (NS) 
CD8αβ+  
(% of T cells) 
No change Decrease 0.31 (NS) -0.49 (<0.01) 
CD45RO+ cells 
(% of  CD8αβ+ cells) 
Increase No change 0.53 (<0.01) 0.13 (NS) 
CD4+ numbers No change Increase -0.1 (NS) 0.61 (<0.001) 
CD4+  
(% of T cells) 
Increase Increase 0.52 (<0.01) 0.52 (<0.01) 
CD45RO+ cells 
(% of CD4+ cells) 
Increase No change 0.53 (<0.01) 0.27 (NS) 
CD4:CD8 ratio Increase Increase 0.41 (0.03) 0.49 (<0.01) 
B cells (% of lymphocytes) No change No change 0.18 (NS) -0.08 (NS) 
NK cells  
(% lymphocytes) 
No change Increase 0.24 (NS) 0.4 (0.03) 
NKT cells  
(% lymphocytes) 
No change No change -0.05 (NS) 0.15 (NS) 
 
1Spearman’s correlation: NS: Not significant [p>0.05],  
 
Table 4.2. Changes in lymphocyte populations in peripheral blood and conjunctiva with age. 
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Figure 4.7: Changes in T cell subsets and memory populations in peripheral 
blood and conjunctiva with age. Changes in the T cell populations in peripheral 
blood (PB) and conjunctival ocular surface impression cytology (OSIC) for 
CD3+CD56- lymphocytes (A), as well as CD8αβ+ and CD4+ subsets (B/C, E/F) with 
their respective CD45RO frequencies (D, G). Statistical analysis was undertaken by 
Spearman’s correlation (NS: Not significant [p>0.05], *P < 0.05, **P < 0.01) (n=30). 
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In light of the increase in conjunctival CD4+ T cells with age, further analysis of their 
phenotype was undertaken (Cohort 6). Conjunctival CD4+ T cells of a cohort of 5 
additional healthy younger (<35 years) and 5 older subjects (>65 years) were 
characterised for the expression of IFNγ, IL-17 and IL-10 following stimulation with 
PMA/Ionomycin (Figure 4.8A). The CD4+ population as a percentage of T cells was 
significantly elevated in the older age group (19%[11-52) vs. those <35 years] (4%[2-
13]; p=0.02), confirming the observation from the larger cohort of 30 individuals 
(Cohort 1) (Figure 4.8B).  
 
18%[14-48] of conjunctival CD4+ T cells were capable of expressing IFN-γ, 3.5%[0-
22] IL-17 and 0%[0-4] IL-10. The absolute number of CD4+ T cells able to secrete 
IFN-γ was significantly elevated with age (<35 years, 7[4-39] vs. >65 years, 43[20-
145];p=0.03) while the percentage of IFN-γ+ CD4+ remained unchanged (17%[14-35] 
vs. 18%[16-48],p=NS, respectively) (Figure 4.8C). Changes in IL-17 and IL-10 
producing CD4+ T cells were not observed with age (Figure 4.8C). 
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Figure 4.8: IFN-γ  producing  TCRαβ+ CD4+ T cells increase with age while IL-17 
producing cells are maintained. Expression of IFNγ, IL-17 and IL-10 in the T cell 
populations in stimulated peripheral blood (PB) and conjunctival ocular surface 
impression cytology (OSIC) for CD45+CD3+CD56-CD4+ live lymphocytes (A). 
Representative figures from a subjects aged <35 and >65 years are shown. The 
number and percentage of CD4+ T cells are shown for this cohort (B), as well as the 
number and percentages of cytokine-secreting cells (C). Statistical comparisons were 
undertaken by the Mann-Whitney U test (NS: Not significant [p>0.05], *P < 0.05). 
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4.3.4 Effector Function of the dominant conjunctival epithelial CD8+ T cells 
 
Although there is an elevation in CD4+ cells in the conjunctival IEL compartment with 
age, the CD8+ T cell population remains unaltered. In order to characterise these 
dominant and stable cells in more detail, the memory status, homing marker 
expression, phenotypic markers and antigen recognition of CD8+ T-cells were 
determined (Cohorts 7 and 8). 85%[59-94] of conjunctival T cells were CD8+ (Figure 
4.9A), in keeping with the normal values demonstrated in 4.3.2. 
 
Memory and Homing 
 
Mucosal homing cells were predicted to have switched to the expression of a 
epithelial homing marker CD103(αE). 99%[92-100%] of conjunctival T cells in this 
cohort expressed the integrin αEβ7 (CD103) compared to 1.8% [0.7-2.3] in peripheral 
blood (p=0.005) (Figure 4.9B, 1D) (n=6). Conversely, 0.1%[0-2] of conjunctival CD8+ 
T cells were αEβ7- (α4β7+) compared to 56%[21-78] in peripheral blood (p=0.005). 
 
The majority of conjunctival epithelial cells were previously identified as being antigen 
experienced (CD45RO+). 88% [62-100] of the conjunctival epithelial CD8+ 
population were in fact CD45RA-(CD45RO+) CCR7- effector memory (EM) cells 
compared to 43%[18-61] in peripheral blood (Figure 4.9 C, E) (n=7). Although there 
was no difference in the proportion of central memory cells between the conjunctiva 
and peripheral blood, these formed a minor population of CD45RO+ (RA-) cells 
(2%[0-28] vs. 1%[0.5-6]; p=0.6). The dominant CD45RO+ population was reflected in 
a significantly lower proportion of naïve cells (CD45RA+CCR7+) in the conjunctiva 
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(0.2%[0-3]) compared to peripheral blood (36%[1-58]) (p<0.05) (Figure 4.9E). There 
were also a significantly lower proportion of effector memory RA ‘revertant’ CD8+ T 
cells in the conjunctiva (6%[0-21] vs. 28%[5-56]; p<0.05). The dominant antigen 
experienced CD8+ T cell population is therefore composed primarily of EM cells and 
were less likely to have reverted to a CD45RA+ CCR7-phenotype, as seen in 
peripheral blood.   
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Figure 4.9: Conjunctival CD8+ lymphocytes are mucosal homing, effector 
memory T cells. The gating strategy for determining CD8+ T cell populations from 
conjunctival ocular surface impressions and accompanying matched peripheral blood 
samples are shown in Panel A. Representative plots for mucosal homing integrin 
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(Panels B and C) Significant differences in homing (Panel D) and memory status 
(Panel E) between conjunctival epithelial leukocyte and peripheral blood populations 
(n=6). Statistical analysis was undertaken by the Wilcoxon signed rank test (Key: NS: 
Not significant (p>0.05), *p=0.01 to 0.05; **p=0.001 to 0.01).  
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Phenotypic Markers of conjunctival epithelial CD8+ T cells 
 
36%[24-80] of antigen experienced conjunctival CD8+ T cells were capable of 
expressing IFN-γ, compared to 34%[20-64] in peripheral blood (p=0.84). Although 
there was no significant difference in the Median Fluorescence Intensity (MFI) of IFN-
γ in the conjunctiva 78[54-112] compared to peripheral blood 134[50-184] (p=0.15), 
the trend indicated that this was lower in the conjunctival population (Figure 4.10 A, 
4.11). Of the conjunctival memory CD8+ T cells, 55[34-68]% produced Granzyme B 
compared to 38%[29-49] in peripheral blood (p=0.03) (Figure 4.10 A, 4.11). The MFI 
however was significantly lower among conjunctival CD8+ T cells; 39[28-47] vs. 
100[76-149] (p=0.03). This demonstrates a cytotoxic phenotype among resident 
conjunctival epithelial CD8+ T cells, but with lower expression of Granzyme B despite 
a relatively higher proportion of cells. Expression of Perforin, also capable of inducing 
cellular apoptosis, was variable in unstimulated cells with a median of 0%[0-13] 
among conjunctival cells compared to 9%[5-10] in peripheral blood (n=3). A 
representative flow cytometric plot of Perforin expression by peripheral blood NK 
cells is demonstrated for comparative purposes (Figure 4.10B, 4.11). 
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A minor but relatively higher percentage of conjunctival CD8+ T cells produced IL-17 
(2%[1-7)] compared to peripheral blood cells (0.3%[0.2-0.4;(p=0.03), indicating a 
potential population of Tc17 cells in the ocular surface mucosa. There was no 
difference in the proportion of CD8+ T cells producing IL-22 (1.4%[0-3] vs. 1%[0-3]; 
p=0.56). Representative plots demonstrating peripheral blood CD4 expression of IL-
17, 10 and 22 are shown in Figures 4.10B and 4.11. There was little evidence for 
regulatory CD8+ population in the superficial conjunctival epithelium. No conjunctival 
CD8+ T cells were capable of producing IL-10, compared to 0.4%[0.2-0.6] of 
peripheral blood cells (p=0.03). No differences were also found in the proportion of 
cells capable of expressing FoxP3 (0.6%[0-1.6] vs. 0.6%[0.2-1.2]; p=1.0). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Conjunctival epithelial CD8+ Granzyme B+ cells are significantly higher in the 
conjunctival epithelium compared to peripheral blood but their Median Fluorescence Intensity 
(MFI) is lower. Comparative analysis of effector function of conjunctival (CI) and peripheral blood 
CD8+ T cells are shown. Comparisons were between % of CD8+ T cells or the MFI. Statistical 
analysis was undertaken by the Wilcoxon signed rank test (Key: NS: Not significant (p>0.05), *p=0.01 
to 0.05). 
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Viral antigen recognition by conjunctival epithelial CD8+ T cells 
 
Given the predominant CD45RA-CCR7- CD8+ population, it was anticipated that the 
CD8+ population may contain cells that recognise the herpetic viruses CMV and/or 
EBV. By pooling tetramers of known viral antigens including CMV - HLA-A1 VTE, 
HLA-A1 YSE, HLA-A2 NLV, HLA-B7 RPH, HLA-B8 ELK, HLA-B8 QIK and EBV - 
HLA-A2 GLC, HLA-A2 YVL, HLA-B8 RAK and HLA-B8 FLR in a cohort of HLA-typed 
volunteers, known to respond to >1 antigen (Cohort 8) we were able to determine 
percentage of CD8+ T cells that were able to recognise respective viruses from 
conjunctival OSIC and peripheral blood. 0.4%[0-7.9] of conjunctival CD8+ cells 
recognised CMV antigens and 0.6%[0-1.9] EBV antigens (n=10), reflecting peripheral 
blood frequencies; 1%[0.3-6.7]% and 2%[0-4] respectively (r=0.95;p=0.0001) (Figure 
4.12 A, B and C). There were also no differences between the frequencies of CMV+ 
and EBV+ CD8+ T cells in the conjunctiva (p=0.62) or in the peripheral blood p=0.25).  
 
EBV+ CD8+ T cells were predominantly Effector Memory (CD45RA-CCR7-) in the 
conjunctiva compared to peripheral blood (75%[0-100] vs. 44%[0-75]; p=0.008), with 
a higher proportion of CD45RA+CCR7- ‘revertant’ CMV+ or EBV+ cells in peripheral 
blood (32%[0-88] vs. 0%[0-78]; p=0.004) (Figure 4.12D).  
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Figure 4.12: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) recognition 
among conjunctival epithelial CD8+ T cells reflects that of peripheral blood. 
Conjunctival CD8+ T cells were stained with pooled CMV or EBV peptide MHC-Class 
I restricted tetramers conjugated to APC (CMV: HLA-A1 VTE, HLA-A1 YSE, HLA-A2 
NLV, HLA-B7 RPH, HLA-B7 NLV, HLA-B8 ELK HLA-B8 QIK and EBV: A2 GLC, HLA-
A2 YVC, HLA-B7 RAG, HLA-B7 FLR, HLA-B8 RAK HLA-B8 FLR). Representative 
plots for CMV+ and EBV+ CD3+CD56-CD8+ T cells are shown in Panels A and B 
respectively. Correlation between percentage CMV+ or EBV+ CD8+ T cells in 
peripheral blood and conjunctiva are shown in Panel C. Differences between % 
Effector Memory and Effector Memory RA populations in peripheral blood and 
conjunctiva are shown in Panel D. Statistical analysis was undertaken by Spearman’s 
correlation or Wilcoxon signed rank test (Key: NS: Not significant (p>0.05), *p=0.01 to 
0.05; **p=0.001 to 0.01; *** p<0.001). 
B A 
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4.4 Discussion 
4.4.1 Optimisation of mucous membrane cellular profiles detection 
 
The ability to take OSICs from healthy participants and patients with PCC such as 
OcMMP has major advantages in facilitating: 
 
(i) A non-invasive means of collecting ocular surface cells  
(ii) A consistent method for longitudinally sampling patients 
(iii) A means of interrogating cell populations in an ex vivo manner 
 
Conjunctival OSIC has been employed in studying ocular surface disease for over 30 
years (Nelson, 1988). First described by Egbert et al, the ability to use cellulose 
acetate filters to collect bulbar conjunctival surface cells allowed fixation, staining and 
examination under a microscope (Egbert et al., 1977). The technique usually 
facilitates the removal of 2-3 layers of superficial cells although visualisation of the 
basal epithelium through multiple impression of the same area can be achieved 
(Singh et al., 2005). Conjunctival OSIC has been used for monitoring OS health in 
contact lens wearers and evaluating ocular surface neoplasia (Knop and Brewitt, 
1992, Nolan et al., 1994, Tole et al., 2001). Perhaps its widest application is the use 
of the technique for the quantification of dry eye severity through determination of 
goblet cell density and changes to the epithelial cell morphology (Nelson, 1988, 
Tseng, 1985, Adams et al., 1988). The data from my experiments now suggest that 
using a Supor filter for OSIC, RPMI as a transport medium and agitating cells for 1 
minute to recover them allows the discrimination of conjunctival epithelial leukocytes 
when combined with an APC anti-CD45 antibody. 
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4.4.2. Defining resident conjunctival leukocyte populations and age-related 
changes in the healthy human conjunctival epithelium 
 
OSIC combined with multicolour flow cytometric analysis enables a comprehensive 
characterisation of the conjunctival epithelial leukocytes superficial to the basement 
membrane zone. In this study, this methodology has afforded a detailed phenotyping 
of conjunctival leukocytes in a cohort of healthy participants and how these change 
with age. The dominant conjunctival epithelial leukocyte population were confirmed 
as CD8+ but the precise subtype was found to be CD3+CD56-TCRαβ+CD8αβ- 
lymphocytes. Interestingly, although this population remained unchanged with age, 
there was an increase in the conjunctival epithelial CD4+ population resulting in an 
alteration in the CD4:CD8 ratio. Furthermore, 14-48% of conjunctival epithelial CD4+ 
cells were capable of producing IFN-γ and 0-22% were capable of producing IL-17. 
This was maintained in older subjects and given the increase in absolute numbers of 
CD4+ cells with age, this resulted in a substantial increase in the number of pro-
inflammatory conjunctival CD4+ T cells.  
 
The role of conjunctival IEL is unresolved. In other mucosal tissues, two subtypes of 
IEL have been defined - Type a (TCRαβ+CD8αβ+) ‘conventional’ and Type b 
(TCRαβ+ CD8αα+, TCRγδ+ CD8αα+ and TCRγδ+ Double Negative (DN)) IEL, with 
differing roles in effector function and regulation (Hayday et al., 2001). This study 
suggests that the dominant IEL population in the human conjunctiva is ‘conventional’ 
(Type a) TCRαβ+CD8αβ+ with less than 1% TCRγδ+. Whether TCRγδ+ cells have a 
relatively minor role to play in conjunctival epithelial biology, or are confined to below 
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the BMZ within the substantia propria (which we were unable to sample using OSIC) 
remains unknown.  
 
Tissue based immunohistochemical analyses identified CD45RO+ cells (75-100%) in 
the bulbar conjunctiva (Hingorani et al., 1997), but those studies were limited as 
precise T cell subsets were not quantified. These data showed that antigen 
experience (defined by the expression of CD45RO) was evident in all CD4+ and 
almost all (median 94%) of CD8αβ+ conjunctival epithelial T cells, whereas a 
significant increase in the CD8αβ+ and CD4+ CD45RO+ T cell population was 
observed in peripheral blood, in keeping with the findings of others (Saule et al., 2006, 
Utsuyama M, 2009). The predominance of CD45RO+ lymphocytes in the conjunctival 
epithelium is expected and consistent with the preferential recruitment of memory 
cells into mucosal tissues. 
 
The major alteration in IEL was an increase in the number and percentage of CD4+ 
cells with age. This resulted in a reduction in the percentage of the dominant 
conjunctival CD8αβ+ population and an increase in the CD4:CD8 ratio.  By contrast, 
there was a decrease in the number of CD8αβ+ T cells in blood, although this too 
resulted in an increase in the CD4:CD8 ratio, as previously reported by Utsuyama et 
al (Utsuyama M, 2009) (see Table 1.3).  
 
As the proportion of T cells decreased in the conjunctival epithelium with increasing 
age, both the proportion and number of NK cells, increased. Although this 
observation has been previously described in peripheral blood (Borrego et al., 1999) 
(and there was an observed trend in this cohort) this is the first time those changes 
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have been defined in the conjunctiva. Whether this represents an accumulation of NK 
cells in the ocular surface reflecting immune senescence, or a direct response to a 
specific change in ocular surface antigen exposure, remains unknown.  
 
It is clear that the changes in IEL populations seen in this cohort, in particular the 
increased TCRαβ+ CD4+ T cell population, have implications for age-matching when 
undertaking comparisons with disease populations, specifically in relation to infective 
or immune-mediated processes affecting the ocular surface including PCC such as 
MMP. Dry-eye problems increase with age (Draper et al., 1999) including dry eye 
disease (Moss et al., 2000, McCarty et al., 1998). Although changes to the lacrimal 
acinar gland have been attributed to age-related ocular surface dryness (Draper et al., 
1999), dry eye syndromes (including Sjögren’s syndrome and non-Sjögren’s 
syndrome related dry eye) are thought to have an underlying inflammatory and 
autoimmune component.  
 
Intriguingly, elevations of CD4+ T cells in both humans and in animal models of dry-
eye have been identified (Stern et al., 2010, De Paiva et al., 2010), but the 
contribution of elevated conjunctival intraepithelial CD4+ cells to a pro-inflammatory 
state is not known and may offer clues to dry-eye vulnerability amongst older 
subjects. The absolute number of CD4+ T cells able to secrete Interferon-γ was 
significantly elevated with age and IL-17 producers were maintained with age in this 
study. An elevation of IFN-γ and IL-17 producing cells has been identified in the 
conjunctiva in murine models of dry eye (De Paiva et al., 2009). Moreover, an 
increase in these cytokines is seen in tears of human subjects with dry eye disease 
(De Paiva et al., 2009). Whether age-associated accumulation of CD4+ cells 
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predisposes to dry eye problems by an increased number of IFN-γ and IL-17 
secreting cells or whether an alteration in function occurs under dry eye conditions in 
humans, remains to be defined.  
 
In murine models there appears to be a defective suppressor function by T regulatory 
cells on Th17 cells (Chauhan et al., 2009). Few conjunctival CD4+ T cells were 
capable of producing IL-10 in this study, and no changes were observed with age. 
The expression of the transcription factor FoxP3 was seen in approximately 2% of 
CD3+ conjunctival T cells (data not shown). This suggests that in the healthy 
conjunctival epithelium, there is not a significant population of CD4+ T cells with an 
IL-10+ or FoxP3+ regulatory phenotype. An increase in the stromal CD4+ population 
has also been identified from histological conjunctival sections (Bernauer et al., 
1993a) taken from patients with MMP (Chan et al., 2002, Foster, 1986, Liesegang, 
2008), that typically affects older patient populations (although disease activity and 
progression is worse in younger patients) (Rauz et al., 2005b). 
 
The possibility of utilising a non-invasive sampling technique such as OSIC to 
characterise changes in supra-basement membrane structures of the ocular mucosa 
in the context of infectious and non-infectious disease affords an attractive method 
for both cross-sectional and longitudinal research into human ocular surface 
inflammatory disease. The importance of ageing on conjunctival leukocyte profiles in 
disease states is yet to be elucidated, but has implications in forming comparative 
healthy control cohorts, indicating that age-matching is essential.  
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4.4.3 Effector Function of the dominant conjunctival epithelial CD8+ T cells 
 
The majority of conjunctival epithelial CD8+ T cells are mucosal homing αEβ7+ 
Effector Memory T cells, capable of secreting IFN-γ and Granzyme B. There was a 
minor population of IL-17 secreting CD8+ T cells, higher than in peripheral blood. 
There were also no IL-10 secreting CD8+ T cells and <1% of cells expressed the 
transcription factor FoxP3. 
 
Circulating T cells are recruited to mucosal tissue such as the gut by expression of 
the integrin α4:β7 (which binds to MadCam-1 on lamina propria vascular endothelium) 
and the chemokine receptor CCR9 (Svensson et al., 2002). It is suggested that a 
switch to (CD103+)αE:β7 integrin expression on these mucosal homing T cells directs 
lymphocytes within the lamina propria to bind to E-cadherin on epithelial cells (Cepek 
et al., 1993, Cepek et al., 1994), although there is evidence that the β7 integrin may 
play as an important role in recruiting the cells from the lamina propria (the 
counterpart to the conjunctival stroma) in the small intestine. Switching from α4 to αE 
is mediated by the expression of TGF-β expression on epithelial cells and E-cadherin 
expression has been identified on normal human conjunctival epithelial cells (Scott et 
al., 1997). It is not know whether the recruitment to the epithelium is wholly CD103+ 
dependent. In the gut, αE:β7 is thought to play an adhesive role and as such the 
actual recruitment across the basement membrane zone (BMZ) may occur through a 
different signalling cascade. It has been suggested that this trafficking may be 
facilitated by BMZ pores (Chan et al., 2008).  
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When T-cells are primed In mucosal tissue, either in draining lymph nodes or MALT, 
the process of becoming antigen experienced conforms an alteration in the CD45 
common leukocyte antigen marker from a high (RA) to a low molecular weight 
isoform (RO) (Faint et al., 2001, Akbar et al., 1988). The process of antigen 
experience in MALT or in draining lymph nodes also results in CCR9 and α4:β7 
expression on T cell subsets, however non-mucosal routes of immunisation (for 
example the skin) can result in mucosal-homing (Agace, 2008, Masopust et al., 
2010). Effector memory ‘primed’ cells are able to home to peripheral mucosal tissues 
and CD8+ CD103+ (αE:β7) mucosal cells have also previously been identified as 
CD45RA-CCR7- (Gupta et al., 2004, Koch et al., 2008). The dominant 
TCRαβ+CD8αβ+ sub-population of our cohort were defined as being effector 
memory cells and CD103+.  
 
Effector memory cells typically secrete IFN-γ upon stimulation (Gupta et al., 2004), 
yet there is evidence of a regulatory/suppressive phenotype among cells that express  
CD103+ (αE:β7) (Koch et al., 2008). The possible role of regulatory CD8+ cells has 
attracted attention and suppression of T-cell proliferation in mixed lymphocyte culture 
via a cell-to-cell contact-dependent mechanism by alloantigen-induced 
CD8+CD103+(αE+) T cells has been reported (Uss et al., 2006). CD8+CD28- (non-
antigen specific) T regulatory cells do not depend on CD80 and CD86 (expressed on 
TLR dependent antigen presenting cells) and suppression is thought to be mediated 
by IL10/TGF-β or direct inhibition of DCs. Additionally CD103+ have been 
demonstrated to secrete IL-10, not IFN-γ, and maintain their phenotype after re-
stimulation with alloantigen (Uss et al., 2006). In human peripheral blood CD103+ 
CD8+ T cells, in keeping with their regulatory phenotype, do not produce Granzyme 
Chapter 4  Characterising the healthy conjunctiva 
158 
B or Perforin (Koch et al., 2008). The conjunctival epithelial CD103+ mucosal homing 
population therefore, and in contrast to peripheral blood, have a cytotoxic phenotype 
– producing IFN-γ upon stimulation and have the capacity to produce Granzyme B (in 
significantly higher proportions than in peripheral blood). Granzyme B is a cytolytic 
granular protein that induces apoptosis in conjunction with pore-formation induced by 
the release of Perforin. Granzyme B production is found in 20% or peripheral blood at 
any time and suggests recent activation of the effector memory CD8+ cells (Nowacki 
et al., 2007).  
 
There was no evidence in this study that conjunctival epithelial CD8+ T cells had a 
regulatory phenotype – there was no IL-10 production and a minor population 
expressed the transcription FoxP3. A small but significant proportion also produced 
IL-17. Tc17 cells have been previously identified in peripheral blood (Kondo et al., 
2009) and that these cells are CD103+ (Yen et al., 2009). The functional role of these 
cells on the ocular surface is unknown, but have been implicated in skin lesions in 
psoriasis (Ortega et al., 2009).  
 
The role for a cytotoxic CD103+ effector memory CD8+ T cell population residing in 
the healthy conjunctival epithelium may be for viral host defence. In human 
peripheral blood, the CD45RA+CCR7- CD8+ pool demonstrates an age-related 
commitment to the recognition of Cytomegalovirus (CMV) (Khan et al., 2002). Failure 
to clear CMV, and another herpetic virus Epstein Barr Virus (EBV), results in clonal 
expansion of EM CD8+ cells that recognize these viruses. Type a IEL have been 
shown to be effective in clearing virus from the gut mucosa, as demonstrated by 
increased cytotoxicity in mice infected with lymphocytic choriomeningitis virus 
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(LCMV) by CD8αβ+ compared to CD8αα+ T cells (Muller et al., 2000).  We were 
able to demonstrate that conjunctival CD8+ CMV and EBV, resulting in increased 
clonal expansion of memory T cells including CD45RA+CCR7-, antigen recognition 
reflect those of peripheral blood. The presence of mucosal homing EBV- and CMV-
specific cells on the conjunctival epithelium suggests that though there is no 
preferential recruitment to this peripheral tissue, the conjunctival CD8+ T cell pool 
might provide protection against a broad range of viruses.  Further characterisation of 
viral antigen recognition implicated in human ocular surface disease such as Herpes 
Simplex Virus may offer further clues to why there is such a limited repertoire of 
CD8+ T cells found in the human conjunctival epithelium. It may be that rapid 
recruitment of other leukocytes in the context of bacterial or fungal insult may take 
place to assist this conserved population of T cells as a front-line defence of the 
ocular surface. 
 
These data suggest that recently activated conventional CD8αβ+ T cells are effector 
memory and have a cytolytic function. Although these cells are able to recognize 
latent herpetic viruses such as CMV and EBV, further evaluation may reveal a 
commitment to an ocular surface pathogen such as HSV or a more promiscuous 
recruitment based on multiple differing viral antigens. 
 
Collectively these data have afforded a greater insight in to the dominant cell 
populations found in healthy conjunctival epithelium and how they change with age. 
More importantly, it has established a means of defining how these populations or 
others may alter in the context of disease. 
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5.1 Introduction 
 
Acquired ocular immunobullous diseases including SJS-TEN and OcMMP can result 
in ocular surface failure, emanating from persistent conjunctival inflammation, 
cicatrisation and eventually corneal scarring and neovascularisation as discussed in 
sections 1.6-1.8. This problem is compounded by disease progression in the 
apparent absence of clinically identifiable inflammation. 
 
Whereas little is known about the ocular surface inflammatory process, keratinocyte 
death in cutaneous SJS-TEN is induced by blister fluid granulysin secreted by CD8+ 
T cells and NK cells (Chung et al., 2008) while OcMMP is an autoimmune disease 
(Chan et al., 2002). The detailed cellular characterisation of ocular disease in the 
conjunctival mucosa has not been clarified for either disease or how this may change 
with time. Furthermore, the ability to undertake longitudinal characterisation of 
leukocyte populations has been limited by the inability to non-invasively sample the 
ocular surface. This is also the case in OcMMP and the aim of this study was 
therefore to determine: 
 
1. The conjunctival epithelial cellular infiltrate in SJS-TEN and OcMMP 
2. How this infiltrate correlates with disease activity and damage 
3. Whether inflammatory infiltrates are maintained over time  
4. Whether conjunctival inflammatory infiltrates can predict disease progression in 
OcMMP and specifically in the context of a clinically uninflamed eye 
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5.1.1 Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) 
 
SJS-TEN is an uncommon condition but with potentially devastating ocular surface 
consequences. The age of presentation, whilst variable, tends to be younger than in 
MMP (Schopf et al., 1991, Pereira et al., 2007), reported as 28 years in one recent 
series (Wetter and Camilleri, 2010) and 40 years [5-100] in a recent BOSU study 
(Radford et al. The Incidence of Cicatrising Conjunctival Disorders in the UK. IOVS 
2011; 52: E-Abstract 1136). The initial, rapid granulysin mediated blistering seen in 
SJS-TEN carries a potentially fatal outcome. Ocular involvement, can result in 
devastation of the ocular surface through conjunctival inflammation, symblephara 
formation and corneal and conjunctival ulceration. Although the disease carries a 
high mortality, the disease is considered temporal. Systemic features would therefore 
be expected to resolve. This is not the case with ocular disease however (Foster et 
al., 1988, De Rojas et al., 2007).  
 
The underlying aetiology of SJS-TEN and OcMMP differ and also manifest in very 
different ways. SJS-TEN is characterised by widespread desquamation of skin and 
mucosal surface, but varying in its severity (Bastuji-Garin et al., 1993). This may or 
may not be associated with ocular involvement. By contrast, OcMMP typically has a 
more insidious onset. Although the skin may be involved in MMP, the symptoms and 
signs are less severe, and confined to the head and trunk (Chan et al., 2002). As 
illustrated in Chapter 3, the median duration of ocular symptoms in a cohort of 
patients with OcMMP was 4 years. Systemic SJS-TEN can occur rapidly, within 
hours or days, and ocular involvement can occur in a very short space of time 
(Gueudry et al., 2009). A recent BOSU study also revealed that there was a 
significantly longer duration of symptoms between ocular SJS-TEN and OcMMP 
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before presentation (7 days vs. 225 days;p<0.001) (Radford et al. The Incidence of 
Cicatrising Conjunctival Disorders in the UK. IOVS 2011; 52: E-Abstract 1136). 
 
The distinction between the acute and chronic stages of ocular SJS-TEN is a moot 
point (Fu et al., 2010). Power and colleagues suggested that this period was up to 6 
weeks after onset (Power et al., 1995). By 6 weeks the systemic disease may have 
completely resolved and in this respect it could be argued that this period is too long 
to be truly considered as the acute phase. Conversely, the only definition suggested 
for chronic ocular SJS-TEN is greater than 12 months (Sotozono et al., 2007). There 
is therefore a discord between the acute systemic and chronic ocular disease. The 
process by which this switch occurs is not established, and understanding how the 
initial disease alters to one that has a phenotype resembling OcMMP is not clear. 
There may be important similarities or indeed differences in the ocular surface cell 
populations of SJS-TEN in the acute or chronic phases, which may help us to 
understand how this disease can contribute to the scarring process and behave like 
OcMMP in some individuals. 
 
In this chapter I have sought to identify inflammatory cellular infiltrates in patients in 
the acute and chronic phases of SJS-TEN. This provided an important preliminary 
study of a potentially younger group of patients with an acquired immunobullous 
disease, before undertaking a more comprehensive assessment of cell changes in 
the more common OcMMP.  
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5.1.2 Ocular Mucous Membrane Pemphigoid (OcMMP) 
 
The underlying disease process in OcMMP is driven by autoantibodies against the 
basement membrane zone (Chan et al., 2002). This in turn leads to the complement 
activation and the recruitment of an inflammatory infiltrate including neutrophils, 
CD4+ T cells and macrophages (Bernauer et al., 1993a, Rice and Foster, 1990). The 
CD4+ infiltrate is thought to be Th2 mediated, leading to activation of TGF-β and IL-
13 (Elder, 1997b, Saw et al., 2009b), but the epithelium is dominated by neutrophils 
(Bernauer et al., 1993a, Rice and Foster, 1990). 
 
The conjunctival cellular infiltrate has been identified from histological sections but 
repeat sampling has been precluded because of the risk of exacerbating scarring. 
Conjunctival OSIC has been previously utilised in OcMMP. Nelson found that there 
were abnormal epithelial cells and the absence of conjunctival goblet cells in 6 eyes 
of 4 patients with MMP when applying a cellulose acetate filter (Nelson, 1982). This 
apparent decrease in goblet cell density was later confirmed in both MMP and SJS 
with a bulbar conjunctiva goblet cell loss of 96-99% (Nelson and Wright, 1984). To 
date however, the characterisation and quantification of the cellular infiltrate by OSIC 
in OcMMP at different stages of disease activity has not been undertaken.  
 
By using non-invasive OSIC combined with multi-colour flow cytometry we were able 
to establish that conjunctival epithelial leukocytes are dominated by TCRαβ+CD8αβ+ 
T cells (Chapter 4) and this population remains unaltered with age in a healthy 
cohort of volunteers while the CD4+ population increases. The aim of this study was 
to characterise infiltrative cellular profiles within the conjunctival epithelium during 
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acute and chronic SJS-TEN and OcMMP using OSIC and multi-colour flow cytometry.  
It is hoped that this could potentially provide a means of objectively monitoring 
disease activity and predicting outcome at a sub-clinical level.  
 
5.2 Methods 
5.2.1 SJS-TEN Study 
Study subjects 
Over a 12-month period, 10 consecutive patients presenting with SJS-TEN (Cohort 
9) to a tertiary OSD service (BMEC) were recruited and followed for one year. 
Comparisons were made with a cohort of healthy, age-matched controls (n=21) 
(median age 50 [range 21-64 years]; 11 females; 16 White European, 5 Asian) 
(Cohort 10). There was no significant difference in age. 
 
Systemic steroids can induce granulocytosis (Bishop et al., 1968). In anticipation of 
our SJS-TEN cohort requiring topical steroids during the course of the study, the 
effects on conjunctival neutrophils we determined by sampling an additional cohort of 
healthy participants (n=7) by OSIC before and after routine cataract surgery (median 
age 74 [range 57-84 years]; 4 females; 6 White European, 1 Asian) (Cohort 11). This 
facilitated a comparison of neutrophils numbers with and without the application of 
topical preservative free Dexamethasone in an uninflamed eye. The repeat samples 
were taken if the following criteria were met (i) Cataract surgery was uncomplicated 
(ii) There was no evidence of ocular surface or intra-ocular surface inflammation at 4 
week review (iii) Individuals were using topical non-preserved Dexamethasone 0.1% 
QID since the time of surgery. 
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Disease Grading and Staging 
Data were collected at presentation and at 12 months follow-up. Chronic disease was 
defined as persistence of ocular disease for >12 months after disease-onset 
(Sotozono et al., 2007). Visual acuity was categorised as described in section 2.1.4.  
Disease activity was based upon the extent of conjunctival inflammation: absent, mild, 
moderate or severe (severe defined as being inflamed in all 4 quadrants, the 
presence of limbitis and/or conjunctival ulceration) (Figure 1.10) (Elder, 1997c). 
Staging of disease was determined by the staging described by Power et al (Absent, 
Mild, Moderate and Severe) (Power et al., 1995) and Sotozono et al (Score:1-39) 
(Sotozono et al., 2007) while quantification of lower and upper conjunctival fornix 
shrinkage using an FDM and number of symblephara were also measured. 
Information regarding therapeutic and surgical intervention was recorded. 
 
Sample collection and laboratory analysis 
Details of conjunctival OSIC sampling and peripheral blood collection are described 
in sections 2.1.6 and section 2.2.3. Details of ex vivo experimentation are fully 
described in sections 2.2.4-2.2.5. 
 
Statistical analysis 
Non-parametric comparisons were undertaken with the Mann Whitney U test, 
Wilcoxon signed rank test and correlations by Spearman’s correlation using Prism 
version 5.0 for Macintosh (GraphPad Software, California 2008). Data were collected 
on all eyes and comparisons were undertaken between the worst affected eye in 
patients and the arbitrarily the right eye in healthy participants for cross-sectional 
analysis. Longitudinal analysis of the same eye was undertaken.  
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5.2.2 OcMMP Study 
Study subjects 
Sixty patients with OcMMP were recruited from patients presenting to the OSD clinic 
at BMEC over a 24 months period and followed for 12 months (Cohort 12). 
Comparisons were made with a group of healthy, age-matched controls (n=21) 
(median age 64 [range 45-83 years]; 12 females; 14 White European, 7 Asian)  
(cohort 13) and a positive disease group with an autoimmune disease associated 
with slowly progressive PCC. Patients with Primary Sjögrens Syndrome (n=19) (1 
Male, 18 Female; Median age 64 ([range 56-79);18 White European, 1 Asian)  
(Cohort 14) were recruited as the positive group from a tertiary multi-disciplinary 
clinic (UHB) (as a positive control group). There was no significant difference in age. 
 
Disease Grading and Staging 
Diagnosis of OcMMP was as described in section 2.1.3. Data were collected at 0, 3, 
6, 9 and at 12 months follow-up. Visual acuity was categorised as described (section 
2.1.4). Disease activity was based upon the extent of conjunctival inflammation: 
absent, mild, moderate or severe (severe defined as being inflamed in all 4 
quadrants, the presence of limbitis and/or conjunctival ulceration) (Figure 1.10) 
(Elder, 1997c). Outcome measures were as defined in Chapter 3: 
Primary outcome measures for disease stage: 
1. Tauber’s proposed staging system combined with the use of the FDM (BEMC 
v2) for determining percentage shrinkage of the lower fornix (Tauber et al., 1992) 
(Figure 1.11, Table 3.1)  
2. Conjunctival shrinkage in mm defined by using the validated FDM (BEMC v2) 
for the lower and upper fornix (Chapter 3.1.3).  
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Secondary outcome measures for disease stage: 
1. Extent of corneal neovascularisation by clock hours of involvement: None, <3°, 
3-6° or >9°  
2. Corneal neovascularisation encroachment: None, periphery, pupil margin or 
central cornea  
3. Corneal opacification: None, <1/3, 1/3 to 2/3, >2/3 
4. Corneal conjunctivalisation: None, <1/3, 1/3 to 2/3, >2/3 
4. Corneal keratinisation: None, <1/3, 1/3 to 2/3, >2/3 
based upon a modification of the grading systems described for chronic SJS-TEN 
by Sotozono (Sotozono et al., 2007) and validated for use in the CRF (Chapter 3).  
 
Progression was defined as an advance in Tauber staging, an increase in forniceal 
shrinkage (1mm or greater) for primary outcome measures, an increase in 
neovascularisation (either clock hours or encroachment) and an increase in corneal 
opacification (opacification, conjunctivalisation or keratinisation) for secondary 
outcome measures.  
 
Immunosuppression strategies used a ‘step–ladder’ approach as previously 
described (Figure 1.12). Information regarding surgical and therapeutic intervention 
was also recorded. 
 
Sample collection and laboratory analysis 
Both eyes were clinically phenotyped and sampled. Sample collection and laboratory 
analysis is described in sections 2.1.6 and 2.2.  
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Statistical analysis 
 
Data were collected on all eyes and comparisons were undertaken between the 
worst affected eye for cross-sectional analysis of inflammation and the better-seeing 
eye for VA. Cross-sectional comparisons were undertaken by non-parametric Mann-
Whitney U test for two groups, the Kruskal-Wallis test with Dunn’s post hoc analysis 
when comparing continuous variables e.g. cell numbers or percentage for both eyes. 
The Jonckheere-Terpstra test was used for ordered alternatives.  
 
Data for both eyes were used for progression, as outcomes could be different for 
each eye for an individual. Initial comparisons were undertaken by non-parametric 
Mann-Whitney U test for two groups. If differences using the Mann-Whitney U test 
were significant, Generalised Estimating Equations (GEEs) were employed when 
using data for both eyes in order to determine correlation and establish whether 
progression data for both eyes were significant whilst taking the effects of correlation 
into consideration. Normality was assessed by using a Kolmogorov-Smirnoff test and 
data was log transformed where necessary. Differences in progression were 
determined by the Wald chi-square test.  
 
Differences in repeated measures were also determined by GEE between the right 
and the left eyes and overall difference over time was determined by the Huynh-Feldt 
test. Differences in progression between Non-inflamed eyes were undertaken by the 
Fishers-exact test or Jonckheere-Terpstra test for ordered alternatives. 
 
Significance was defined as p<0.05. 
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5.3 Results 
5.3.1 SJS-TEN study 
Demographic Information 
Of 10 patients (median age 44 [range 18-67 years], 8 females) (Cohort 9), seven 
where of White European decent, 2 were Black and 1 was Asian. Six individuals 
presented within 12 months of disease onset which for the purposes of this study we 
defined as “acute” [<12 months after disease-onset] and four with chronic [12 months 
after disease-onset]) disease. Five patients were categorised as TEN and all but one 
patient had a SCORTEN of 1 (Table 5.1). Drugs were the most common causative 
agent (n=7). Visual acuity was found to be unchanged during the study period with 
7/10 patients having a VA of 6/18 or better at presentation. All patients were using 
non-preserved topical lubricants and 9/10 required topical non-preserved steroids 
(Dexamethasone 0.1% in 7/9). 
 
Disease Activity and Staging 
Clinically identifiable inflammation of the conjunctiva was deemed to be absent or 
mild in 9/10 patients (18/20 eyes) (Table 5.2). At presentation, 9/10 had severe 
disease according to the grading system described by Power and colleagues (Power 
et al., 1995) whereas the scoring grade was milder according to the staging 
described by Sotozono and colleagues (Sotozono et al., 2007) (Table 5.2) (median 
score of 8/39 [range 1-21]). Objective evidence of fornix shrinkage using a Fornix 
Depth Measurer was seen in 9/10 subjects, and this inversely correlated with 
duration of disease (p<0.05).  
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At 12 months follow-up, all patients reviewed had mild conjunctival inflammation: all 
had severe disease according to Power’s classification (indicating that one had 
evidence of disease progression) and the median Sotozono score remained 
unchanged (8/39 [range 1-21]) although 3 patients had progressed according to this 
scale. Only one patient each had evidence of lower and upper fornix shrinkage 
during the study period (Table 5.2). 
 
*Acute defined as <365 days post onset (sub-acute defined as 30-364 days); Chronic defined as >365 days post 
onset (Power et al 2005; Sotozono et al 2007 Ophthalmology)  
AMG = Amniotic Membrane Grafting 
iv=Intravenous 
Phaco=Phacoemulsification cataract extraction 
Table 5.1. Demographic information, aetiology and therapy during the SJS-TEN study. 
  
Patient Ethnicity Age Gender Disease 
Severity 
 
 
 
Precipitant Days post 
onset at 0 
months 
assessment
* 
Topical 
steroids 
during 
study 
period 
Other 
steroids/ 
Immuno- 
suppression 
during study 
period 
Surgery 
during 
study 
1 White 18 Female TEN Amoxicillin 114 
(Subacute) 
Yes Pulse iv 
methyl-
prednisolone 
Phaco/ 
AMG 
2 Black 41 Female SJS Mycoplasma 168 
(Subacute) 
Yes None None 
3 White 67 Female SJS Trimethoprim 16 
(Acute) 
Yes None None 
4 White 59 Female TEN Phenytoin 9178 
(Chronic) 
None Azathioprine None 
5 White 27 Male SJS Unknown 9 
(Acute) 
Yes None None 
6 Black 20 Male SJS Carba-
mazepine 
1 
(Acute) 
Yes None None 
7 White 48 Female TEN Unknown 3657 
(Chronic) 
Yes None None 
8 White 37 Female TEN Penicillin 592 
(Chronic) 
Yes None None 
9 Asian 57 Female SJS Unknown 2047 
(Chronic) 
Yes None None 
10 White 46 Female TEN Carba-
mazepine 
25 
(Acute) 
Yes Subtarsal 
Triamcinolone 
AMG 
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 ✚Worst (Right) Eye 
Scoring references:   
1. Elder et al Cicatrising Conjunctivitis (Elder, 1997c)   
2. Power et al. Ophthalmology (Power et al., 1995) 
3. Sotozono et al. Ophthalmology  (Sotozono et al., 2007) 
4. Tauber et al. Cornea  (Tauber et al., 1992) 
5. Schwab et al. Ophthalmology (Schwab et al., 1992)  
Table 5.2. Disease activity and staging at 0 and 12 months during the SJS-TEN study. All 
patients had a SCORTEN of 1 (with the exception of patient 10 who had a score of 2). None had an 
episode of scleritis during the study period. Conjunctival inflammation and staging systems were 
assessed at 0 and 12 months. 9/10 patients were reviewed at 12 months (1 individual declined follow 
up). 
 
 Conjunctival 
inflammation
✚1
 
 
Disease Stage 
(Power
✚2
) 
 
Disease 
Stage 
(Sotozono: 
out of 
39
✚3
) 
Lower Fornix Upper Fornix 
Symblephara: 
mm 
horizontal 
involvement 
of fornix 
(number
 
)
 ✚4
 
 
Fornix Depth 
in mm 
(shrinkage
✚5
) 
Symblephara: 
mm 
horizontal 
involvement 
of fornix 
(number
 
) 
Fornix 
Depth  
in mm
✚4
 
Time 
point 
0 12 0 12 0 12 0 12 0 12 0 12 0 12 
1 Mild Mild Severe Severe 7 4 3(1) 3(1) 8 
(Yes) 
6 
(Yes) 
0 (0) 0 (0) 16 15 
2 None Mild Severe  Severe  8 10 10(2) 10(2) 8 
(Yes) 
8 
(Yes) 
0 (0) 0 (0) 16 15 
3 Mild Mild Severe Severe 9 10 10(3) 16(3) 4 
(Yes) 
3 
(Yes) 
0 (0) 4 (1) 16 16 
4 
 
 
 
None Mild Severe  Severe  12 17 12(3) 18(2) 2 
(Yes) 
2 
(Yes) 
8 (2) 12 (2) 4 8 
5 
 
 
 
Mild - Mild - 1 - 0(0) - 10 
(Yes) 
- 0 (0) 0 (0) 18 - 
6 None Mild Severe Severe 3 3 4(1) 2(1) 12 
(No) 
12 
(No) 
0 (0) 0 (0) 20 20 
7 Mild Mild Severe Severe 21 21 8(3) 8(3) 0 
(Yes) 
0 
(Yes) 
4 (2) 4 (2) 10 10 
8 None Mild Severe Severe 5 5 0(0) 0(0) 6 
(Yes) 
4 
(Yes) 
0 (0) 0 (0) 16 17 
9 Mild Mild Mild Severe 5 5 0(0) 2(1) 9 
(Yes) 
10 
(Yes) 
0 (0) 0 (0) 18 18 
10 Moderate Mild Severe  Severe  8 8 6(1) 10(2) 8 
(Yes) 
8 
(Yes) 
0 (0) 0 (0) 18 16 
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Conjunctival Epithelial Leukocyte Populations  
Gating strategies to characterise cellular populations are shown in Figure 5.1. There 
were no differences in the number of conjunctival epithelial leukocytes (p=0.15) or 
lymphocytes in SJS-TEN compared with healthy controls (median 337[range 35-
6383] vs. 488[10-3026], p=0.75). There was also no difference between the total 
number of CD3+CD56- T cells, or of the number of cells for T cell subsets including 
TCRαβ+CD3+CD8αβ+ cells (Figure 5.2). A reduction in the percentage of 
TCRαβ+CD3+CD8αβ+ T cells was however seen (57% vs. 80%;p<0.01), with a 
corresponding elevation of  TCRαβ+CD3+CD8β-CD4- (Double Negative) T cells 
(23% vs. 7%;p=0.11). No differences were seen in the TCRαβ+CD3+CD4+ (9% vs. 
9%;p=0.67) or TCRαβ+CD3+CD8αα+ T cell subsets (1% vs. 3%;p=0.16), or in other 
lymphocyte subsets including NK cells (7.5% vs. 5%;p=0.45) (Figure 5.2), NKT cells 
(2% vs. 5.5%;p=0.28) or CD19+CD20+ B cells (3% vs. 3%;p=0.72). 
 
Granulocytes were further defined as CD45INTCD11b+CD16+CD14- cells. This gating 
strategy discriminates neutrophils from other granulocytes (such as basophils and 
eosinophils) and monocytes (Stelzer et al., 1993, Gopinath and Nutman, 1997), so 
that the CD45INTCD11b+CD16+CD14- granulocyte population would be comprised 
primarily of neutrophils. A significant increase in the number and percentage of 
CD45INTCD11b+CD16+CD14- neutrophils (186 vs. 3.4, p<0.01;31% vs. 0.8%, 
p<0.001) were seen in individuals with SJS-TEN (Figure 5.2). At presentation 
however, the elevation in neutrophils was found to inversely correlate with disease 
duration (r=-071,p=0.03) (Figure 5.3A). This suggests that neutrophil levels were 
highest in the acute stages of disease. Of interest, this elevation was maintained over 
the study period ((p=1.0) indicating a persistent elevation in this inflammatory 
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infiltrate (Figure 5.3B). This was confirmed when comparing the number and 
percentage of neutrophils between patients with SJS-TEN at 12 months with the 
same cohort of healthy participants (247 vs. 3.4, p<0.01;15% vs. 0.8%, p<0.001). 
 
As the majority of our patients were prescribed topical Dexamethasone, it was 
important to determine the influence of this synthetic glucocorticoid on conjunctival 
neutrophils. This was particularly important given the elevation in neutrophils seen. A 
cohort of 7 healthy volunteers were therefore sampled before and after cataract 
surgery in order to test the effect of Dexamethasone on healthy participants. There 
was no significant difference in the CD45INTCD11b+CD16+CD14- neutrophil 
populations before and after the use of topical treatment (13 vs. 0, p=0.06;1.7% vs. 
0%, p=0.13), although the trend suggested a reduction in the numbers present on the 
occur surface (Figure 5.4). The use of topical Dexamethasone in the majority of the 
SJS-TEN cohort is unlikely therefore to have contributed to an elevation in ocular 
surface granulocytes. 
 
The total number and percentage of monocytes was elevated in SJS-TEN (185 vs. 
21, p=0.02;12% vs. 6%, p=0.02) and this was attributable to an increase in the 
number of CD14+CD16- monocytes (140 vs. 6, p=0.03). No change in the total 
leukocyte (p=0.82), or lymphocyte populations (p=0.57) was observed during the 
study period and CD8αβ+ T cells (p=0.57) and NK cells populations also remained 
unaltered (p=1.0) (Figure 5.3B). 
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Figure 5.1. Gating strategy to determine cellular populations in disease using 
OSIC. Representative plots of a subject with SJS-TEN demonstrating the gating 
strategy used to identify conjunctival leukocytes. Live leukocytes populations 
(lymphocytes, monocytes and granulocytes) were identified in conjunctival cells by 
gating for CD45+ cells that were negative for the dead cell exclusion dye Sytox blue 
and back-gated to show the forward and side scatter profiles of the CD45+ live cells 
(Panel A). Lymphocyte subsets were identified according to the expression of CD3 
and CD56 in one panel (to discriminate T cells [CD3+CD56-], Natural Killer Cells 
[CD56+CD3-], NKT cells [CD3+CD56+]) and B cells [CD19+CD20+] (Panel B) (CD8+ 
cell populations shown are TCRαβ+). Monocytes were further characterized by the 
presence of CD14 and CD16 (Panel C). Neutrophils were defined as CD45  CD14-
CD11b+CD16+ granulocytes (Panel D). Cell populations of interest are boxed (blue).  
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Figure 5.2. The dominant cellular infiltrate in the conjunctival epithelium in SJS/
TEN is characterised by an increase CD45  CD11b+ CD16+ CD14- neutrophils. 
21 healthy subjects were compared with 10 patients with SJS-TEN (6 patients in the 
acute stages   and 4 in the chronic stages of disease  ). Representative flow 
cytometry plots are shown. Statistical comparisons between healthy and SJS-TEN 
conjunctival leukocyte (Panel A), lymphocyte (A), CD8αβ+ (B), NK (CD56+CD3-) and 
CD45  CD11b+CD16+CD14- neutrophil (D) populations were undertaken by the 
Mann-Whitney U test (NS: Not significant [p>0.05], **p < 0.01). 
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Figure 5.3. CD45   CD11b+CD16+CD14- neutrophils are inversely correlated with 
disease duration but persist with time. CD45 11b+CD16+CD14- neutrophil 
populations were correlated with disease duration at presentation (0 months; Panel B) 
using Spearman’s correlation (NS: Not significant [p>0.05]; *p< 0.05). 9/10 patients 
with SJS-TEN (6 patients in the acute stages   and 4 in the chronic stages of systemic 
disease  ) were sampled at 0 and 12 months. Paired analysis of SJS-TEN conjunctival 
leukocyte, lymphocyte, CD8ab+, Natural Killer (CD56+CD3-) and CD11b+CD16+ 
neutrophil populations at 0 (closed squares) and 12 months (open squares) were 
undertaken by the Wilcoxon signed rank test (NS: Not significant [p>0.05]) (Panel A).  
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Figure 5.4. Epithelial neutrophil populations are unaltered by topical 
Dexamethasone. Neutrophils (defined as CD45 CD11b+CD16+CD14- live 
granulocytes) are shown as absolute numbers and percentage of leukocytes before 
and after the use of topical steroids (preservative free Dexamethasone 0.1%). 
Individuals had conjunctival OSIC before and after uncomplicated cataract surgery. 
Repeated samples were taken at 4 weeks post-op and in the absence of ocular 
surface and intra-ocular inflammation (NS: Not significant [p>0.05]). 
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5.3.2 OcMMP study 
Demographic information, histological profile of disease and extra-ocular 
features in OcMMP 
 
The conjunctival epithelium in a younger cohort of patients with SJS-TEN was shown 
to have significant elevation of CD45INTCD11b+CD16+CD14- neutrophils. This 
alteration in neutrophils was also maintained over the course of the 12-month study 
period. Although this cohort was of a modest size, it has offered an insight to the 
inflammatory infiltrate in one type of acquired ocular immunobullous disease. The 
next step was to determine leukocyte changes in a larger cohort of patients with 
OcMMP. 
 
Of the sixty patients with OcMMP approached, 57 were recruited to the study. The 
median age was 72[range 49-97 years]; 30 females (54%); 55 White European, 1 
Asian and 1 Afro-Caribbean. 
 
The majority, 70%(40/57), of patients were biopsy positive OcMMP. Thirteen were 
biopsy negative and four did not undergo biopsy; 3 were greater than 95 years and 
not considered for immunosuppression and 1 patient declined a conjunctival biopsy. 
Forty two per cent (24/57) had evidence of extra-ocular involvement, of whom 40% 
had oral MMP. Demographic information is summarised in Table 5.3. 
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 All patients 
Total no. of patients  57 
Total no. of eyes  114 
Male: Female (% Female) 27:30 (53%) 
Median age (yrs) [Range] 72(48-97) 
Median duration of  
symptoms (Days) [Range] 
 
930(30-14600) 
No of patients sampled 
longitudinally for 12 months ¶ 
35 
Biopsy * 
DIF +ve 
IIF  +ve † 
 
70% (40/57) 
30% (17/57) 
Extra ocular mucocutaneous 
involvement 
All mucocutaneous tissues 
Skin 
Oral  
 
 
42% (24/57) 
4% (2/57) 
40% (23/57)  
Visual Acuity ‡    
Normal: 6/6 ->6/18 91% (43/47) 
Visual impairment: <6/18- 6/60 4% (2/47) 
Severe visual impairment:  6/60-3/60 0% (0/47) 
Blind: <3/60 4% (2/47) 
‡Excluded due to other causes 18% (10/57) 
  
 
Table 5.3 Patient demographics and characteristics in the OcMMP study. Direct 
immunofluorescence (DIF) and Indirect immunofluorescence (IIF) refer to the proportion of patients 
who demonstrated the linear deposition of immunoglobulin G, A or complement (C3) along the 
basement membrane zone (BMZ) or had measurable titres of immunoglobulin in the serum 
respectively.  
¶ Follow-up: 35 patients were followed longitudinally and underwent clinical phenotyping and 
OSIC sampling at 0, 3, 6, 9 and 12 months. Of the 22 who did not undergo longitudinal assessment, 6 
declined longitudinal sampling, 4 did not attend for repeated sampling, 3 died and 9 could not be 
followed up for longitudinal sampling as they were sampled within 12 months of the end of the study. 
* Four patients in total did not undergo a conjunctival biopsy (3 patients with advanced age (> 95 
years) and immunosuppression was systemically contraindicated and the remaining 1 patients declined 
a confirmatory biopsy. 
† All patients who were IIF were also DIF positive. There were no patients who were IIF positive in 
the absence of positive DIF studies.  
‡   VA represents a comparison of visual acuity in the better-seeing eye, after exclusion of 
other causes of reduced vision such as cataract, glaucoma, uveitis and optic neuritis (n=10). 
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Disease Activity and Damage at Presentation 
 
Conjunctival inflammation was present in 65% (37/57) individuals with 35%(20/57) 
patients having no clinically identifiable conjunctival inflammation at presentation. 
Details of the severity of inflammation are outlined in Table 5.4 
 
Disease Activity  Right Eyes Left Eyes All Eyes 
Conjunctival Inflammation    
Absent 40% (23/57) 42% (24/57) 41% (47/114) 
Mild 39% (22/57) 35% (20/57) 37% (42/114) 
Moderate 16% (9/57) 19% (11/57) 17.5% (20/114) 
Severe 5% (3/57) 3.5% (2/57) 4% (5/114) 
    
 
Table 5.4 Disease Activity – Clinically identifiable conjunctival inflammation in the OcMMP 
study. Conjunctival inflammation was graded by the scale described by Elder et al (Elder, 1997c). 
 
Table 5.5 summarises the primary damage indices derived from clinical data 
recorded in CRFs. Tauber scores for the right and left eyes are shown together with 
Mondino and Foster scores for comparative reasons (documentation was complete 
with the exception of one individual where the Tauber score could not be calculated). 
 
Primary scarring measurements for scarring included upper fornix depth, lower fornix 
depth and the scale described by Tauber et al (Tauber et al., 1992) (Table 5.5). 
Median upper fornix depth was 14mm[0-22], the number of upper fornix symblephara 
was 0[0-4], symblephara involvement was 0mm[0-15]. In the absence of 
anthropological information about the normal upper fornix depth, Tauber scale cannot 
be calculated. Median lower fornix depth was 4mm[0-13] the number of lower fornix 
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symblephara was 2[0-6], with symblephara involvement 6mm[0-30]. Forty three per 
cent eyes (49/114) were Mondino stage III/IV, reflecting the median lower fornix 
depth of 4mm. Ninety six per cent of eyes (110/114) were Foster stage III/IV. The 
Tauber scale’s ability to stratify disease further by the extent of symblephara is 
reflected by the distribution within Tauber stage III. 
 
Secondary scarring measures were also quantified from CRFs and reveal that 41% 
of eyes (47/114) had evidence of at least 3° (clock hours) of corneal 
neovascularisation (36% of eyes (41/114) had encroachment to the periphery or 
greater). Opacification was seen in 33% (38/114) whereas conjunctivalisation was 
evident in 27% (31/114) and keratinisation in 10% (11/114). 
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Disease Damage  Right eyes  Left eyes All eyes 
Upper Fornix     
Depth in mm (median[range]) 14mm[0-22] 13mm[0-22] 14mm[0-22] 
Symblephara number 
(median[range]) 
 
0[0-3] 
 
0[0-4] 
 
0[0-4] 
Symblephara involvement 
(median[range]) 
 
0[0-15] 
 
0[0-15] 
 
0[0-15] 
    
Lower Fornix     
Depth in mm (median[range]) 4mm[0-13] 4mm[0-12] 4mm[0-13] 
Symblephara number 
(median[range]) 
 
2[0-6] 
 
2[0-5] 
 
2[0-6] 
Symblephara involvement 
(median[range]) 
 
8[0-30] 
 
6[0-30] 
 
6[0-30] 
Mondino    
I 12% (7/57) 12% (7/57) 12% (14/114) 
II 26% (15/57) 26% (15/57) 26% (30/114) 
III 35% (20/57) 39% (22/57) 37% (21/114) 
IV 26% (15/57) 23% (13/57) 25% (28/114) 
Foster    
I 1.5% (1/57) 1.5% (1/57) 1.5% (2/114) 
II 10.5% (6/57) 10.5% (6/57) 10.5% (12/114) 
III 65% (37/57) 61% (35/57) 63% (72/114) 
IV 23% (13/57) 26% (15/57) 24% (28/114) 
Tauber    
I 1.5% (1/57) 1.5% (1/57) 1.5% (2/114) 
IIa 3% (2/57) 5% (3/57) 4% (5/114) 
IIb 1.5% (1/57) 1.5% (1/57) 1.5% (2/114) 
IIc 4.5% (3/57) 3% (2/57) 4% (5/114) 
IId 0% (0/57) 0% (0/57) 0% (0/114) 
IIIa 26% (15/57) 26% (15/57) 26% (30/114) 
IIIb 28% (16/57) 25% (14/57) 26% (30/114) 
IIIc 7% (4/57) 7% (4/57) 7% (8/114) 
IIId 1.5% (1/57) 0% (0/57) 1% (1/114) 
IV 23% (13/57) 28% (16/57) 25% (29/114) 
 
Table 5.5 Disease Damage: Primary measures of scarring at presentation in the OcMMP study. 
Stratification of patients by upper and lower fornix scarring. Primary measures were considered to be 
upper fornix depth, lower fornix depth and lower fornix Tauber scoring (Tauber et al., 1992) (Mondino 
and Foster scales are shown for comparative purposes) (Mondino and Brown, 1981, Foster, 1986).  
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Disease Damage  Right eyes  Left eyes All eyes 
Cornea    
Neovascularisation (clock hours)    
None  54% (31/57) 60% (34/57) 57% (65/114) 
<3 5% (3/57) 10.5% (6/57) 8% (9/114) 
3-9 7% (4/57) 5% (3/57) 6% (7/114) 
>9 32% (18/57) 23% (13/57) 27% (31/114) 
Neovascularisation (encroachment)    
None 60% (34/57) 65% (37/57) 62% (71/114) 
Periphery 28% (16/57) 18% (10/57) 23% (26/114) 
Pupil margin 3.5% (2/57) 10.5% (6/57) 7% (8/114) 
Central 7% (4/57)) 5% (3/57) 6% (7/114) 
Opacification    
None 65% (37/57) 65% (37/57) 65% (74/114) 
<1/3  18% (10/57) 18% (10/57) 18% (20/114) 
1/3 to 2/3 7% (4/57) 10.5% (6/57) 9% (10/114) 
>2/3 9% (5/57) 5% (3/57) 7% (8/114) 
Conjunctivalisation    
None 70% (40/57) 72% (41/57) 71% (81/114) 
<1/3  10.5% (6/57) 10.5% (6/57) 10.5% (12/114) 
1/3 to 2/3 9% (5/57) 10.5% (6/57) 10% (11/114) 
>2/3 9% (5/57) 5% (3/57) 7% (8/114) 
Keratinisation    
None 86% (49/57) 91% (52/57) 89% (101/114) 
<1/3  5% (3/57) 0% (0/57) 2.5% (3/114) 
1/3 to 2/3 1.5% (1/57) 1.5% (1/57) 1.5% (2/114) 
>2/3 5% (3/57) 5% (3/57) 5% (6/114) 
 
Table 5.6 Disease Damage: Secondary measures of scarring at presentation in the OcMMP 
study. Stratification of patients by corneal scarring. Secondary measures were considered to be 
corneal neovascularisation (clock hours of involvement and encroachment), opacification, 
conjunctivalisation and keratinisation (all measured by the extent of corneal involvement). 
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Surgical and Therapeutic Intervention  
The details of surgical and therapeutic intervention are summarised in Table 5.7. The 
most common intervention was eyelid/fornix intervention at presentation and during 
the course of the study. The majority of patents required topical steroids and almost 
all of the cohort required topical preservative free lubrication. Fifty six per cent 
(30/57) were on some form of immunosuppression at presentation and this had 
increase as a proportion to 72% (25/35) by 12 months. 
 
 intervention Presentation   0 to 12 
months 
 
Surgery      
 Eyelid/fornix surgery 35% (20/57)  20% (7/35)  
 Corneal intervention 3.5% (2/57)  0% (0/35)  
 Cataract surgery 12% (7/57)  3% (1/35)  
Topical Therapy      
 PF Lubrication 86% (49/57)  97% (34/35)  
 PF Steroid* 54% (31/57)  52% (18/35)  
Systemic 
Immunosuppression 
  Step Up  Step Up 
   16% (9/57)  20% (7/35) 
 Oral Prednisolone 14% (8/57)  14% (5/35)  
 Dapsone 16% (9/57) 6% (2/35) 
 Azathioprine/ 
Mycophenolate 
23% (13/57) 34% (12/35) 
 Cyclophosphamide 2% (1/57) 9% (3/35) 
 Biologics 
(Rituximab) 
2% (1/57) 3% (1/35) 
* Dexamethasone was the topical steroid used in 55% (17/31) at presentation and 67% (12/18) between 0 and 12 months 
Table 5.7 Therapeutic Intervention including surgery, topical therapy and systemic 
immunosuppression in the OcMMP study. A step up in therapy was considered to be an escalation 
of treatment according to the validated step-ladder described by Rauz et al (Rauz et al., 2005a); 
Figure 1.12. 
.  
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Conjunctival epithelial cell populations in OcMMP 
Cross-Sectional Comparison at Presentation:  
OcMMP vs. healthy controls vs. positive disease controls  
 
Comparisons between the conjunctival leukocyte populations in the worst inflamed 
eye in the cohort with OcMMP, a healthy group (right eyes) and those with Primary 
Sjögrens Syndrome (PSS) (right eyes) revealed that there was no difference in the 
total number of leukocytes (including the total number of lymphocytes, monocytes 
and neutrophils) between groups (Table 5.8). Gating strategies were as described in 
Figure 5.1. 
 
Comparisons between individual populations revealed no difference between the 
total numbers of lymphocytes (median[range] Healthy(H):684[73-9775] vs. 
PSS(P):849[70-7013] vs. OcMMP(M):772[23-6059];p=0.2) or monocytes (H:107[2-
1949] vs. P:224[2-1945] vs. M:229[0-10763];p=0.12) although the lymphocytes 
percentage was lower in the OcMMP cohort (Table 5.8 and Figure 5.5). This was 
accounted for by a significantly higher number and percentage of neutrophils, 
compared to healthy participants and those with PSS (n; H:5.8[0-151] vs. P:0.8[0-
109] vs. M:109[1-197799];p<0.0001 and %; H:0.8[0-38] vs. P:0.2[0-4] vs. M:18[0.1-
86.7];p<0.0001 respectively) (Table 5.8 and Figure 5.5). 
 
Individual lymphocyte subset comparisons demonstrated that there were less T cells 
(CD3+CD56- live cells) as a total number and percentage of lymphocytes in the 
conjunctiva of patients with MMP (Table 5.9). In addition, the dominant CD8αβ+ 
population was significantly lower in patients with MMP (H:445 vs. P:104 vs. M:371; 
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p=0.0001), resulting in an increased percentage of CD4+ cells as a proportion of T 
cells and subsequently an elevation in the CD4:CD8 ratio in OcMMP compared to 
healthy controls (0.15 vs. 0.4 vs. 0.5; p=0.003) (Figure 5.6). This alteration was 
greater despite an expected elevation in CD4+ T cells in PSS (Stern et al., 2002). An 
elevation in the percentage of CD8αα+ and Double Negative (CD8αβ-CD4-) T cells 
was also observed. 
 
No changes in the B cell or NK populations were seen, but a reduction in the NKT 
cell population was seen in MMP compared to healthy controls (Table 5.9). 
 
Table 5.8. Conjunctival leukocyte populations in healthy volunteers, PSS and OcMMP. 
Comparisons were undertaken by comparing the most inflamed eye in patients with MMP (M) vs. the 
right eye of healthy participants (H) and patients with PSS (P). Median values are shown and 
comparisons were undertaken by the Kruskal-Wallis test with Dunn’s post hoc analysis test (Key: NS: 
Not significant, *p=0.01 to 0.05; **p=0.001 to 0.01;  *** p<0.001). 
 
Cell population Healthy PSS MMP Kruskal-Wallis Dunn’s post hoc 
CD45+ live leukocytes 870.9 1459 1987 0.44 (NS) NS 
Leukocytes subsets      
Total lymphocyte, monocytes 
& neutrophils 766.3 1041 1504 
 
0.53 (NS) 
 
NS 
Lymphocytes numbers 684 849 772 0.20 (NS) NS 
Lymphocytes % of leukocytes 73.0 65.1 35.6 <0.0001 H v M ***, P v M *** 
Monocyte numbers  107 204 229 0.12 (NS) NS 
Monocytes % of leukocytes 7.00 15.0 10.7 0.12 (NS) NS 
Neutrophil numbers  5.80 1.80 109 <0.0001 H v M ***, P v M *** 
Neutrophils % of leukocytes 0.800 0.200 18.1 <0.0001 H v M ***, P v M *** 
CD11b+ MFI 374 0.0 588 0.002 P v M ** 
Figure 5.5: Ocular Mucous Membrane Pemphigoid is characterised by an 
elevation in conjunctival epithelial CD45 CD11b+CD16+CD14- neutrophils. 
Comparisons were undertaken by comparing the most inflamed eye in patients with 
MMP vs. the right eye of healthy individuals and patients with PSS (Flow cytometric 
plots are shown in Panel A). Three group comparisons were undertaken by the 
Kruskal-Wallis test (Panel B) (Key: NS: Not significant, *p=0.01 to 0.05; **p=0.001 to 
0.01;  *** p<0.001). 
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Cell population Healthy PSS MMP Kruskal-Wallis Dunn’s post hoc 
T cells      
T cell numbers 436 686 312 0.005 P v M ** 
T cells (% of lymphocytes) 69.9 70.8 53.7 <0.0001 H v M**, P v M*** 
CD8αβ+ numbers 371 445 124 0.0001 H v M **, P v M *** 
CD8αβ+ % of T cells 76.0 61.5 50.0 0.0008 H v M*** 
CD8αβ+ CD45RO+ % 92.7 96.1 94.6 0.10 (NS) NS 
CD4+ numbers 38.2 199 50.3 0.05 (NS) NS 
CD4+ % of T cells 10.7 25.2 24.5 0.02 H v M* 
CD4+CD45RO+ % 100 100 100 0.88 (NS) NS 
CD4:CD8 ratio 0.150 0.400 0.500 0.003 H v M** 
DN numbers 13.9 52.9 34.0 0.07 (NS) NS 
DN% of T cells 5.40 7.90 17.5 0.0006 H v M*** 
CD8αα+ numbers 8.00 20.1 12.6 0.17 (NS) NS 
CD8αα+ % of T cells 1.80 4.60 7.05 0.01 H v M** 
      
B cell numbers 18.5 43.2 17.6 0.32 (NS) NS 
B cell % of lymphocytes 2.50 2.70 4.40 0.4 (NS) NS 
      
NK cell numbers 46.5 60.2 49.5 0.48 (NS) NS 
NK cells % lymphocytes 6.90 5.60 7.90 0.62 (NS) NS 
NKT cell numbers 31.5 43.9 18.6 0.02 P v M* 
NKT cells % lymphocytes 5.10 6.30 2.90 0.14 (NS) NS 
Table 5.9 Conjunctival lymphocyte populations in healthy volunteers, PSS and OcMMP. 
Comparisons were undertaken by comparing the most inflamed eye in patients with MMP (M) vs. the 
right eye of healthy participants (H) and patients with PSS (P). Median values are shown and 
comparisons were undertaken by the Kruskal-Wallis test with Dunn’s post hoc analysis test (Key: NS: 
Not significant, *p=0.01 to 0.05; **p=0.001 to 0.01;  *** p<0.001). 
 
Figure 5.6: Ocular Mucous Membrane Pemphigoid is characterised by a 
reduction in the dominant CD8αβ+ T cell population and an elevation in the 
CD4:CD8 ratio. Comparisons were undertaken by comparing the most inflamed eye 
in patients with MMP vs. the right eye of healthy individuals and patients with PSS. 
Three group comparisons were undertaken by the Kruskal-Wallis test (Key: NS: Not 
significant, *p=0.01 to 0.05; **p=0.001 to 0.01;  *** p<0.001). 
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No differences in the total leukocyte populations were observed in the peripheral 
blood of patients with MMP, healthy volunteers and those with PSS (153,838 cells/ml 
blood vs. 155052 vs. 188391; p=0.68). Lymphocytes (n(%);59,408(37%) vs. 
73,188(44) vs. 53,874(35);p=0.2), neutrophils (n(%);74,786(52%) vs. 93,421(45) vs. 
76,314(49);p=0.78) and monocyte populations were also unaltered.  
 
Some alterations in the subsets of lymphocytes and monocytes were evident. The 
total CD14INTCD16+ monocyte population was lower in MMP compare to PSS 
(n(%);961(9.8%) vs. 833(9.1) vs. 1533(18.6);p=0.006). The proportion of T cells 
populations were significantly lower in MMP compared to PSS (65.8% vs. 70.1 vs. 
75;p=0.01). Antigen experienced (CD45RO+) CD4+ T cells were also higher in MMP 
(81%) v Healthy (65%) vs. PSS (70.1) (p=0.01). No difference in the CD8αβ+ T cell 
(7602 vs. 9205 vs. 11,067;p=0.2) or CD4+ (25,227 vs.  35,209 vs. 20,220;p=0.06) 
population was seen however. 
 
Cross-Sectional Comparison at Presentation:  
Biopsy Positive vs. Biopsy Negative OcMMP  
 
There was no difference in the total number/percentage of leukocytes (1579 vs. 
2595;p=0.18), monocytes (194 vs. 289;p=0.51) and neutrophils (102 vs. 239;p=0.94) 
between biopsy positive (n=40) and negative (n=17) MMP patients. The total 
lymphocyte (543 vs. 1080; p=0.048) and T cell numbers (including CD8αβ+, CD4+, 
DN and CD8αα+) (238 vs. 630; p=0.006) were lower in the biopsy positive group. 
The percentage of lymphocytes (35 vs. 41%; p=0.36), T cells (54 vs. 54%; p=0.18) 
and CD4:CD8 ratio (0.5 vs. 0.6; p=0.6) however were not different and no other 
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changes were seen. There was no statistically significant difference in the duration of 
symptoms between the biopsy positive and negative groups to account for 
differences in lymphocytes (730[30-14600] vs. 1009[180-9125]; p=0.12). 
 
Cross-Sectional Comparison at Presentation:  
The inflammatory cellular infiltrate and clinically identifiable conjunctival inflammation  
 
The number and percentage of conjunctival epithelial CD45INTCD11b+CD16+CD14- 
neutrophils correlated with the severity of conjunctival inflammation; Healthy 
5.8(0.8%) vs. Non-inflamed MMP 44.3(7.9%) vs. Mildly inflamed MMP 94.3(7.3%) vs. 
Moderately/Severely inflamed 1912(42.3%) (p<0.0001), shown in Figure 5.7A,B. 
However, when comparing the Non-inflamed conjunctival neutrophil population, this 
was still significantly higher than when compared to healthy controls 44.3(7.9) vs. 
5.8(0.8);p=0.02 and p=0.004 (Figure 5.7C). This suggests that neutrophils are 
present, even in the absence of clinically manifest conjunctivitis. 
 
 
 
 
 
 
 
 
 
 
Mild 
A 
Figure 5.7 The severity of clinically identifiable conjunctival inflammation 
correlates with the number of epithelial CD45   CD11b+CD16+CD14- neutrophils 
but these cells are present even in clinically uninflamed eyes. Panel A shows 
representative flow plots for CD45  CD11b+CD16+CD14- live granulocytes for a 
healthy individual, patients with OcMMP with a clinically uninflamed, mildly inflamed 
and moderately inflamed eye. The number and percentages of neutrophils were 
correlated with the degree of conjunctival inflammation and healthy individuals (Panel 
B). Healthy and clinically uninflamed individuals were also compared (Panel C). 
Comparisons were undertaken by the Jonckheere-Terpstra test and the Mann-
Whitney U test (Key: NS: Not significant, *p=0.01 to 0.05; **p=0.001 to 0.01;  *** 
p<0.001). 
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Longitudinal Comparisons:  
The inflammatory cellular infiltrate and disease progression  
 
Table 5.10 shows the progression rates for the primary and secondary measures of 
scarring. For comparison, the median depth [range], symblephara numbers and 
extent for the upper fornices are also shown.  
 
Disease Damage   Right eyes  Left eyes All eyes 
Upper Fornix     
 Depth in mm 
(median[range]) 
14mm[0-19] 12mm[0-19] 12mm[0-19] 
 Symblephara number 
(median[range]) 
0[0-3] 1[0-2] 1[0-3] 
 Symblephara involvement 
(median[range]) 
0[0-15] 0[0-30] 2[0-30] 
  Central Depth 49%(17/35) 46%(16/35) 47%(33/70) 
Lower Fornix     
 Depth in mm 
(median[range]) 
4mm[0-8] 3mm[0-8] 3mm[0-8] 
 Symblephara number 
(median[range]) 
 
2[0-6] 
 
3[1-5] 
 
3[0-6] 
 Symblephara involvement 
(median[range]) 
 
12[0-30] 
 
10[3-26] 
 
12[0-30] 
 Central Depth  51%(18/35) 54%(19/35) 53%(37/70) 
 Tauber¶ 63%(22/35) 71%(25/35) 67%(47/70) 
Cornea      
 Neovascularisation 26%(9/35) 29%(10/35) 27%(19/70) 
 Opacification* 26%(9/35) 26%(9/35) 26%(18/70) 
¶  One patient did not have Tauber scoring documented at 12 months 
* Progression of neovascularisation was defined as an escalation of degrees clock hours or encroachment 
Progression of opacification of was defined as an escalation of opacification, conjunctivalisation or keratinisation 
Table 5.10 Disease progression by primary and secondary outcome measures in the OcMMP 
study. 
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Primary outcome measures:  
The median upper fornix depth had contracted in 47% of eyes, resulting in a median 
depth of 12mm. A median of 1 symblephara involving 2mm of the upper fornix was 
seen at 12 months follow up. For the lower fornix, there had been progression of 
scarring (measured by central depth) in 53% of eyes, resulting in a median depth of 
3mm. The number and extent of symblephara had also progressed (median 3 
symblephara; 12mm of lower fornix involvement). Tauber scoring had increased in 
67% of eyes at 12 months. 
 
In light of the significant elevation in neutrophils, reduction in CD8αβ+ T cells and 
alteration in CD4:CD8 ratio when comparing MMP to other diseases, comparisons 
among cell populations at presentation and disease progression were determined.  
 
Neutrophil numbers and percentage were significantly elevated in the group that 
progressed compared to the group that did no progress according to lower fornix 
shrinkage (n;143[2-36,636] vs. 27[1-5910];p=0.004 and %;10[0.1-74] vs. 3.7[0-
71];p=0.04) (Figure 5.8). In light of the significant changes seen in the elevation of 
neutrophils (total numbers and percentage) a generalised estimating equation (GEE) 
was undertaken to account for the effects of correlation between the right and left 
eyes. A ‘moderate’ (see fc value) degree of correlation was observed between the 
right and the left eyes (correlation matrix fc=0.376). The number of neutrophils was 
found to be 128 in the eyes that progressed vs. 39 (p<0.001) in the non-progressed 
group, confirming the test statistic using the Mann-Whitney U test. The percentage of 
neutrophils was also significantly higher among eyes that progressed using the GEE 
(fc=0.605; 10% vs. 5%;p=0.02). 
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Figure 5.8 Neutrophil numbers and percentage are significantly higher among eyes that 
develop lower fornix shrinkage in OcMMP. Comparisons between the 
CD45INTCD11b+CD16+CD14- neutrophils numbers and percentage of leukocytes was undertaken by 
the Mann-Whitney U test (Key: NS: Not significant, *p=0.01 to 0.05; **p=0.001 to 0.01). 
 
The levels of CD8αβ+ T cells and the CD4:CD8 ratio were no different among those 
with or without evidence of lower fornix shrinkage (n(%);139(39%) vs. 97(45);p=0.75 
and 0.6 vs. 0.4;p=0.32 respectively).  
 
There was no significant difference in the number/percentage of neutrophils among 
eyes that progressed vs. those that did not progress according to upper fornix depth 
(n(%);49(4) vs. 69(12%);p=0.56). This was also the case for the CD8αβ+ T cell 
population (n(%);124(27) vs. 138(28%);p=0.8) and CD4:CD8 ratio (0.5 vs. 
0.6;p=0.98). This indicated that inflammatory infiltrate with neutrophils, a reduction in 
CD8αβ+ T cell populations and an alteration in the CD4:CD8 ratio did not predict 
upper fornix shrinkage during this study period. 
 
When assessing progression by Tauber staging, there was no significant difference 
in the number/percentage of neutrophils among eyes that progressed (n(%);49(6%) 
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vs. 41(4);p=0.27). This was also the case for the CD8αβ+ T cell population 
(n(%);114(40%) vs. 144(52);p=0.36) and CD4:CD8 ratio (0.6 vs. 0.2;p=0.08). This 
indicated that inflammatory infiltrate with neutrophils and a reduction in CD8αβ+ T 
cell populations also did not predict progression by Tauber stging in this cohort. 
There was a trend towards an elevation in the CD4:CD8 ratio but this was not 
statistically significant.  
 
In summary, elevation of CD45INTCD11b+CD16+CD14- neutrophils at presentation 
was seen in eyes that went on to develop lower fornix shrinkage, as measured with 
an FDM. 
 
Secondary outcome measures:  
Corneal neovascularisation had increased in 27% and opacification had progressed 
in 26% of eyes by 12 months.  
 
When measuring inflammatory cell changes in eyes that demonstrated progression 
according to secondary outcome measures, no significant differences were observed. 
Neutrophil numbers and percentage (n(%);42(4%) vs. 64(7);p=0.25), CD8αβ+ 
(n(%);19(41%) vs. 139(45);p=0.23) and CD4:8 ratio (0.9 vs. 0.5;p=0.34) were not 
different among eyes that had evidence of established corneal vessels. No significant 
differences were also seen between the neutrophil numbers or percentage among 
those who did or did not have evidence of corneal opacification (n(%);64(28%) vs. 
46(4);p=0.18). This was also the case for the CD8αβ+ (n(%);109(37%) vs. 
140(45);p=0.5) and CD4:CD8 ratio (0.8 vs. 04.;p=0.08). 
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Longitudinal Comparisons:  
The inflammatory cellular infiltrate and time  
 
Given that the elevation of conjunctival epithelial neutrophils seen in patients with 
OcMMP at presentation (Figure 5.5) was more likely to result in lower fornix depth 
shrinkage (Figure 5.8), changes over time were determined. In order to verify if this 
inflammatory infiltrate was maintained over time, a GEE was employed. Neutrophil 
numbers at 0, 3, 6, 9 and 12 months were unaltered with no significant difference 
seen over this period (p=0.46) and no change was observed in neutrophils 
percentage (p=0.76) (Figure 5.9). This suggests that the inflammatory neutrophil 
infiltrate is maintained in OcMMP, signifying that the elevation demonstrated at time 0 
continued during the course of the study. 
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Figure 5.9 Elevated CD45 CD11b+CD16+CD14- neutrophils in OcMMP are 
maintained over time, indicating a persistent inflammatory infiltrate. The median 
neutrophil numbers and percentage are shown for the right eyes (Panel A) and left 
eyes (Panel B). Changes over time were calculated by using a generalised estimating 
equation (GEE) at 0, 3, 6, 9 and 12 months follow up for both eyes (Panel C) (Key: 
NS: Not significant, p>0.05).  
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Longitudinal Comparisons:  
The inflammatory cellular infiltrate and disease progression in clinically uninflamed 
eyes 
 
Having determined that an inflammatory infiltrate with CD45INTCD11b+CD16+CD14- 
neutrophils was present in patients with OcMMP and that this infiltrate was higher 
even among those without evidence of inflammation on clinical examination, it was 
important to determine whether this elevation could predict progression in this 
challenging group of patients. Sub-group analysis of progression rates among 
clinically uninflamed eyes (patients with uninflamed eyes followed up at 12 months; 
n=14) was therefore undertaken in order to establish whether an inflammatory 
neutrophil infiltrate could predict lower fornix shrinkage.  
 
First, the change in lower fornix depth (ΔFDM) correlated with the number of 
neutrophils seen in the right eyes of patients with OcMMP (p=0.035; Jonckheere-
Terpstra test) (Figure 5.10). Second, an alternative means of addressing this 
question was undertaken by comparing progression among the right eyes of those 
with an elevated neutrophil count against those without an elevation of 
CD45INTCD11b+CD16+CD14- granulocytes. An elevation in neutrophils was defined 
by using the median number of neutrophils (44) determined in the uninflamed group 
at cross sectional analysis (Figure 5.7). A count of >44 neutrophils was therefore 
considered elevated and those with <44 neutrophils were deemed not to be elevated. 
Progression rates were found to be significantly higher among those with a higher 
neutrophil infiltrate (p=0.02; Fishers exact test).  
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These data indicate that progression is more likely with an elevation in the number of 
conjunctival epithelial neutrophils. Neutrophil percentages did not correlate with 
ΔFDM or determine progression by fornix shrinkage (p=0.85; p=0.52).  
 
 
 
 
 
 
 
 
 
 
Figure 5.10 In clinically uninflamed eyes, the number of CD45INTCD11b+CD16+CD14-
neutrophils correlates with the degree of central lower fornix shrinkage in OcMMP. The number 
and percentage of neutrophils were compared by ΔFDM (The change in central lower fornix measured 
in mm between 0 and 12 months). Comparisons were undertaken by the Jonckheere-Terpstra test 
(Key: NS: Not significant, *p=0.01 to 0.05). 
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5.4 Discussion 
 
Characterisation of inflammatory cells in ocular surface disease started with the 
application of immunocytochemistry to conjunctival OSIC (Pflugfelder et al., 1990, 
Baudouin et al., 1992). This preceded the use of flow cytometry in OSIC, a powerful 
tool for quantitative cellular and cytokine analysis (Kellar and Iannone, 2002, 
Baudouin et al., 1997). This has been used to demonstrate the increased expression 
of HLA-DR in dry eye states, and the presence of leukocytes (CD45+ cells) in the 
ocular surface (Brignole et al., 2000, Baudouin et al., 2002, Barabino et al., 2010).  
 
In this study, I have demonstrated by non-invasive OSIC how in two forms of 
acquired ocular immunobullous diseases, SJS-TEN and OCMMP, there was an 
epithelial infiltrate with granulocytes composed primarily of 
CD45INTCD11b+CD16+CD14- neutrophils. Moreover, the persistent elevation of 
these cells was demonstrated in both diseases and in the case of OcMMP their 
elevation was associated with disease progression, even in the absence of clinically 
identifiable inflammation. This may offer a new, non-invasive and previously 
impossible way of quantifying sub-clinical inflammation. 
 
5.4.1 SJS-TEN study 
 
The initial insult in acute SJS-TEN has been identified as a cell-mediated 
phenomenon regulated by granulysin produced by CD8+ T-cells (a type of NK+ cell) 
resulting in severe disruption of epithelial surfaces including the skin (Chung et al., 
2008). Although these studies did not evaluate ocular disease, CD8+ T cells have 
Chapter 5  Characterising the conjunctiva in acquired ocular 
immunobullous disease 
203 
been identified in the cornea of a patient with TEN (Williams et al., 2007) and the 
healthy human conjunctival epithelium is dominated by a population of CD8+ T cells 
(Chapter 4), (Hingorani et al., 1997).  
 
The idea that ocular SJS/TEN was temporal and did not progress once the initial 
acute phase has resolved, has been superseded by the understanding that many will 
develop chronic disease, requiring long-term specialist care including systemic 
immunosuppression in severe cases (De Rojas et al., 2007). The precise definition of 
acute and chronic ocular SJS-TEN has not been universally agreed. A cut-off of 12 
months to define chronic disease was used as described by Sotozono and 
colleagues (Sotozono et al., 2007). The very acute stages of disease are probably 
better reflected by the 2-6 weeks described by Power and colleagues (Power et al., 
1995, Fu et al., 2010), and while 4/6 ‘acute’ patients were <30 days of disease onset 
in this study, 2/6 were greater than 30 days (one 114 and the other 168 days) and 
were therefore defined as ‘sub-acute’.  
 
Discriminating acute and chronic ocular features of SJS-TEN are challenging 
because of the absence of a universally agreed grading system or indeed one that 
discriminates markers of activity and damage. These limitations meant that two 
current scoring systems to classify acute and chronic disease respectively were 
employed (Power et al., 1995, Sotozono et al., 2007). The staging system described 
by Sotozono and colleagues is a more detailed system, but may present challenges 
in the very acute stages of severe disease e.g. ascertaining meibomian gland 
secretion by manual expression due to the friable nature of eyelid skin in severe 
acute disease. Nonetheless, the other parameters allow for a systematic 
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determination of eyelid, conjunctival and corneal disease severity. The median score 
according to the Sotozono system of 8/39 in our patients suggests less severe 
disease than the 9/10 patients having severe disease according to the system 
described by Power. The increased weighting given to the presence of symblephara 
in the Power scale may account for this discrepancy, and for this reason we used 
objective evidence of conjunctival scarring by employing formal fornix depth 
assessment.  
 
The median lower fornix depth was 8 [0-12]mm indicating that the severity of scarring 
may not be as severe as the Power scoring system would indicate through the 
presence of symblephara alone. In addition, there was little evidence of disease 
progression in this cohort, although this was limited to a follow-up of 12 months only 
and the cohort size may also have been too small to demonstrate significant 
differences. Fu and colleagues have recently made the argument for a more 
universal scoring system (Fu et al., 2010), and predicting outcome as well as 
monitoring disease activity will undoubtedly be facilitated by a consistent and easily 
applied grading system.  
 
In this cohort the CD8+ and NK+ populations were not significantly elevated 
compared to healthy controls and that this remained unaltered over time. This finding 
may be explained by the fact that the damage induced is thought to be mediated by 
the soluble factor granulysin, explaining how disease severity may be out of keeping 
with the degree of inflammatory cellular infiltrate by cytotoxic cells as release of 
granulysin is not dependent on recruitment of additional CD8+ T cells and Natural 
Killer cells (Quinn et al., 2005). Early vacuolation of the cornea has been seen in the 
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very early stages of ocular TEN in the absence of a lymphocytic infiltration (Williams 
et al., 2007). In addition, the healthy conjunctival epithelium is dominated by CD8+ 
cells, with a proportion of NK cells also residing in this layer (Chapter 4), so a major 
alteration in the context of disease may not be surprising. 
 
Both monocyte and CD45INTCD11b+CD16+CD14- neutrophils were elevated in the 
context of SJS-TEN in the acute and chronic stages of disease together with an 
elevation TCRαβ+CD3+CD8β-CD4- (Double Negative) T cells. The elevation in 
neutrophils was inversely correlated with the duration of disease indicating a higher 
proportion in those with acute disease. During the study period of 12 months 
however, the elevation of neutrophils was maintained with time, indicating a 
persistent inflammatory response. In a cohort of volunteers undergoing cataract 
surgery, the use of topical Dexamethasone (which most of our SJS-TEN patients 
were prescribed) did not result in an elevation of neutrophils. In fact, although this 
was not significant different, the trend suggested a reduction in these cells. These 
data would suggest that alterations in neutrophils seen in this study cannot be 
attributed to the use of topical steroids, where systemic administration of 
Prednisolone and Cortisol are known to cause a systemic granulocytosis (Bishop et 
al., 1968).  
 
It is unclear whether the presence of a persistently elevated neutrophil infiltrate 
represents enhanced recruitment or contributes to scarring in the context of PCC 
such as SJS-TEN. The role for innate immune processes however has attracted 
greater attention including the presence of TLR-3 polymorphisms in a cohort of 
Japanese patients with SJS-TEN (Ueta et al., 2007). Disruption of the innate immune 
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responses in genetically susceptible individuals has been postulated as one reason 
for abnormal drug reactions in some individuals and a predisposition to SJS (Ueta 
and Kinoshita, 2010). 
 
These data highlight that in ocular SJS-TEN, an inflammatory infiltrate with 
CDINTCD11b+CD16+CD14- neutrophils is present even in mildly involved or clinically 
quiescent conjunctival mucosa and are maintained indicating the persistence of 
clinically occult inflammation. There was also a reduction in the percentage of 
CD8αβ+ cells in the superficial conjunctival epithelium during acute and chronic 
disease and an elevation in ‘double negative’ T cells. TCRγδ+ double negative T cells, 
considered to be a type b IEL, have a regulatory phenotype (Hayday et al., 2001) and 
it is unclear whether an inflammatory environment in ocular SJS-TEN or the 
reduction in resident CD8+ T cells results in the recruitment of these cells. 
 
OSIC recovers cells from the superficial layers of the epithelium due to its non-
invasive nature, but cannot access the deeper layers including the stroma. OSIC has 
been used to identify a reduction in conjunctival goblet cells on the conjunctiva of 
patients with TEN (Lopez-Garcia et al., 2011), but it has not been combined with cell 
surface markers to quantify inflammatory cellular infiltrates. The potential to study the 
presence of neutrophils in early SJS-TEN by OSIC is attractive, not least because of 
its non-invasive methodology, and it also affords the opportunity to undertake 
longitudinal sampling. In the absence of both a consistent clinical scoring system and 
biomarker of ocular disease, this technique combined with multi-colour flow 
cytometry warrants further investigation in the context of SJS-TEN. This may allow us 
to identify a cohort of patients with acute SJS-TEN and explore the potential role of 
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neutrophils in developing chronic inflammation, and its effects on local ocular 
sequelae. It is also intriguing that in a PCC with a very different aetiology to the 
autoimmune disease OcMMP, that a persistent elevation of these innate cells has 
been identified. 
 
5.4.2 OcMMP study 
 
This is the first longitudinal ex vivo demonstration of cellular infiltrates in the 
conjunctiva in OcMMP. These data confirm that an inflammatory cellular infiltrate 
occurs in the conjunctival epithelium in MMP compared to healthy participants and 
differs from patients with PSS. An elevation of neutrophils is evident (akin to that 
demonstrated in SJS-TEN), combined with a reduction in the dominant CD8αβ+ T 
cell population and resultant alteration in the CD4:CD8 ratio.  
 
The OcMMP cohort in this prospective study (Cohort 12) had a duration of symptoms 
similar to the EOD group (Cohort 1) (930 days). The levels of conjunctival 
inflammation were similar (65% vs. 76%) but as previously discussed (Chapter 3) 
the rates of progression can be variable and depend on the accuracy of 
measurement. This study provided the opportunity to utilise the objective FDM and 
calculate the Tauber staging system and perhaps it was not surprising therefore that 
were able to detect progression as high as 53 and 67% of eyes respectively. It also 
re-emphasises the concern that sub-clinical inflammation is taking place. 
 
Elevation in inflammatory cellular infiltrates has previously been identified from 
histological sections of conjunctiva of patients with OcMMP (Bernauer et al., 1993a, 
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Rice and Foster, 1990, Sacks et al., 1989). In the presence of clinically defined 
minimal inflammation, this was found to be a predominantly T cell infiltration of the 
conjunctiva and neutrophils in the epithelium (with a CD4:CD8 ratio of 0.5) (Bernauer 
et al., 1993a, Rice and Foster, 1990). In severe conjunctival inflammation however 
the CD4:CD8 ratio increases to 1.0 (Bernauer et al., 1993a, Rice and Foster, 1990). 
This alteration has previously been shown to arise form an elevation in CD4+ T cells, 
demonstrated also in PSS (Stern et al., 2002, Bernauer et al., 1993a). In the case of 
PSS, both murine models and human studies have led to a more comprehensive 
phenotyping of CD4+ subsets, demonstrating the importance of a Th17 phenotype in 
dry eye disease (Stern et al., 2010, De Paiva et al., 2010). Although there was a 
trend toward elevated CD4+ T cells in MMP and PSS in this study (this did not reach 
significance), the major influence on the alteration in CD4:CD8 ratio was a reduction 
in CD8αβ+ T cells. More recently a small cohort of patients with MMP had OSIC 
applied to their conjunctiva, also demonstrating an altered CD4:CD8 ratio. 
Characterisation of neutrophils was not undertaken however (Rolando et al. Immune 
Response of the Ocular Surface in Ocular Cicatricial Pemphigoid Patients; IOVS 
2010; 51: E-Abstract 2365.). 
 
The implications of a decrease in the dominant CD8αβ+ lymphocyte population are 
not clear. Whether this represents an alteration in the effector function of these cells 
or simply reflects abnormal architecture of the ocular surface secondary to scarring 
remains to be determined. A similar finding was identified in the CD8% in patients 
with SJS-TEN although direct comparisons were precluded because of the significant 
age difference between disease groups (median 44 years[range 18-67] vs. 72[48-97]; 
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p<0.001). It is possible that turnover of cells may be impeded in diseased conjunctiva 
due to epithelial cell damage or the presence of scar tissue.  
 
Alterations in the CD4+ T cell population and CD4:CD8 ratio were demonstrated in a 
cohort of healthy volunteers with age (Chapter 4). These effects were circumvented 
by undertaking age-matched comparisons, indicating that changes were independent 
of natural ageing changes in the conjunctival epithelium. Whether naturally occurring 
elevations in CD4+ T cells contribute to an inflammatory phenotype and promote 
disease activity, and indeed damage, are undetermined.  
 
The most compelling evidence for an underlying inflammatory process was seen by 
the significant increase in the percentage of CD45INTCD11b+CD16+CD14- 
neutrophils in both the uninflamed and inflamed eyes of patients with MMP. In severe 
conjunctival inflammation however there is a 3-fold increase in neutrophils compared 
to controls (Bernauer et al., 1993a, Rice and Foster, 1990). Our data therefore 
confirm that neutrophils are present in the conjunctival epithelium, correlate with the 
grade of clinical inflammation but importantly can be demonstrated in a clinically Non-
inflamed eye. The presence of neutrophils in the clinically ‘white’ eye was shown in a 
small study previously  (in 5/6 conjunctival samples) (Rice and Foster, 1990), but the 
ability to demonstrate ex vivo has not previously been achieved. 
 
Having previously established that progression rates were similar in clinically 
inflamed and uninflamed eyes (Chapter 3), it was important to determine the role of 
neutrophils might play in progressive cicatrisation. It was apparent that neutrophil 
numbers and percentage were higher among eyes at presentation that had evidence 
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of lower fornix shrinkage at 12 months follow up. Furthermore, this elevation in 
neutrophils was maintained over time, similar to the findings in the SJS-TEN cohort. 
This would indicate a persistent, chronic inflammatory process. When considering 
clinically uninflamed eyes, the number of neutrophils also determined the extent of 
lower fornix shrinkage and was more likely with an elevation of neutrophils. The 
presence of an elevation in neutrophils therefore suggests that chronic inflammatory 
responses in the conjunctiva may lead to an increase in scarring and potentially open 
an avenue for exploration of this cell population as a non-invasive biomarker of 
disease activity and/or damage. Changes in Tauber staging or secondary outcome 
measures could not be predicted by an elevation in neutrophils in this cohort which 
may relate to the duration of the study, or the difficulty in accurately quantifying 
symblephara numbers, even with an FDM. This warrants further investigation. 
 
The importance of the complement-mediated component in the inflammatory process 
in OcMMP has previously been emphasised (Bernauer, 1997), with antibodies 
inducing the classical complement cascade via C3, leading to chronic recruitment of 
neutrophils to the conjunctival BMZ. Historically neutrophils were thought to be short 
lived, becoming primed and leaving the peripheral blood compartment via the 
endothelium and entering infected/inflamed tissue along a chemotactic gradient. By 
utilising lysosome bound peptides such as the azurophilic granules - elastase, 
cathepsin and proteinase 3 as well as toxic ROS e.g. superoxide (O2-) and Nitrous 
Oxide (NO) to destroy pathogens (Janeway, 2005, Doring, 1994). The short life-span 
of neutrophils is controlled in part by apoptosis of activated neutrophils, but 
alterations in apoptotic regulation can lead to a prolonged inflammatory response 
(Wright et al., 2010). This interaction with other inflammatory cells in an inflamed site 
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is a complex process but there is evidence for dysregulation resulting in a number of 
chronic inflammatory conditions e.g. rheumatoid arthritis (Witko-Sarsat et al., 2000). 
 
Persistent elevation of neutrophils is known to induce localised tissue damage 
through the mechanisms outlined above including the destructive properties of the 
azurophilic granules such as elastases (Doring, 1994). Although azurophilic granules 
are normally confined to lysosomal compartments, they may extravasate in to tissue, 
inducing disruption that should ordinarily disrupt phagocytised bacteria (Witko-Sarsat 
et al., 2000, Nathan, 2006). Elastase release can also modulate innate responses 
and alter the epithelial glycocalyx in mucosal sites (Doring, 1994). It is unknown 
whether chronic elevation in neutrophils diminishes resistance to pathogens but a 
recent study revealed that there was an alteration in the normal micro flora with an 
increase in pathogenic micro-organism on the ocular surface of patients with MMP 
(Agarwal M et al. The Prevalence Of Bacterial Pathogens On The Lids And 
Conjunctiva In Ocular Cicatricial Pemphigoid IOVS 2011;52: E-Abstract 4250). 
 
The possibility of a persistent localised destruction of tissue resulting in scarring has 
been recognised in other diseases. Mice lacking neutrophil elastase have been 
shown to be resistant to pulmonary fibrosis (Chua et al., 2007) and this finding may 
be important in the persistence of human scarring disease. Indeed, pulmonary 
fibrosis is characterised by a local infiltrate of neutrophils (Hara et al., 2009). Similar 
findings were found in the context of cryptogenic fibrosing alveolitis (CFA), with an 
elevation of neutrophil numbers and elastase seen in CFA compared to the clinically 
less severe fibrotic process evident in systemic sclerosis (Obayashi et al., 1997).  
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The evidence suggests that the recruitment of and persistence of conjunctival 
epithelial neutrophils is associated with progressive fibrosis, even in the absence of 
clinically identifiable disease activity. The presence in the very superficial layers may 
reflect what is occurring in the ‘business end’ of the scarring process, namely the 
underlying BMZ. This in turn could result in underlying stromal fibrosis. Further 
clarification and validation of this process is required to determine whether this 
neutrophil infiltrate contributes to the inflammatory process, disrupts the architecture 
of the epithelium e.g. reducing the CD8+ population and how the mechanisms of this 
progressive fibrosis takes place. 
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6.1 Introduction 
 
This thesis has provided an opportunity to measure clinical parameters in acquired 
ocular immunobullous disease, develop a non-invasive technique for phenotyping the 
resident healthy conjunctival epithelial leukocyte population and determine how this 
is altered in the context of age and diseases such as SJS-TEN and OcMMP. I have 
demonstrated that:  
 
1. Early onset of OcMMP is associated with significant increases in the levels of 
clinically identifiable inflammation but less evidence of conjunctival scarring. 
2. Progression rates between early onset or established disease are similar and 
confirmed that this can occur in the absence of clinically identifiable 
inflammation. 
3. Clinical documentation rates may be sub-optimal, compounded by the absence 
of objective measurement of conjunctival scarring. This can be overcome by 
using a validated FDM and a CRF, with potential for use in other PCC. 
4. OSIC combined with multi-colour flow cytometry offers a non-invasive means of 
characterising IEL and other leukocytes from the conjunctival epithelium 
5. TCRαβ+CD3+CD56-CD8αβ+ lymphocytes are the dominant population in the 
healthy conjunctival epithelium. These are effector memory (CD45RA-CCR7-), 
CD103+ T cells with the ability to produce Granzyme B and IFN-γ. The ability to 
recognise CMV and EBV viral antigens correlate with peripheral blood. 
6. The second most common cell population in the conjunctival epithelium are 
TCRαβ+CD3+CD56-CD4+ lymphocytes. These T cells also produce IFN-γ and 
a smaller population IL-17. Importantly the number of CD4+ cells increases with 
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age and while the IL-17 population is maintained, the IFN-γ producers increase. 
By contrast, the CD8+ population remains unaltered. 
7. Both SJS-TEN and OcMMP are characterised by a significant elevation in 
CD45INTCD11b+CD16+CD14- neutrophils. In OcMMP there is an altered 
CD4:CD8 ratio, resulting from a decrease in the dominant CD8+ population. 
8. In OcMMP neutrophils correlate with clinically identifiable conjunctival 
inflammation, but this is still detectable in clinically Non-inflamed eyes. 
9. In both SJS-TEN and OcMMP there is a persistent elevation in conjunctival 
epithelial neutrophils. In the case of OcMMP this is associated with evidence of 
progressive conjunctival scarring as measured by a FDM. 
10. Even in a clinically uninflamed eye, an elevation of neutrophils is accompanied 
by evidence of lower fornix shrinkage. 
 
The major changes in the conjunctival leukocytes are summarised in Table 6.1. 
Table 6.1 Summary of the major conjunctival epithelial cellular changes in health, ageing and 
in acquired ocular immunobullous disease. Key: Increases (), decreases () or no change (-) 
where / ≈ twofold increase/decrease (T-cell/neutrophil % are of lymphocytes/leukocytes). 
 
In this chapter, these results will be discussed in the context of their respective 
findings and how they may inform future studies. 
 Health Ageing SJS-TEN PSS Uninflamed 
OcMMP 
Inflamed 
OcMMP 
CD8+ T cells 80% - - -   
CD4+ T cells 10%  -  - - 
CD4:CD8 ratio 0.15      
Neutrophils  <1% -  -   
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6.2 Measuring clinical parameters in acquired ocular immunobullous disease  
 
It was clear from undertaking a retrospective review of patients with OcMMP 
presenting to two large tertiary referral centres in the UK that there was a significant 
lag between the onset of symptoms and presentation to specialist centres for care (a 
median of 4 years). When patients were referred ‘early’ (<3 years) these individuals 
were more likely to have evidence of clinically identifiable inflammation but less 
fibrotic damage to the conjunctiva. Conversely, ‘late’ presenters had less manifest 
activity but greater evidence of cicatrisation. Crucially however, both groups needed 
more aggressive immunosuppression to control disease yet the rates of progression 
were no different. A further complexity was the conformation of the finding that 
clinically uninflamed eyes progressed in up to 42%. 
 
Progression rates are difficult to assess in the clinical setting, not least because of 
the limitations of the Mondino and Foster systems (Mondino and Brown, 1981, 
Foster, 1986). In this thesis, I demonstrated sub-optimal documentation using the 
Foster scale and how the provision of a CRF can aid the ophthalmologist in recording 
changes when faced with a number of clinical parameters.  
 
The production and validation of a FDM has also shown how more sensitive scales 
such as the Mondino system can be enhanced through objective measurement of 
fornix shrinkage. In addition, the FDM has demonstrated how Tauber’s proposed 
system (Tauber et al., 1992) can be enumerated and introduced in to the clinical 
setting and how millimetric determination of fornix shrinkage rather than relying on an 
ordinal scale such as Mondino can be employed.  
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There is clearly additional work that can be undertaken to help improve the scoring in 
OcMMP. The work of Sotozono and colleagues has shown how a scoring system can 
be developed in PCC, with a 39-point scale utilised for chronic SJS-TEN (Sotozono 
et al., 2007). The scale considers the ocular surface sequentially, incorporating 
scales for the eyelids, conjunctiva, fornices, cornea and tear film. The corneal scales 
were adapted for our CRF but in order to standardise these scales and consider 
which others are acceptable, a consensus is required. 
 
The first international consensus on MMP sought to address many areas of 
disagreement and confusion surrounding the disease. Indeed the mission statement 
was defined as follows: ‘The purposes of the consensus statement are to define a 
single nomenclature for this groups of diseases, to establish a unified set of 
diagnostic criteria, to provide recommendations for medical treatment and to facilitate 
future clinical and laboratory investigation’ (Chan et al., 2002). The format of the 
consensus was to gather experts in their field (26/36 approached participated) based 
on a literature search undertaken by the principal author, Lawrence S. Chan. A 
consensus meeting was organised and 17 participants attended. Three rounds of 
revisions were undertaken to the consensus statement, based on the literature 
search undertaken. The first international consensus on MMP was the first attempt to 
standardise the nomenclature and definition of the disease as well as the other 
objectives outcomes in the statement. Three challenges have arisen from the 
consensus statement however, and the panel has not re-convened since.  
 
The first challenge is the requirement for a confirmatory DIF positive biopsy. The 
difficulties surrounding this requirement have been discussed in Chapter 1 (section 
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1.7.2) but briefly, there is a cohort of MMP patients where the biopsy is ‘negative’, but 
have no other identifiable cause for PCC e.g. SJS-TEN to account for their identical 
clinical phenotype (Thorne et al., 2004, Bernauer et al., 1994, Saw, 2008). Consistent 
with the consensus statement a biopsy is certainly advocated, not least to exclude 
neoplastic causes of cicatrisation, but excluding the diagnosis of MMP based on a 
negative result could jeopardise patient care. These patients still require 
immunosuppressive intervention, as a patient with positive biopsy result would 
expect. Furthermore the consensus statement makes it clear that distinguishing 
OcMMP from Bullous Pemphigoid, Linear IgA disease and Epidermolysis Bullosa 
acquista should be made on clinical grounds as a biopsy positive result could be 
expected in all conditions (Chan et al., 2002). 
 
The second challenge is that the mode of recording and grading the clinical features 
of MMP, crucially and especially OcMMP, were not addressed in the consensus 
statement. There has been no impetus therefore to address the difficulties outlined 
with current systems. Finally, and related to this point, the mechanism for reaching 
consensus was very different to the Delphi approach, utilised in dry eye and thyroid 
eye disease in the field of ophthalmology or the outcome measure in rheumatology 
(OMERACT) (Behrens et al., 2006, Douglas et al., 2009, Tugwell et al., 2007, Naredo 
et al., 2011). In order to determine a scoring system using the Delphi approach, it is 
suggested that questionnaires are employed following the establishment of an expert 
panel. It is important that patients are involved and the use of questionnaires avoids 
a situation where individuals can impose their views on participants. On publication 
the size and composition of the panel, the methodology and the results should be 
clearly stated (Sinha et al., 2011). 
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The Delphi approach has been utilised in numerous fields and adopted for clinical 
trials. By undertaking a systematic approach such as this there is also the ability to 
gather information form multiple experts without the risk of greater weight being 
favoured by senior or vocal experts (Sinha et al., 2011). This approach has allowed 
outcome measures in large-scale clinical trials to be agreed. It is crucial in the 
process of developing a disease scoring scale that good intra- and inter-observer 
agreement can be achieved so a process of validating the agreed scores is 
undertaken with patients to assess reproducibility among clinicians (Kempen et al., 
2008, Bowman et al., 2007, Barry et al., 2008). 
 
The implementation of such an approach for MMP would be welcome; in particular as 
there is a heavy reliance on subjective documentary systems. It is hoped that 
developing a method for producing an FDM in a mechanised or semi-automated 
fashion would allow cheap production for use in specialist clinics beyond our own. In 
order to aid the process of determining forniceal shrinkage, anthropological studies of 
upper fornix and inter-canthal distances could aid percentage shrinkage calculations 
akin to the lower fornix outlined by Schwab and colleagues (Schwab et al., 1992). 
Such studies are being conducted in both BMEC and MEH among White European 
and Asian populations. 
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6.3 The conjunctival epithelial leukocyte population in health and in acquired 
ocular immunobullous disease 
 
Devising expanded multi-colour antibody panels for use with flow-cytometry has 
allowed a far greater understanding of IEL and other leukocyte populations in the 
conjunctiva. This has also facilitated the exploration of a non-invasive technique for 
collecting cells, previously restricted by tissue access and/or limitation of material. 
 
The dominance of CD3+CD8+ T cells and the presence of CD45RO+ antigen 
experienced cells have been previously established in the conjunctiva. The novelty in 
the data generated in this thesis is the confirmation of a dominant Type a IEL 
TCRαβCD3+CD56-CD8αβ+ lymphocyte population with a cytotoxic phenotype, 
which does not alter with age (Chapter 4). Cells were able to produce IFN-γ and 
Granzyme-B but did not have regulatory features (expression of IL-10 or FoxP3), 
seen in other mucosal CD8+ subsets such as the gut. The presence of CD103+ has 
also been associated with a regulatory phenotype (Uss et al., 2006) but this was not 
the case in this conjunctival IEL population and despite their cytotoxic phenotype, all 
expressed CD103.  
 
Few Type b IEL were identified in health and alterations in disease were confined to 
the elevation in double negative (DN) cells seen in SJS-TEN and percentage 
changes within T cells in OcMMP, including and elevation of CD8αα+ populations. In 
chronic disease, this could represent a repair mechanism, in response to disruption 
of the ocular surface following acute disease. Type b IEL populations play a role in 
repair such as CD8αα+ and TCRγδ+ T cells. Depletion of TCRγδ+ T cells has been 
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shown to reduce epithelial barrier integrity in response to Toxoplasma gondii in mice 
(Dalton et al., 2006).  An elevation in gamma-delta T cells has been observed in the 
context of OcMMP (Soukiasian et al., 1992), but no alterations in TCRαβ-(TCRγδ+) T 
cells were seen in the conjunctiva in this study however (Healthy 0.1% of T-cells vs. 
PSS 0.2% vs. OcMMP 0.2%;p=0.95, data not shown). Whether the Type b IEL play a 
minor role in human conjunctival epithelial immune regulation or have a more 
important function in the deeper stromal layers is not known.  
 
The effector memory, cytotoxic status of the CD8+ population demonstrated in this 
thesis reflected the ability of these cells to recognise common immuno-dominant viral 
antigens in CMV and EBV (Chapter 5). Murine virus-specific mucosal IEL CD8+ 
memory cells differ from virus-specific CD8+ T cells isolated from the spleen, with a 
higher production of Granzyme B (Masopust et al., 2006). The role of CD8+ type a 
IEL in ocular surface viral regulation warrants further exploration, in particular their 
role in recognising viruses such as HSV. HSV is a major cause of ocular morbidity, 
causing an initial blepharo-conjunctivitis followed by persistent latent residence in the 
trigeminal nerve root ganglion, triggering recurrent episodic epithelial, stromal or 
endothelial reactivation. This results in potentially blinding complications including 
corneal scarring and neovascularisation. The prevalence has been reported as 150 
cases per 100,000 and therapeutic intervention in the US was placed at $18 million 
per annum to treat recurrences (Liesegang et al., 1989, Lairson et al., 2003). 
 
In mice infected by HSV via the skin, effector memory skin cells continue to reside 
within the epidermis, even following the transport of the virus to the trigeminal nerve 
ganglion and resolution of acute infection. Furthermore, grafting previously infected 
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skin on to naïve donors results in re-circulation of HSV specific CD103+ CD8+ T cells 
to the skin epidermis of the recipient but not splenic tissue, providing protection 
against HSV infection. After resolution of infection, these effector memory peripheral 
CD8+T cells persisted in the epithelium, even when they were not present in 
peripheral blood (Gebhardt et al., 2009, Gebhardt et al., 2011). The role of human 
conjunctival epithelial TCRαβCD8αβ+ T cell in regulating HSV infection could be 
explored by HLA-typing patients with recurrent ocular viral infections such as HSV 
keratitis, and constructing HLA-typed tetramers bound to known viral antigens. This 
process is complex and lengthy however but could offer an interesting insight in to 
why such a dominant population of IEL is found in the conjunctival epithelium.  
 
Questions remain about how CD8+ T cells are recruited and retained within the 
conjunctival epithelium and it may be that the epithelial cells themselves play a role in 
regulating the immune recruitment process. Certainly, the concept of the 
‘epimmunome – epithelial molecules that direct the actions of immune cells’ (Swamy 
et al., 2010) has garnered interest because of the possibility that rather than being 
simple barriers, epithelial cells respond to micro-organisms targeting mucosal 
epithelial surfaces and help establish and maintain immune responses via numerous 
pathways e.g. the TLR mediated regulatory pathway NF-κB, where inhibition of 
intestinal epithelial-cell-specific NF-kB  results in colonic inflammation in mice (Nenci 
et al., 2007).  
 
TGF-β, produced by the epithelium, is known to induce a switch from α4 to αE 
expression on CD8+ T cells, facilitating their recruitment to the epithelium from the 
underlying stroma. TGF-  derived from intestinal epithelial cells influences the 
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antigen- presenting cells, which migrate to the draining lymph nodes to prime local T 
cell responses (Sheridan and Lefrancois, 2011). OSIC may offer a novel avenue for 
exploring the epimmunome. Preliminary data has suggested that conjunctival 
epithelial cells can be isolated using the epithelial cell marker EpCam. These cells 
may then be subjected to microarrays to elucidate transcript profiles before formal 
validation by RT-PCR. This may provide another opportunity to understand 
conjunctival disease and to achieve this characterisation of human mucosal epithelial 
cells by using a readily accessible tissue and collection technique. In the presence of 
a reduced CD8αβ+ T cell population in both SJS-TEN and OcMMP, it is conceivable 
that up-regulation of TGF-β seen in OcMMP, may represent a way of replacing IEL 
lost during the scarring processes.  
 
Disruption to the BMZ may also impair T cell trafficking as cicatrisation alters the 
architecture of the conjunctiva. The BMZ, which IEL would normally have to cross 
when trafficking to the epithelial surface (Chan et al., 2008), becomes disrupted in 
OcMMP and may therefore compromise CD8+ T cell recruitment. The reduction in 
CD8+ cells may therefore alter the natural equilibrium seen in human conjunctival 
epithelium by compromising immune regulatory mechanisms involved in ocular 
surface health such as targeting infected cells. This may be one of the reasons that 
alterations in the micro-flora were recently demonstrated in relation to OcMMP 
(Agarwal M et al. The Prevalence Of Bacterial Pathogens On The Lids And 
Conjunctiva In Ocular Cicatricial Pemphigoid IOVS 2011; 52: E-Abstract 4250). OSIC 
or even conjunctival swabs could be employed to recover cells and PCR-based 
technology may offer an insight in to the composition of the normal flora in health and 
how these changes occur in disease.   
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At a stromal level, elevation in CD4+ T cells has been recognised in relation to 
OcMMP during the initial inflammatory insult. Age-related elevations in CD4+ cells 
were demonstrated (Chapter 4) and with the careful age matching undertaken in this 
thesis, a change in CD4:CD8 ratio was observed (Chapter 5). In the gut lamina 
propria CD4+ cells are predominantly Th17 or TREGs, and these are regulated by the 
presence of commensal bacteria (van Wijk and Cheroutre, 2009). Th17 cells can 
induce granulopoiesis and recruit neutrophils to inflammatory sites (Cua and Tato, 
2010). Although not demonstrated directly in our patients with PCC, one would 
hypothesise that Th17 CD4+ cells are implicated in the process of recruiting 
neutrophils to the ocular surface and again alterations to the normal ocular surface 
flora my provoke such responses. Indeed, a small population of both CD4+ and 
CD8+ IL-17 producing cells were demonstrated in our healthy cohorts and our data 
suggests that IL-17 producing CD4+ cells are maintained with age (Chapter 4). In 
trachoma, an infective cause of cicatrisation induced by the pathogen Chlamydia 
trachomatis, this was recently associated with an elevation in IL-17 transcripts 
(Burton et al., 2011).  
 
Whether locally produced anti-BMZ antibody contributes to the pathology in 
OcMMP has not been explored. At present there are no data regarding local anti-
BMZ Ab production in affected tissue from secondary lymphoid tissue such as EALT 
or the lacrimal gland. Furthermore, there are no data to suggest whether local 
antibody targets local tissue more effectively e.g. tear anti-BMZ IgG directed against 
conjunctiva more than buccal mucosa. This may be of relevance as evidence of 
local inflammation may correlate with the presence of local antibody production and 
in turn fibrotic damage. Whether the inflammatory response is also influenced by 
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local antibody production e.g. by EALT, or whether tertiary lymphoid structures 
develop is unknown. Determining specific anti-BMZ tear and serum IgA levels could 
offer a means of exploring this question by calculating a Goldmann-Witmer co-
efficient (van der Voet et al., 1989). Whether there is specific binding in this context 
is also unknown such as tear binding to conjunctiva or saliva to oral mucosa. This 
could be explored by immunofluorescent studies. 
 
In OcMMP, the complement cascade is activated at the BMZ in response to 
autoantibodies. Presumably this involves the classical pathway via IgG binding to 
C1q (the first component of the complement cascade), resulting in the BMZ being 
coated in C3b. Although murine models have suggested that the complement 
cascade was not involved in subepithelial lesions in skin, closer scrutiny of the 
mouse conjunctiva has not been undertaken (Lazarova et al., 1996). The murine 
ocular surface may or may not have had evidence of blistering but in humans this 
again is not a prominent feature - scarring takes place without gross evidence of 
blister formation. It is therefore quite possible that autoimmune mediated recruitment 
of complement contributes to the inflammatory infiltrate by recruiting neutrophils. This 
may be compounded by recruitment of other cells to the inflammatory environment 
within the conjunctiva as in other mucosal sites. Indeed, CD4+ T cells have been 
shown to regulate neutrophil recruitment to the site of inflammation in a mouse colitis 
model (van Lierop et al., 2010). In addition, the alternative complement pathway is 
able to recruit phagocytic cells such as neutrophils, in the absence of antibodies.  
 
Having established the elevation in CD45INTCD11b+CD16+CD14- neutrophils in 
OcMMP, it should be possible to compare the presence of these cells collected and 
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recovered by OSIC with matched tissue sections. We are currently undertaking 
evaluation of matched OSIC and conjunctival biopsies to address this question. This 
will also provide histological evidence that these cells are neutrophils, as opposed to 
other granulocytes such as eosinophils and could be determined by cytospin and 
light microscopy (Saraiva-Romanholo et al., 2003). 
 
Having a non-invasive test available in the clinic to detect ocular surface 
inflammation could provide a major improvement in monitoring disease activity, 
especially when considering patients who have an apparently uninflamed eye. 
Escalating therapeutic intervention is based on clinically identifiable inflammation 
(Figure 1.12) so selected immuno-modulatory targeting of patients at greater risk of 
progression could not only be more cost effective but hugely beneficial to patients.  
 
Revalidation of CD45INTCD11b+CD16+CD14- granulocytes by OSIC may help 
produce a simplified flow cytometric determination of neutrophils without having to 
use multi-colour panels including CD45, CD11b, CD14 and CD16. Alternatively OSIC 
or swabbing the conjunctiva may also facilitate a study of elevated azurophilic 
granules such as Proteinase 3. Again, PCR based assays could be employed to 
determine this. The advantage of course is that cells collected could be stored and 
transferred to a diagnostic lab if this was established as a biomarker.  
 
Additional non-invasive means of characterising ocular surface inflammatory 
changes by in vivo confocal microscopy could also be explored. Alterations in 
dendritiform cells and other inflammatory profiles have been identified in trachoma 
(Hu et al., 2011a, Hu et al., 2011b). Although labelling of cells by monoclonal 
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antibodies is precluded in humans, correlating OSIC evidence of conjunctival 
neutrophils with a characteristic cell ‘signature’ by in vivo confocal microscopy could 
provide an additional clinic-based tool for determining disease activity. 
 
How a persistent inflammatory infiltrate contributes to the fibrotic process has not 
been resolved. TGF-β has been heavily implicated in the fibrotic process in OcMMP 
and in many other fibrotic diseases (Bernauer et al., 1993b, Elder, 1997b, Goodwin 
and Jenkins, 2009). More recently pro-fibrotic IL-13 has been identified in the context 
of OcMMP (Saw et al., 2009b). Neutrophils may well be inducing fibrotic changes 
through local tissue damage and the marked reduction in goblet cells seen in both 
SJS-TEN and OcMMP may play a role in up-regulating IL-13, in particular as this is 
an important molecule in the control of goblet cell homeostasis (De Paiva et al., 
2011).  
 
In SJS-TEN, granulysin is a key mediator in the disease and recently, serum 
elevation has shown to correlate with systemic disease (Fujita et al., 2011). An 
obvious adaptation to this technique would be to collect tears (although this may be 
very challenging in patients with severe dry eye problems) or undertake OSIC to 
determine granulysin by ELISA or Western blotting. This may help predict local 
disease alterations and inform closer clinical monitoring and/or detection of cell 
changes to commensal organisms. This could help bridge the gap between the initial 
cell-mediated toxicity and elevation in innate cells such as neutrophils.  
 
The contribution of persistently elevated neutrophils to the fibrotic as well as the 
inflammatory process may help to guide treatment. Anti TNF-α and anti CD20 
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therapies are used in MMP, but are usually reserved for refractory disease. Anti TNF-
α therapy may play a role in modulating neutrophil function directly as this cytokine 
stimulates ROS while immune-complex induction of neutrophils could be abrogated 
by targeting antibody production by B cells with Rituximab (Wright et al., 2010). 
Future directions may also include the use of anti-complement therapy. C5 is a 
terminal component of the complement cascade which is cleaved into C5a and C5b 
convertases of the classical/lectin and alternative pathways (Woodruff et al., 2011).  
These in turn can recruit phagocytes such as neutrophils. Eculizumab is a 
humanised monoclonal antibody that inhibits C5, and has been demonstrated to 
prevent complement destruction of erythrocytes in paroxysmal nocturnal 
haemoglobinuria (Kelly et al., 2011). Although further investigation is clearly 
warranted, it illustrates how novel therapeutic intervention may be guided by the 
composition of the conjunctival inflammatory infiltrate. 
 
6.4 Conclusions 
 
In this thesis, I have tested the hypothesis that progressive fibrosis in OcMMP, 
occurring in the apparent absence of clinical inflammation, was driven by underlying 
inflammatory processes. The cohort of patients studied confirmed that an 
inflammatory infiltrate with neutrophils occurred in both SJS-TEN and OcMMP, and 
that this was significantly elevated in patients with clinical evidence of disease 
progression in OcMMP, even in Non-inflamed eyes.  These findings have therefore 
confirmed my hypothesis and provide a platform for future studies in to the role of 
neutrophils in mediating or promoting fibrosis and developing OSIC as a means of 
biomarking these alterations. 
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Evaluation of
early and late
presentation of
patients with ocular
mucous membrane
pemphigoid to
two major tertiary
referral hospitals in
the United Kingdom
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Abstract
Purpose Ocular mucous membrane
pemphigoid (OcMMP) is a sight-threatening
autoimmune disease in which referral to
specialists units for further management is a
common practise. This study aims to describe
referral patterns, disease phenotype and
management strategies in patients who
present with either early or established
disease to two large tertiary care hospitals
in the United Kingdom.
Patients and Methods In all, 54 consecutive
patients with a documented history of
OcMMP were followed for 24 months. Two
groups were deﬁned: (i) early-onset disease
(EOD:o3years, n¼ 26, 51 eyes) and
(ii) established disease (EstD:45years,
n¼ 24, 48 eyes). Data were captured at ﬁrst
clinic visit, and at 12 and 24 months follow-up.
Information regarding duration, activity and
stage of disease, visual acuity (VA),
therapeutic strategies and clinical outcome
were analysed.
Results Patients with EOD were younger and
had more severe conjunctival inﬂammation
(76% of inﬂamed eyes) than the EstD group,
who had poorer VA (26.7%¼VAo3/60,
Po0.01) and more advanced disease. Although
40% of patients were on existing
immunosuppression, 48% required initiation
or switch to more potent immunotherapy.
In all, 28% (14) were referred back to the
originating hospitals for continued care.
Although inﬂammation had resolved in 78%
(60/77) at 12 months, persistence of
inﬂammation and progression did not differ
between the two phenotypes. Importantly,
42% demonstrated disease progression in the
absence of clinically detectable inﬂammation.
Conclusions These data highlight that
irrespective of OcMMP phenotype, initiation
or escalation of potent immunosuppression is
required at tertiary hospitals. Moreover, the
conjunctival scarring progresses even when
the eye remains clinically quiescent. Early
referral to tertiary centres is recommended to
optimise immunosuppression and limit
long-term ocular damage.
Eye advance online publication, 29 July 2011;
doi:10.1038/eye.2011.175
Keywords: cicatrising conjunctivitis;
conjunctival scarring; progression;
immunosuppression
Introduction
Mucous membrane pemphigoid (MMP) is a
potentially fatal autoimmune disease1 with a
mortality usually secondary to aero-digestive
tract stricture formation, quoted as 0.029 per
100 000 in the United States during 1992–2002.2
Although the condition is associated with skin
and mucous membrane involvement including
the oral cavity, oesophagus, trachea and
genitals,3 ocular manifestations of MMP
(OcMMP) are deﬁned as ‘high risk’ and can be
blinding.3 Management strategies are aimed at
early diagnosis together with the prevention of
both life- and sight-threatening complications
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through the removal of factors that precipitate
inﬂammation, careful immunomodulation and/or
surgical intervention.
The course of ocular disease is variable, and
determining disease activity and progression represents
a major challenge.4 Patients are often diagnosed at an
advanced stage of disease or with an acutely inﬂamed
eye,5,6 which if left untreated, may result in an
acceleration of disease progression that can be
unresponsive to pharmacological manipulation.7,8 In
order to delay or arrest this process, early intervention
with systemic immunosuppression is required,3–5,9–12
usually by adopting either a validated stepladder
approach based on the severity of disease activity,10,13 or
the primary use of oral cyclophosphamide,11 both
inducing long-lasting remission.
In the United Kingdom, streams of hospital referral are
to tertiary care services specialising in the management
of OcMMP, from ophthalmologists practicing in
secondary care, directly from the primary care services
such as general (family) practitioners or optometrists,
and from dermatologists/oral medicine specialists
referring patients for screening with a diagnosis of MMP
at extra-ocular sites. Although the possibility of a referral
bias of patients with a more severe phenotype is
recognised,11 there is limited information regarding the
clinical features of patients with early or established
disease who present to specialised services, whether
these patients require continued tertiary care, or are
discharged back to their referring unit.
Amongst our patient cohorts, we have noted that
delaying referral of patients with OcMMP to our
specialist hospitals seemed to augment a clinical
phenotype that is refractory or only partially responsive
to therapeutic intervention. The aim of this study,
therefore, was to characterise referral patterns and
disease phenotype (including activity, staging and
progression) in patients with OcMMP who present either
early or late according to duration of symptoms, to the
two largest tertiary specialist hospitals in the United
Kingdom, and the strategies employed to manage these
patients.
Materials and Methods
Study population
A total of 54 consecutive patients with a documented
history of OcMMP referred to dedicated ocular surface
disease clinics over a 3-year period at the two largest
specialist referral centres in the United Kingdom,
Moorﬁelds Eye Hospital (MEH, London, UK) and the
Birmingham and Midland Eye Centre (BMEC,
Birmingham, UK) were identiﬁed from electronic
databases and followed for 24 months. Patients were
stratiﬁed according to duration of symptoms, where
symptoms were deﬁned as redness, tearing, burning,
decreased vision or foreign body sensation.14 The
frequency distribution of the duration of disease deﬁned
two groups straddling either side of the median (1460
days (4 years); Supplementary Figure 1). Group1 (n¼ 26,
51 eyes) consisted of patients with o1095 days (o3
years) history and was termed the ‘early-onset’ disease
(EOD) group, whereas group 2 (n¼ 24, 48 eyes)
comprised patients with 41825 days (45 years) history
and was termed the ‘established’ disease (EstD) group.
Four patients had a duration of symptoms that fell on the
median (4 years), and these patients were excluded from
further analysis. The study was conducted following
ethical approval and conformed to the tenets of the
Declaration of Helsinki.
Diagnosis
Diagnosis of OcMMP was based on clinical ﬁndings
characteristic for the disease, namely progressive
conjunctival cicatrisation in the absence of other causes of
conjunctival scarring. If patients did not had a previous
positive tissue biopsy, a conﬁrmatory perilesional
conjunctival and/or oral mucosal biopsy for direct
immunoﬂuorescence was undertaken. A positive result
was deﬁned as linear deposition of immunoglobulin G,
A or complement (C3) along the basement membrane
zone.3 If typical clinical characteristics were evident, a
negative result did not exclude the diagnosis10,14–16
because of the recognition of a subgroup of ocular
patients who have ocular features consistent with
OcMMP but have a negative biopsy.15,17 In accordance
with the ﬁrst international consensus, a positive indirect
immunoﬂuorescence was not an essential requirement
for diagnosis.3
Study design
Data were captured at presentation, immediately
following ﬁrst consultation, at 12 and 24 months for both
the EOD and EstD groups. Visual acuity (VA) was
classiﬁed as good (6/6–6/18), or in accordance with the
WHO deﬁnitions of ‘visual impairment’ (o6/18–6/60),
‘severe visual impairment’ (o6/60) and ‘blind’ (o3/60).
Disease activity was based upon the degree of
conjunctival inﬂammation: absent, mild, moderate or
severe (including inﬂammation in all four quadrants,
limbitis and/or conjunctival ulceration).18 Stage of
disease and progression was determined by using the
staging systems described by Mondino and Brown
(I, 0–25%; II, 25–50%; III, 50–75%; IV, 75–100% loss of
inferior fornix)7 and Foster (I, subconjunctival scarring
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and ﬁbrosis; II, fornix foreshortening of any degree;
III, presence of any degree of symblepharon; IV, end-
stage cicatricial pemphigoid).19 Progression was deﬁned
as an advance in either Mondino or Foster staging
criteria. Immunosuppression strategies used a ‘step–
ladder’ approach as previously described (Figure 1).13
Information regarding surgical intervention was also
recorded.
Statistical analysis
Statistical analysis was by SPSS 16.0 for Macintosh and
14.0 for Windows (SPSS, Chicago, IL, USA; 2006), and
Prism version 5.0 for Macintosh (GraphPad Software,
CA, USA; 2008) using Fishers-exact test, McNemar’s test
and Kendall’s t-b for rank correlations. Continuous
variables were analysed by non-parametric tests
(Mann–Whitney U-test). Data were collected on all eyes
and comparisons were undertaken between the worst
affected eye for cross-sectional analysis of inﬂammation/
ﬁbrosis and the better-seeing eye for VA. When
determining disease progression, comparisons were
undertaken between patients (either one or both eyes).
In order to determine whether changes seen at differing
time points were signiﬁcant rather than as a result of a
change in the cohort (eg, because of the patients being
discharged back to the referring hospital or missing
data), longitudinal analysis of the same eye was
undertaken. Owing to the referral of patients back to the
originating physician, the sample sizes at the three time
points differ and percentages rather than absolute counts
are therefore reported.
Results
Demographic information and referral patterns
The geographical origin of our patient cohort is
illustrated in Figure 2, where the furthest referral was
from Newquay in Cornwall to MEH (238 miles).
Associated patient demographics and subgroup
stratiﬁcation (EOD vs EstD) is detailed in Table 1. The
EOD group was younger than the EstD group (62 (32–82)
vs 69 (39–91) years (median, range; P¼ 0.02)). In all, 19
patients (37 eyes) from the EOD and 16 patients (32 eyes)
from the EstD were followed for the full 24 months. Of
the 15 patients, not reviewed at 24 months, 1 patient in
the EstD group died before 12 months follow-up and
14 (28%) were referred back to the referring hospital.
Of these, 11 had no clinically detectable inﬂammation at
their last visit before discharge from the tertiary centre,
2 had mild inﬂammation, which continued to be
monitored and treated at the local referring hospital, and
1 patient repeatedly failed to attend for follow-up despite
recall. The remaining cohort (EOD 19; EstD 16) consisted
of patients with more severe ocular disease.
Biopsies
A total of 87.2% (34/39) of patients, who underwent a
biopsy, were direct immunoﬂuorescence (DIF) positive.
By contrast, indirect immunoﬂuorescence studies were
positive in only 34.8% (8/23) of tested individuals, all of
whom were also DIF positive (Table 1). Although ﬁve
Figure 1 Immunosuppression strategies (based on Rauz et al13).
A step–ladder approach to treatment with agents having the
fewest side effects to those that have the greatest side effects is
adopted according to disease activity (mild, moderate or severe),
which is used to guide therapy. Dapsone (25–50mg twice a day)
or sulphapyridine (500mg twice a day) can be used for mild
inﬂammation; azathioprine (1–2.5mg/kg/day) or mycopheno-
late mofetil (500–1000mg twice a day if intolerant to azathiopr-
ine) may be added or substituted for persistent disease. Severe
inﬂammatory disease is treated with cyclophosphamide
(1–2mg/kg/day) and adjuvant prednisolone (1mg/kg/day
with or without supplementary loading doses of 1 g intravenous
methylprednisolone preceding oral therapy) for up to 3 months
until the optimal effects of cyclophosphamide have taken effect.
Patients with refractory disease are managed through intrave-
nous immunoglobulin or ‘biological’ agents such as anti-CD 20
(rituximab) or anti-TNFa therapy.
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(12.8%) patients were biopsy negative, these patients had
clinical features consistent with OcMMP in the absence of
other causes of progressive conjunctival scarring.
Ten patients in total did not undergo a conjunctival
biopsy: seven patients were of advanced age (480 years)
with co-morbidities in which systemic immunosuppression
was contraindicated; and the remaining three patients had
end-stage disease (deﬁned as Mondino/Foster stage 4)
in which the sensitivity of a positive DIF conjunctival
biopsy is low due to physical destruction of the basement
membrane zone architecture.15
Extra-ocular features
Extra-ocular mucocutaneous involvement was present in
52% (26/50) of patients at presentation (62% (16/26) of
the EOD group; 42% (10/24) of EstD group; P¼ 0.257;
Table 1). A total of 18% (9/50) patients had a history of
skin involvement and this was more frequently reported
in the EstD group (29.2% (7/24)) than the EOD group
(7.7% (2/26)). Conversely, oral involvement was more
common in the EOD group (57.7% (15/26)) compared
with 20.8% (5/24) in the EstD group (P¼ 0.01).
Visual acuity
After excluding other causes of reduced vision such as
cataract, age-related macular degeneration, glaucoma and
diabetic retinopathy (n¼ 14, EOD 5; EstD 9) at presentation,
95% (20/21) of patients in the EOD group and 60% (19/15)
in the EstD group had a Snellen VA of between 6/6 and
6/18 in the better-seeing eye. Only patients in the EstD
group were severely visually impaired (o3/60, 26.7%
(4/15)) and overall VAwas signiﬁcantly worse for the EstD
group (Po0.01; Kendal t-b; Table 1).
Inﬂammation
At presentation, 53% (50/94) of all eyes had clinical
evidence of conjunctival inﬂammation where the
majority (76% (38/50 eyes)) were in the EOD group
(Po0.001) when comparing the worst affected eye
(Figure 3a). Patients with moderate/severe inﬂammation
were also more likely to have EOD. By 12 months follow-up
(Figure 3a), inﬂammation had resolved in 78% (60/77) of
all eyes (EOD¼ 83% (35/42) vs EstD¼ 71% (25/35),
P¼ 0.917) and there were no patients with residual
severe conjunctival inﬂammation. These data were
endorsed by McNemar’s longitudinal analysis, showing
a signiﬁcant reduction in inﬂammation in the EOD
(Po0.001) compared with the EstD group (P¼ 1.0).
A recalcitrant group of patients with persistent
inﬂammation not responsive or only partially responsive to
treatment was identiﬁed in 29.9% (20/67) of eyes examined
at 24 months. Interestingly, the persistence of inﬂammation
was independent of group phenotype (EOD¼ 27% (10/37)
vs EstD¼ 33.3% (10/30), P¼ 0.967; Figure 3a).
Figure 2 Map containing ordnance survey data (& Crown copyright and database right 2010) showing the combined geographical
distribution of referrals (!) to the two tertiary referral hospitals: Moorﬁelds Eye Hospital, London, UK (circled, L) and the
Birmingham and Midland Eye Centre, Birmingham, UK (circled, B). The furthest referral was for Newquay, Cornwall to Moorﬁelds
(238 miles).
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Stage of disease and progression
Eyes in the EstD group had more severe conjunctival
ﬁbrosis at presentation (Figures 3b and c) gauged by
staging systems described by both Mondino (stage IV:
EOD¼ 5% (2/40) vs EstD¼ 39.5% (17/45), Po0.001) and
Foster (stage IV: EOD¼ 3.9% (2/51) vs EstD¼ 13%
(16/46), Po0.035). At 12 months, the EstD group
demonstrated signiﬁcantly advanced stage of disease,
irrespective of staging system used (Figures 3b and c),
despite a total of 20.8% of all eyes having progressed
according to both Mondino and Foster systems.
There was no signiﬁcant difference when comparing
progression (deﬁned by worsening of clinical stage of
disease in at least one eye) amongst patients in both the
groups, neither between presentation and at 12 months
(Mondino: EOD¼ 33.3% (4/12) vs EstD¼ 23.1% (3/13),
P¼ 0.67; Foster: EOD¼ 18.2% (4/22) vs EstD¼ 38.9%
(7/18) P¼ 0.173), nor during the subsequent 12 to 24
months follow-up period (Mondino: EOD¼ 53.8% (4/22)
vs EstD¼ 16.7% (2/12), P¼ 0.10; Foster: EOD¼ 23.5%
(4/17) vs EstD¼ 28.6% (4/14) P¼ 1.0; Fishers exact test).
Progression and the presence of conjunctival
inﬂammation
Differences in the rates of progression (deﬁned by an
advance in Mondino or Foster staging) were stratiﬁed
Table 1 Patient demographics and characteristics
All patients Early-onset disease Established disease P-value
Total no. of patients 50 26 24 F
Total no. of eyes 99 51 48 F
Male: female (% female) 23:27 (54) 11:15 (58) 12:12 (50) F
Median age (years; range) 67 (32–91) 62 (32–82) 69 (39–91) P¼ 0.02
Median duration of symptoms (years; range) 3 (0–41) 1.5 (0–3) 14 (5–41) Po0.0001
Patient follow-up (eyes)
12 months 43 (85) 23 (45) 20 (40) F
24 months 35 (69) 19 (37) 16 (32) F
No. of patients discharged back to referring hospitala
Total number discharged 14 7 7 F
12 months follow-up 4 1 3 F
24 months follow-up 10 6 4 F
Biopsyb
DIF positive 87.2% (34/39) 92% (23/25) 78.6% (11/14) P¼ 0.33
IIF positivec 34.8% (8/23) 42.9 % (6/14) 2.2% (2/9) P¼ 0.4
Extraocular mucocutaneous involvement
All mucocutaneous tissues 52% (26/50) 62% (16/26) 42% (10/24) P¼ 0.26
Skin 18% (9/50) 7.7% (2/26) 29.2% (7/24) F
Oral 40% (20/50) 57.7% (15/26) 20.8% (5/24) P¼ 0.01
Visual acuityd
Normal: 6/6 to 46/18 80.6% (29/36) 95.2% (20/21) 60% (9/15) P¼ 0.007
Visual impairment: o6/18 to 6/60 8.3% (3/36) 4.8% (1/21) 13.3% (2/15)
Severe visual impairment: 6/60 to 3/60 0% (0/36) 0% (0/21) 0% (0/15)
Blind: o3/60 11.1% (4/36) 0% (0/21) 26.7% (4/15)
Excluded due to other causesd 28% (14/50) 19% (5/26) 38% (9/24)
Abbreviations: DIF, direct immunoﬂuorescence; IIF, indirect immunoﬂuorescence.
aFollow-up: one patient from the established disease group died before 12 months follow-up, and one from the established disease group failed to attend
between 12 and 24 months, and was referred back to their local hospital for continuing care.
bTen patients in total did not undergo a conjunctival biopsy (seven patients with advanced age (480 years) and immunosuppression was systemically
contraindicated and the remaining three patients had end-stage disease (deﬁned as Mondino/Foster stage 4)). Data were missing for one individual and
this patient was excluded from analysis.
cAll patients who were IIF were also DIF positive. There were no patients who were IIF positive in the absence of positive DIF studies.
dVisual acutiy represents a comparison of visual acuity in the better-seeing eye, after exclusion of other causes of reduced vision such as cataract,
glaucoma, age-related macular degeneration and diabetic retinopathy (n¼ 14, early-onset disease 5; established disease 9).
The early-onset disease group consisted of a younger cohort of patients with increased frequency of oral mucous membrane pemphigoid. DIF and IIF
refer to the proportion of patients who demonstrated the linear deposition of immunoglobulin G, A or complement (C3) along the basement membrane
zone or had measurable titres of immunoglobulin in the serum, respectively. Comparisons were undertaken with Fishers-exact test, Kendall’s t-b for rank
correlations and continuous variables were analysed by nonparametric tests (Mann–Whitney U-test).
Signiﬁcant P-values are in bold text.
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according to the presence or absence of clinically
identiﬁable conjunctival inﬂammation in at least one
eye. There was no signiﬁcant difference observed
between the ﬁrst and second 12 months follow-up
periods (data not shown). Moreover, despite the absence
of clinically detectable inﬂammation, progression of
disease occurred in 42% of patients according to the
Mondino system (Figure 4a, left panel), and 16 and 38%
of patients according to the Foster (Figure 4a, right panel)
system for each of the 12 months follow-up periods,
respectively.
Surgical intervention
At initial presentation to the specialist units, 32% (16/50)
of patients had previously undergone eyelid or fornix
reconstructive surgery by the referring hospital with the
Figure 3 Cross-sectional analysis of clinically detected conjunctival inﬂammation (a) and ocular staging using Mondino (b) and
Foster (c) systems in the worst eye at presentation, 12 months and 24 months follow-up in the EOD (&) and EstD groups (&).
Differences in the extent of conjunctival inﬂammation and stage of disease were compared between the two groups by rank correlation
using Kendal’s t-b. At 12 months follow-up, inﬂammation had resolved in the majority of eyes within both groups, and there were no
patients with severe inﬂammation. By 24 months, 30% of the remaining patients at the tertiary centres had residual inﬂammation not
responsive to treatment. Note that patients in the EstD had more advanced stage of disease compared with the EOD throughout the
follow-up period, but there was no difference in the progression rate (worsening of clinical stage of disease) between the two groups.
NB 14 patients had been referred back to their original hospital by 24 months and 1 had died. These patients have been excluded from
the analysis thereby accounting for the apparent increase in the percentage of patients at stage 1 and decrease in the percentage of
patients at stage 4 disease during the 12 and 24 months according to the Mondino staging system.
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majority of cases being performed in the EstD group
(Po0.01; Supplementary Table 1). Although both groups
required oculoplastic surgical intervention at the tertiary
hospitals, this did not differ between the two groups, nor
during the ﬁrst and second 12 months follow-up periods.
Immunosuppression strategies
In all, 40% (20/50) of all patients were on immuno-
suppression at the time of referral. After ﬁrst
consultation, 36% (18/50) required initiation and 12%
Figure 4 Progression rates, deﬁned by worsening of either Mondino or Foster clinical staging of MMP, in the presence or absence of
clinically detectable conjunctival inﬂammation are shown in the upper composite (a). Note there was no signiﬁcant difference in
progression between eyes with clinically detectable inﬂammation or those that were seemingly uninﬂamed (Fishers exact test). The
percentage of patients requiring immunosuppression at presentation, following the ﬁrst follow-up (FU) clinic visit, 12 months and
24 months follow-up time points are shown in the lower b and c. Immunosuppression strategies were ranked according to the
hierarchy described by Rauz et al.13 Overall, a signiﬁcant initiation or escalation in ‘strategic-step’ was required at the ﬁrst FU visit
(b; McNemar’s test), but this did not signiﬁcantly differ when the early onset (EoD) and established disease (EstD) groups were
compared (c; Kendal’s t-b). By 12 months follow-up, ﬁve patients stabilised on immunosuppression and were discharged back to their
originating hospitals, and similarly a further 10 between the 12 and 24 months follow-up.
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(6/50) a switch to a more potent immunomodulatory
treatment representing a signiﬁcant overall ‘step-up’ on
the step ladder approach (P¼ 0.001; Figure 4b).
During the ﬁrst 12 months follow-up period, a further
30% (13/43) of patients required ‘step-up’ treatment
(P¼ 0.215; Figure 4b) equating to a total of 88%
(38/43) of patients requiring initiation or changes in
immunosuppression at presentation or during the ﬁrst
year of follow-up. By 24 months, immunosuppression could
be withdrawn in only one patient but no further escalation
in therapy was required. In all, 28% (14) patients had
stabilised and were discharged to the referring unit for
immunosuppression monitoring (Table 1). There was no
statistical difference between the requirements for
immunosuppression for each of the patient groups at each
of the time points (Figure 4c).
The most commonly used drug by the referring unit
was Dapsone (26%, n¼ 13) followed by either
azathioprine or mycophenolate (8%, n¼ 4) with only one
patient on cyclophosphamide (2%, n¼ 1). The majority of
these patients were commenced on azathioprine or
mycophenolate (10%, n¼ 5) or switched to these drugs
from dapsone (10%, n¼ 5). Two further patients required
oral cyclophosphamide to control inﬂammation. By 12
months, an additional seven patients had initiated
cyclophosphamide therapy and this was either because
of the presence of exuberant inﬂammation (n¼ 3) not
adequately responding to less potent agents (two
requiring intravenous (i.v.) methylprednisolone) or there
was a requirement for an increase in immuno-
modulation before ocular or eyelid reconstructive
surgery. Resolution of inﬂammation occurred in two
patients who were ‘stepped down’ to less potent agents.
By 24 months, oral cyclophosphamide was withdrawn in
three patients (because of completing the maximum safe
duration of therapy of approximately 14 months, that is,
a cumulative dose (oral or i.v.) of o20 g. The majority
(40%) of patients were maintained on either
mycophenolate or azathioprine. There was no statistical
difference in the immunosuppressive agents used
between the EOD and EstD groups. i.v. immunoglobulin
or biological agents were not administered during the
course of this study.
Adverse reactions to immunosuppression
Only 6 of the 38 patients that required
immunosuppression suffered from adverse effects.
Adverse events included one episode of anaemia
following dapsone; two patients reported headaches
after the use of azathioprine and one had induction
of hepatic enzymes; three patients developed
lymphopaenia while taking cyclophosphamide,
including one patient who developed respiratory failure
secondary to a combined cytomegalovirus and
Pneumocystis carinii pneumonitis, which resolved
following admission to the intensive care unit and
treatment with i.v. ganciclovir and oral cotrimoxazole.
Discussion
OcMMP is a bilateral sight-threatening disorder
characterised by progressive conjunctival cicatrisation
associated with corneal vascularisation and scarring. The
true incidence is not known although the outcome of a
recent British Ophthalmological Surveillance Unit study
suggests a minimum United Kingdom incidence of 0.7
per 1000 000 population with a regional variance
exempliﬁed by 1.1 per million in Greater London and 1.8
per million in the West Midlands20 (Radford et al,
unpublished data). MMP usually presents between 30
and 90 years of age, with a peak age of onset after 70
years.3,7,19 Although disease progression is more
aggressive in younger patients,13 the disease is lifelong
causing chronic discomfort, with 75% of patients
requiring immunosuppression to control inﬂammation
and limit disease progression.8 The presence of extra-
ocular manifestations of MMP in approximately half of
our patients is consistent with other studies,5,10 although
higher rates have been reported.17
In this series, two disease phenotypes of OcMMP were
statistically deﬁned: (i) those with EOD who were
characterised as having less advanced disease stage but
signiﬁcantly greater conjunctival inﬂammation, and
(ii) those patients with EstD who had less clinically
identiﬁable inﬂammation but more advanced stage of
disease. Although 40% of the patient cohort were on
existing systemic immunosuppression, the majority of
patents required initiation or escalation in systemic
immunosuppression following either their ﬁrst clinic
visit, or during the ﬁrst year of follow-up in order to
control inﬂammation, facilitate corrective eyelid surgery
or prevent further progression in already advanced
disease states. Despite these measures, 20.8% of eyes
demonstrated disease progression during the ﬁrst 12
months and another 20.8% between 12 and 24 months;
and this progression was independent of the EOD or
EstD clinical phenotypes. These results indicate that
OcMMP may progress at any stage of disease,7,8 and
more importantly, progression rates amongst eyes that
are clinically inﬂamed and those that are not do not
differ. These data endorse previously reported
literature,4,10,21 and signify a molecular, ﬁbrotic process
independent of inﬂammation, which can be seen
clinically.
Accurately identifying early disease and documenting
progression presents difﬁculties. The staging systems
currently used are reliant on subjective assessment of
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Figure 5 An algorithm highlighting clues to the diagnosis of OcMMP (ocular features, systemic involvement, autoimmune disease
associations), together with differential diagnoses for conjunctival scarring subdivided into ‘static or slowly progressive’ or ‘progressive’
aetiologies is shown. A putative model for early referral to tertiary care hospitals is also suggested. w, A subset develop autoantibody-
positive progressive conjunctival scarring similar to MMP; IF, immunoﬂuorescence; MMP, mucous membrane pemphigoid.
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conjunctival ﬁbrosis and obliteration of the inferior
fornix, with judgment of progression open to individual
interpretation. Information regarding horizontal
obliteration of the fornix by symblephara is not routinely
documented, precluding use of the proposed and
improved staging system described by Tauber.22 In
addition, there is no standardised method for measuring
and documenting disease progression of the upper
fornix, when the disease is clearly not conﬁned to the
inferior conjunctival surface. Subsequent to this study,
we have designed and adopted the use of a validated
bespoke Fornix depth measurer to routine clinical
practise to enable quantiﬁcation of upper and lower
forniceal obliteration and to monitor disease
progression.23
The difﬁculty lies not only in identifying early disease
and determining which patients may progress, but also
recognising when this is happening. ‘Activity’ and
‘damage’ indices have been validated and accepted for a
number of autoimmune conditions including systemic
lupus erythematosis and primary Sjo¨gren’s syndrome.24–27
These indices facilitate not only comparison of clinical
cohorts worldwide, but also inform clinical trials
speciﬁcally those targeting therapeutic intervention.
As such, we suggest that clearer strategies for
discriminating MMP disease ‘activity’ and ‘damage’
are necessary to afford a uniform language and
understanding when describing OcMMP phenotypes,
before molecular targeting and evaluation of novel
therapeutic approaches through randomised controlled
trials can be considered.
These difﬁculties in determining activity and
progression highlight the challenge in directing
appropriate therapy. The issue of suboptimal therapeutic
immuno-modulation of disease course has been widely
described.4,5,9–11,28 We highlight a recalcitrant group of
patients with persistent mild or moderate inﬂamma-
tion in keeping with the ﬁndings of others.10,11,13
Unfortunately, there is also a disease subset that either is
completely refractory to conventional immuno-
suppression or relapses despite initial success.11 A few
isolated case reports indicate that ‘biological’ agents,
such as rituximab (anti-CD20) or inﬂiximab (anti-TNFa),
may be beneﬁcial in some of these patients, but as
randomised trials are lacking, funding for such treatment
in the United Kingdom prohibits regular use.29–34 These
data re-emphasise the fact that the pathogenesis of
OcMMP is not resolved and strengthen the case for
further study of clinically involved and seemingly
uninvolved mucous membranes.35–37
The reasons for a delay in presentation in our EstD
group are not clear. It is possible that the clinical features
or the severity of the disease may not have been
recognised until late, as early symptoms may have been
insidious and non-speciﬁc.9,38 A variable duration of
disease and course have been described by others,11 but
the true deﬁnition of early disease in the context of
OcMMP is not known. This may well lie under the 3 year
duration of symptoms statistically deﬁned in our cohort,
and this is particularly relevant if disease activity or
progression is initially either subtle or sub-clinical.
Experience in other more common autoimmune diseases,
such as rheumatoid arthritis, point to the clinician
actively pursuing identiﬁcation of early disease to enable
early therapeutic intervention in order to limit tissue
damage.39 In the light of the potential for disease
progression in both early or late onset OcMMP disease
forms, irrespective of whether inﬂammation is clinically
detected or not, it may be prudent for ophthalmologists
to take precedence from the rheumatological concepts
for capturing early disease, and adopt a similar
approach.
Many of our patients travelled long distances to our
centres and this may represent a barrier to early tertiary
care of this rare disease, resulting in initiation of
suboptimal immunomodulation and/or surgery.
Stringent efforts to identify features characteristic of
OcMMP are necessary in order to avoid missing an early
diagnosis. Where local diagnosis or management is not
possible, or where the identiﬁcation of high risk features
including severe refractory inﬂammation or evidence of
progression is manifest, prompt referral of cases with
OcMMP to specialised tertiary centres is essential for
optimisation of immunosuppression aimed at limiting
long-term tissue damage. Furthermore, this may include
implementation of shared care pathways or stabilisation
of disease before discharge back to local referring centres,
as evident in many (28%) of our patients. We therefore
propose a referral algorithm as a putative model to help
educate these decisions and prompt early referral
(Figure 5).
Although our study is limited by its retrospective
nature and bias in our study population towards a more
severe clinical phenotype, a high proportion (48%) of
patients required initiation or a switch to more potent
immunosuppression following referral to our tertiary
centres. In addition, 28% of patients were eventually
returned to their local referring unit for monitoring after
stabilisation of disease. Most importantly, however, up to
42% of patients (irrespective of disease phenotype, early
or late) continued to demonstrate progressive
conjunctival scarring in the absence of clinically
detectable inﬂammation. A greater understanding of
disease pathology is required to facilitate earlier
recognition of disease, improved activity and damage
scores, and more accurate therapeutic targeting,
speciﬁcally for patients recalcitrant to existing
immunomodulatory therapy.
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What was known before
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K There is evidence that young patients have a more
destructive phenotype despite the average age of onset in
the seventh decade.
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aggressive in the context of severe conjunctival
inﬂammation that may or may not be responsive to
immunotherapy.
.
What this study adds
K There is a wide range of clinical characteristics that
prompt referral to tertiary centres. Those with early-onset
disease (deﬁned according to the duration of symptoms at
presentation) have more severe ocular surface
inﬂammation than those with more established disease.
K Despite initiation or escalation to more potent
immunosuppression at ﬁrst visit, only 28% of patients are
discharged back to the originating hospitals after
stabilisation of disease. Almost 50% of the referred
patients demonstrate progressive ocular surface scarring
independent of disease duration, which continues to
progress in a clinically quiescent eye.
K In the absence of a biomarker to facilitate monitoring of
disease activity and/or progression, a putative
algorithmic model for early detection of ocular mucous
membrane pemphigoid is proposed, to enable prompt
referral to specialist tertiary care clinics.
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Validation of a fornix depth measurer: a putative tool
for the assessment of progressive
cicatrising conjunctivitis
Geraint P Williams,1 Valerie P J Saw,2 Tariq Saeed,1 Simon T Evans,3 Paul Cottrell,
S John Curnow,1 Peter Nightingale,4 Saaeha Rauz1
ABSTRACT
Background/aims Documentation of conjunctival
forniceal foreshortening in cases of progressive cicatrising
conjunctivitis (PCC) is important in ascertaining disease
stage and progression. Lower fornix shortening is often
documented subjectively or semi-objectively, whereas
upper forniceal obliteration is seldom quantiﬁed. Although
tools such as fornix depth measurers (FDMs) have been
described, their designs limit upper fornix measurement.
The purpose of this study was to custom-design a FDM to
evaluate the upper fornix and to assess variability in
gauging fornix depth.
Methods A polymethylmethacrylate FDM was
constructed using industry-standard jewellery computer
software and machinery. Two observers undertook
a prospective independent evaluation of central lower
fornix depth in a heterogeneous cohort of patients with
clinically normal and abnormal conjunctival fornices both
subjectively and by using the FDM (in mm). Upper
central fornix depth was also measured. Agreement was
assessed using BlandeAltman plots.
Results Fifty-one eyes were evaluated. There was 100%
intraobserver agreement to within 1 mm for each
observer for lower fornix measurement. The mean
difference in fornix depth loss using the FDM between
observer 1 and 2 was 1.19%, with 95% conﬁdence of
agreement (62SD) of 15% to +20%. In total, 86%
(44/51) of measurements taken by the two observers
agreed to within 10% of total lower fornix depth (ie,
61 mm) versus only 63% (32/51) of the subjective
measurements. Mean upper fornix difference was
0.57 mm, with 95% conﬁdence of agreement of
between 2 and + 3 mm.
Conclusions This custom-designed FDM is well
tolerated by patients and shows low intraobserver and
interobserver variability. This enables repeatable and
reproducible measurement of upper and lower fornix
depths, facilitating improved rates of detection and
better monitoring of progression of conjunctival scarring.
INTRODUCTION
Sequential documentation of forniceal fore-
shortening in cases of progressive cicatrising
conjunctivitis (PCC), such as ocular mucous
membrane pemphigoid (OcMMP), is important in
assessing stage and progression of disease.1e3 The
Foster staging relies on subjective evaluation of
subepithelial ﬁbrosis and extent of symblepharon
formation,3 and the system described by Mondino
and Brown2 4 describes grading of percentage
shrinkage of the lower fornix. A modiﬁcation
encompassing both systems was described by
Tauber et al,1 who proposed that counting the
number of, and percentage horizontal obliteration
of the lower fornix by symblephara could potentially
improve detection of disease progression.
We have previously shown that lower fornix
shortening is documented either subjectively or
semi-objectively by utilising a slit-light beam, the
degree of upper forniceal obliteration is seldom
quantiﬁed.5 Furthermore, we have shown that, at
the initial visit to tertiary referral centres, Foster ’s
staging of disease is undertaken in 100% of
patients’ lower fornix, but only 78% of patients had
quantiﬁcation of forniceal shrinkage. This is prob-
ably related to the difﬁculty in assessing lower
fornix depth accurately without the aid of a made-
for-purpose tool.6
Measurement of the fornices using devices such
as the fornix depth measurer (FDM) has previously
been described, but their design restricts accurate
upper fornix measurements.7 8 Speciﬁcally, the
depth and curvature of the upper fornix dictates
that the ideal FDM must be sufﬁciently long and
curved to enable comfortable and accurate assess-
ment of it. We previously used in routine clinical
practice an FDM based on that designed by Schwab
et al,7 but its design was suboptimal (ﬁgure 1). In
2004, a modiﬁcation of the Schwab FDM was
designed at Moorﬁelds Eye Hospital for a clinical
trial9 and is currently being used in an epidemio-
logical study. In 2007, we wanted to redesign and
evaluate a bespoke comfortable prototype that
could provide an accurate tool for improving
forniceal sac documentation in the outpatient clinic
setting, with potential for wider-scale commercial
manufacture. In this study we describe this
custom-designed FDM constructed speciﬁcally to
facilitate evaluation of the depth of the upper
conjunctival fornix, and we assess intraobserver
and interobserver variability in gauging the extent
of the upper and lower fornices by validating the
FDM and comparing it with subjective assessment
of fornix shrinkage.
MATERIALS AND METHODS
Design of a bespoke FDM
Apolymethylmethacrylate FDMwasdesignedusing
industry-standard jewellery computer software
(CAD V5, 3Design, Brussieu, France, 2007). The
virtual model was then exported as an. STL ﬁle into
a program to set the cutting parameters for the
milling machine (Modela Player V4; Roland DG,
Shizuoka, Japan, 2002) (ﬁgure 2A).The virtualmodel
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was cut with a machine to a precision of 2 mm/step, and incre-
ments were expressed at 2 mm intervals at both ends of the FDM:
the main ‘body ’ and the ‘handle’. This design feature enables
measurement of the fornix in the context of multiple symble-
phara, which could potentially hinder the smooth passage of the
FDM to the limits of the conjunctival sac. The FDM measured
25 mm3 5 mm and was moulded to a biconcave shape to ensure
ease of insertion and comfort (ﬁgures 1C and 2B).
Patients
An evaluation of the bespoke FDM was undertaken through
a prospective, masked, independent assessment of central lower
fornix depth by two observers (GPW, TS), following the Tenets
of the Declaration of Helsinki. This was undertaken as a service
evaluation at the Birmingham and Midland Eye Centre (BMEC).
The validation of the FDM was conducted on a heterogeneous
group of patients comprising clinically normal and abnormal
conjunctival fornices presenting to BMEC. This heterogeneity
enabled a wide range of fornix depths to be tested with the
bespoke FDM.
The cohort consisted of 51 eyes of 26 patientswith amedian age
of 64 years (range 42e100), of whom 65% (17/26; 33/51 eyes) had
an identiﬁable cause of cicatrising conjunctivitis (OcMMP, 10; dry
eyes, ﬁve (including three with Sjögren’s syndrome); Stevense
Johnson syndrome, two) and 35% (18/51) had no evidence of
conjunctival scarring (age-related macular degeneration, four;
uveitis, three; peripheral ulcerative sclerokeratitis, two).
After instillation of one drop of 0.4% oxybuprocaine hydro-
chloride, patients were asked to look in the opposite direction to
the placement of the FDM (upper fornix, down-gaze; lower
fornix, up-gaze) in order to protect the cornea, ensure consis-
tency in readings, and circumvent variability in the eyelid
position in primary gaze. The central conjunctival fornix was
measured to the eyelid margin, deﬁned as the posterior lip of the
meibomian gland oriﬁce (ﬁgure 1C). All FDM readings were
taken in triplicate, with the ﬁrst measurement taken used for
interobserver comparison. A semi-objective estimation of lower
fornix conjunctival shrinkage was also performed by gauging the
central lower fornix depth, measured from the inferior fornix to
the eyelid margin with the aid of a vertical 1 mm wide slit-lamp
beamwith illumination and observation axes in a coaxial position
(NB a subjective assessment of the upper fornix is impossible).
The FDM was sterilised by soaking the device in 0.05% sodium
dichloroisocyanurate solution for 5 min between patients (as per
the BMEC infection control policy for reusable tonometer heads).
Patients were also asked about their tolerance to the FDM.
Calculations and statistical analyses
The percentage loss of lower fornix for both methods of
measurement (subjective and objective) was calculated using the
equation:
f½fornix depth ðFDÞ age  FDM measurement=FD ageg 3100
¼ % loss of fornix
A correction factor for age was implemented, as the lower
forniceal depth is known to progressively shorten with age.7 The
‘FD age’ values were derived from published age-speciﬁc lower
fornix depths in normal eyes detailed in table 1.7 For example,
Figure 1 Colour photographs
illustrating the evolution of the fornix
depth measurer (FDM). (A) The original
adaptation of an FDM described by
Schwab et al7 (produced by our local
prosthetics department). (B) An FDM
constructed at Moorﬁelds Eye Hospital,
which is an elongated
polymethylmethacrylate modiﬁcation of
the Schwab FDM using a hand-made
plaster cast (designed by VS, Scott Hau
and David Carpenter, ocular prosthetist
at Moorﬁelds Eye Hospital, speciﬁcally
to facilitate upper fornix depth
measurement for use in a clinical trial).
For comparison, (C) illustrates the
computer-designed bespoke FDM
prototype. This is an elongated,
biconcave design with engraved
markings to a precision of 2 mm/step,
and increments expressed at 2 mm
intervals on both the main body of the
FDM and the narrower ‘handle’. The
markings on the handle facilitate upper
fornix measurement and the ability to
measure the fornix in the presence of
symblephara (D). The accuracy and
reproducibility of the computer-
generated design and jewellery
precision engraving provides potential
for commercial manufacture.
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for a patient aged 80 years with a lower fornix measurement of
6 mm, the calculated percentage shrinkage is as follows:
f½10:2 6=10:23100g ¼ 41:2%
It is important to note that it was not possible to calculate
percentage loss of the upper fornix because the normal range of
age-speciﬁc upper forniceal depths is currently unknown.
Intraobserver and interobserver agreement was assessed using
BlandeAltman plots of differences in measurements versus
mean measurements using Excel for Macintosh (Microsoft
Ofﬁce 2008).10 11 The mean difference in observations and the
95% limits of agreement (the mean difference 62 standard
deviations)10 were calculated using SPSS V16.0 for Macintosh. A
continuity correction was applied to the 95% limits of agree-
ment to take account of the fact that BlandeAltman plots
assume that the variables measured are continuous.
A 10% threshold or ‘tolerance’ was chosen as an allowance for
intraobserver variation. Agreement was also evaluated by
determining the percentage of observations that agreed to
within the 10% ‘allowance’ for both observers.
RESULTS
Lower fornix assessment
Intraobserver variation
Triplicate measurements of FDM readings of the same
anatomical position by each observer (central lower fornix)
showed exact agreement of 86% (42/49) and 89% (41/46) of
measurements within observer 1 and observer 2, respectively.
When allowing for 1 mm ‘tolerance’ (approximating to 10% of
the normal lower fornix, see table 1), 100% of intraobserver
observations fell within 1 mm for both observers.
Interobserver variation
Interobserver variation between the subjective and objective
measurements of the central lower fornix by the two observers
was also assessed. Assessment of the lower fornix shrinkage was
expressed as a percentage for both subjective and objective
estimations, the latter using the age correction factor described
in the methods.7
Figure 2 (A) A
polymethylmethacrylate fornix depth
measurer (FDM) was constructed using
industry-standard jewellery software
and machinery. A screenshot of the
3design prototype is shown in (A). The
ﬁnal prototype is illustrated in (B).
Increments are expressed at 2 mm
intervals to a precision of 2 mm/step,
and the FDM was heat moulded to
a biconcave shape for comfort. The FDM
was applied after instillation of one drop
of 0.4% oxybuprocaine hydrochloride
(C). Patients were asked to look in the
opposite direction to the placement of
the FDM, and the central conjunctival
fornix was measured to the eyelid
margin, deﬁned as the posterior lip of
the meibomian gland oriﬁce.
Table 1 Age-speciﬁc normal values for the conjunctival
lower fornix
Age
Mean depth of
normal lower
fornix (mm) (‘100%’)
10% of normal
lower fornix (mm)
40e49 11.9 1.19
50e59 11.3 1.13
60e69 11.0 1.10
70e79 10.6 1.06
80+ 10.2 1.02
Adapted from Schwab et al.7
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The mean difference in calculated percentage fornix depth
using measurements obtained from the FDM by observer 1 and
2 was 1.19%, and, with a continuity correction, the 95% limits
of agreement (62SD) were narrower for interobserver objective
(FDM) measurements than for those obtained subjectively
(15% and + 20%) (ﬁgure 3). The interobserver agreement
within the 10% allowance (ie, approximately 61 mm) of total
lower fornix depth was 86% (44/51) (ﬁgure 4).
In contrast, the interobserver mean difference in subjective
estimation of percentage fornix depth was 1.86%, and, with
a continuity correction, the 95% limits of agreements (62 SD)
were between 30% and +25% (ﬁgure 3). Only 63% (32/51)
of the subjective measurements taken by the two observers
agreed to within a 10% allowance of total lower fornix depth
(ﬁgure 4).
These data highlight that the FDM afforded greater consis-
tency in fornix depth measurement by each observer (intra-
observer variation) and between observers (interobserver
variation).
Upper fornix assessment
Intraobserver variation
Triplicate measurements (to assess intraobserver variation) of
FDM readings of the same anatomical position of the central
upper fornix by each observer showed minimal variation (ie,
identical objective measurements) in 88% (45/51) and 70%
(33/47) of measurements by observer 1 and observer 2, respec-
tively. There are no data regarding normal upper fornix depth in
the published literature, preventing calculations for age-based
corrections and percentage fornix depth foreshortening and
tolerance threshold.
Interobserver variation
Interobserver variation of the upper fornix showed a mean
difference in fornix depth measurement using the FDM for
observer 1 and 2 of 0.57 mm, with 95% limits of agreement
(62SD) of 2 and + 3 mm (ﬁgure 5). The absence of normal
upper fornix values precludes evaluation of the 10% allowance;
however, 84.3% (43/51) of upper fornix measurements were
within 1SD of the mean difference of 0.57 mm (+2 to 1 mm of
the mean with a continuity correction).
Patient comfort and tolerance
The FDM was well tolerated by patients, with only a few
(three) experiencing mild discomfort during upper fornix
measurement, despite repeated measurements. None of these
patients reported prolonged discomfort or pain.
DISCUSSION
PCC comprises a group of disorders characterised by progressive
scar formation in response to conjunctival inﬂammation
affecting the stromal layers of the conjunctiva.12 These include
ocular immunobullous diseases such as OcMMP, Stevense
Johnson syndrome and toxic epidermal necrolysis, lichen planus,
linear IgA disease, paraneoplastic pemphigus and epidermolysis
bullosa. Other causes include graft-versus-host disease, Sjögren’s
syndrome, acne rosacea and those associated with topical
therapy where progression is reported to be more insidious with
less destructive clinical sequelae.
Because of the sight-threatening consequences of OcMMP, the
ocular phenotype of MMP is regarded as ‘high risk’,13 particu-
larly as disease progression is more aggressive in younger
Figure 3 BlandeAltman plots showing
interobserver variation in lower fornix
assessment ((A) objective and (C)
subjective). Some data points are
identical and therefore overlay each
other on the ﬁgures. The percentage
difference in assessment between
observer 1 and 2 is plotted against the
mean percentage loss of fornix for each
eye. If there was a completely normal
fornix, this is represented as 0% loss of
fornix on the x axis. Note the increase in
the 95% limits of agreement (62SD) for
subjective assessment (arrowed),
demonstrated also by the histograms
(B,D).
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patients14 and 50% of patients continue to have progression of
cicatrising disease in the apparent absence of inﬂammation.15
Determining progression in PCC is a challenging aspect of
patient management. When considering OcMMP, for example,
the most common of the acquired immunobullous diseases that
cause PCC,12 16 progression may occur at any stage of disease,2 17
which can be aggressive early in the disease course,14 but,
importantly, is often independent of clinically identiﬁable
inﬂammation.15 Determining disease progression in the cica-
trising conjunctivitides therefore relies upon accurate docu-
mentation of disease, in particular conjunctival shrinkage of the
fornices. Although the Mondino staging system is considered to
be more sensitive than Foster ’s staging system15 and is inte-
grated into the system proposed by Tauber et al,1 Mondino
fornix depth measurement is reported to be undertaken in only
78% of new patients in tertiary referral centres compared with
100% documentation of the Foster ’s system.
Vigilant assessment, quantiﬁcation and documentation of
forniceal foreshortening is mandatory for enabling accurate
patient follow-up, currently not achieved by subjective or semi-
objective assessments of the fornix. These approaches are
limited by inconsistency and poor reproducibility and reliability,
but are overcome by the development and implementation of
fornix depth measuring devices for the assessment and
progression of diseases that cause conjunctival scarring.7 8 18 Our
aim was to design an FDM based upon the original concept of
Schwab et al,7 but with additional upper fornix depth capability.
Speciﬁcally, our custom-made FDM was found to be comfort-
able and accurate. Designed and made using industry-standard
computer software and machinery, this FDM prototype was
modelled mathematically taking into account the curvature of
the globe necessary for comfortable measurement of the upper
fornix. We tested our bespoke FDM on patients with a range of
fornix depths in the presence or absence of conjunctival ﬁbrosis.
Our ﬁndings showed low intraobserver and interobserver vari-
ability, enabling repeatable and reproducible measurements of
both upper and lower fornix depths, highlighting its potential in
facilitating both accurate and robust clinical documentation of
disease stage. This FDM prototype is currently being optimised
with further modiﬁcations to improve comfort and ﬁt.
Crucially, the conjunctival cicatrising process is not conﬁned
to the lower fornix, and sight-threatening sequelae secondary to
subtarsal ﬁbrosis, upper lid entropion or lash trauma commonly
ensue. These clinicopathological processes are not taken into
Figure 4 Difference in objective (A) and subjective (B) lower fornix
assessment between observer 1 and 2. The number of individuals that
agree to within a 10% ‘allowance’ are boxed and are higher for objective
measurements (86% (44/51)) than for subjective measurements (63%
(32/51)).
Figure 5 (A) BlandeAltman plot showing interobserver variation in upper fornix assessment. As there are no deﬁned limits for the upper fornix, the
calculations are in mm. The mm difference in assessment between observer 1 and 2 is plotted against mean mm measurement for each patient. The
95% limits of agreement are vertically arrowed and also represented by a histogram (B). (C) Difference in upper fornix assessment between observer 1
and 2; the 10% allowance cannot be calculated in the absence of normal upper fornix values, but 71% (36/51) of measurements were within 1 mm, and
92% (47/51) of observations were within 2 mm of each other.
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consideration by ocular staging systems that calculate
percentage obliteration of the lower fornix,1 2 4 although are
reﬂected in the staging system described by Foster where fornix
shortening or symblephara of any degree throughout the
conjunctival surface are thought to be important.3 The
decreased sensitivity in relying solely upon this system, or those
that include direct measurement of the lower fornix alone,
increase the risk of type 2 errors (false negatives) in determining
disease progression, which are considerably rescinded by the use
of fornix depth measuring devices for the upper fornix.
The larger depth of the upper fornix and difﬁculty of access
explains the omission of detailed upper fornix pathology in
currently recognised scoring systems.1 2 4 Perhaps not surpris-
ingly therefore, there appear to be few data in the ophthalmic
literature regarding the anthropology and normal depth of the
upper fornix. Kawakita and colleagues8 have recently discussed
the use of a non-curved 15032 mm FDM in Japanese patients
with StevenseJohnson syndrome and healthy volunteers. They
found that the mean superotemporal and superonasal upper
fornix depths were 14.162.5 mm in normal people. Our ﬁndings
show a median central upper fornix depth of 16 mm in
a caucasian group of patients, even in the presence of recognised
cases of cicatrising conjunctivitis. The variation in central upper
fornix depth among healthy populations using anthropological
ethnography together with differences in age remains unre-
solved. This has recently been highlighted in the context of
other diseases affecting the size of the upper fornix such as the
giant fornix syndrome described by Rose.19 These data illustrate
the need for population-based studies of normal age-based upper
fornix depths to facilitate calculations of percentage shrinkage in
conjunctival scarring diseases. Such studies are currently being
undertaken at BMEC and Moorﬁelds Eye Hospital.
In summary, our custom-designed FDM was well tolerated by
patients in this study, with only three experiencing short-lived
mild discomfort during assessment of the upper fornix. This
FDM shows low intraobserver and interobserver variability,
enabling repeatable and reproducible measurements of lower
fornix depths. We believe that the custom design of an FDM
using industry-standard jewellery software and machinery,
curved to ﬁt the globe, provides an accurate and comfortable
means of assessing lower fornix depth. Furthermore, it offers the
potential to measure upper fornix depth, currently not routinely
carried out in clinical practice, thereby improving both the
detection and monitoring of progressive conjunctival ﬁbrosis in
this group of devastating disorders.
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The dominant human conjunctival epithelial CD8αβ+ T cell
population is maintained with age but the number
of CD4+ T cells increases
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Abstract The conjunctiva is a highly specialized ocular
mucosal surface that, like other mucosa, houses a
number of leukocyte populations. These leukocytes
have been implicated in age-related inflammatory
diseases such as dry-eye, but their phenotypic character-
istics remain largely undetermined. Existing literature
provides rudimentary data from predominantly immu-
nohistochemical analyses of tissue sections, prohibiting
detailed and longitudinal examination of these cells in
health and disease. Using recovered cells from ocular
surface impression cytology and flow cytometry, we
examined the frequency of leukocyte subsets in human
conjunctival epithelium and how this alters with age. Of
the total CD45+ leukocyte population within the
conjunctival epithelium, 87% [32–99] (median) [range]
comprised lymphocytes, with 69% [47–90] identified as
CD3+CD56- Tcells. In contrast to peripheral blood, the
dominant conjunctival epithelial population was
TCRαβ+CD8αβ+(80% [37–100]) with only 10%
[0-56%] CD4+ cells. Whilst a significant increase in
the CD4+ population was seen with age (r=0.5; p<0.01)
the CD8+ population remained unchanged, resulting in
an increase in the CD4:CD8 ratio (r=0.5;p<0.01). IFNγ
expression was detectable in 18% [14–48] of conjuncti-
val CD4+ Tcells and this was significantly higher among
older individuals (<35 years, 7[4–39] vs. >65 years, 43
[20–145]; p<0.05). The elevation of CD4+ cells high-
lights a potentially important age-related alteration in the
conjunctival intra-epithelial leukocyte population, which
may account for the vulnerability of the aging ocular
surface to disease.
Keywords Aging . Tcell . Lymphocyte . Conjunctiva .
Mucosa
Introduction
The ocular surface consists of the cornea, corneal–
scleral limbus and conjunctiva, closely interrelated
with adnexal structures (lacrimal gland, eyelids and
lashes) that together are vital for optical clarity,
immune and mechanical protection. The conjunctiva
is a highly specialized, delicate mucosa comprising of
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a bi-layered substantia propria underlying a non-
keratinized, stratified squamous epithelium inter-
spersed with goblet cells. It extends from the muco-
cutaneous junction of the eyelid margins, lining the
posterior surface of the eyelids and reflects forward
over the sclera to become continuous with the cornea
at the corneal scleral limbus.
The avascular central cornea is largely devoid of
immune cells (Knop and Knop 2007), whereas the
vascularized conjunctiva contains numerous resident
immune cells including intra-epithelial lymphocytes
(IELs) (Allansmith et al. 1978; Hayday et al. 2001;
Knop and Knop 2005; Knop and Knop 2007). In
common with other mucosal sites, the presence of
conjunctiva-associated lymphoid tissue provides a
local immune microenvironment, which includes the
production of immunoglobulins such as IgA that
confers immuno-protection to the ocular surface.
Although an abundance of CD3+ cells (including
CD8+ cells) has been identified in the human conjunc-
tival mucosa (Hingorani et al. 1997), the subtypes of
IELs have not been defined. Non-invasive means of
sampling conjunctival leukocytes such as ocular
surface impression cytology (OSIC) have been utilized
to characterize ocular surface changes in diseases such
as dry eye (Baudouin et al. 1997; Brignole et al. 2000;
Baudouin et al. 2004), but this methodology has not
been extended to afford a comprehensive examination
of resident epithelial leukocytes in healthy conjunctiva.
Of interest, is the observation that the severity of
ocular surface infections such as microbial or herpetic
keratitis is clinically worse in the elderly (van der
Meulen et al. 2008) and autoimmune diseases e.g.
Mucous Membrane Pemphigoid (Foster 1986; Chan
2001) typically affect people in later life. Dry eye is a
‘multifactorial disease of the tears and ocular surface
that results in symptoms of discomfort, visual
disturbance, and tear film instability with potential
damage to the ocular surface’ (2007). It is accompa-
nied by increased osmolarity of the tear film and
inflammation of the ocular surface (2007). Some
studies have demonstrated an increased prevalence of
dry eye problems with age (McCarty et al. 1998;
Moss et al. 2000; Stern et al. 2010). Despite this, little
is known about age-related changes in the leukocyte
populations within the ocular surface (Gwynn et al.
1993). The aim of this study was therefore to utilize
OSIC in combination with multi-color flow cytometry
(Baudouin et al. 1992; Baudouin et al. 1997) to
provide a detailed characterization of the frequency of
leukocyte subsets in the healthy human conjunctival
epithelium and whether these alter with age.
Materials and methods
Study subjects
Clinical data collection and patient sampling were
undertaken following ethical approval in accordance
with the Declaration of Helsinki. Healthy volunteers
were defined as individuals with no history or current
clinical evidence of ocular, systemic inflammatory or
autoimmune disease (including dry eye) (Behrens et
al. 2006; 2007), contact lens wear, previous ocular
surgery, cataract surgery within 3 months or use of
topical ophthalmic medication.
Two separate cohorts were evaluated:
Cohort 1 (Figs. 1, 2 and 3): OSIC of right and left
eyes of 30 individuals (median age,
61 years [21–83]) together with matched
peripheral blood were collected. Twenty
out of 30 individuals were White (Europe-
an) and ten out of 30 were Asian (defined
according to the ethnic demographic cate-
gories employed in the UK census 2011).
Fifteen were male and 15 were female.
Cohort 2 (Fig. 4): OSIC of right and left eyes were
collected and pooled for each of ten
healthy individuals (five young; median
age, 24 [23–33] and five older; median
age, 66 [65–83], p=0.01) in order to
evaluate conjunctival T cell cytokine pro-
duction. All were White (European) with
five males and five females. Samples were
pooled in this cohort in order to maximize
the yield of cells for cytokine staining.
Conjunctival epithelial cell collection and recovery
Collection of conjunctival cells was undertaken with
autoclaved synthetic membranes divided in two semi-
circles (measuring 13×6.5 mm2 each) (Brignole-
Baudouin et al. 2004). Supor 200 polyethersulfone
filters (0.2 μm membranes) were applied following
instillation of 0.4% Oxybuprocaine (as a topical
anesthetic). Conjunctival OSIC was performed with
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four semi-circle membranes per eye (equivalent to
two full impressions) from the superior unexposed
bulbar conjunctiva for 5–10 s using a sterile technique
(Brignole et al. 2000; Brignole-Baudouin et al. 2004)
and before the application of topical fluorescein drops
for clinical examination (Fig. 1a).
Fig. 1 Lymphocytes are the dominant conjunctival epithelial
leukocyte population. Conjunctival OSIC of the superior
unexposed bulbar conjunctiva is shown in A. Representative
plots of a subject demonstrating the gating strategy used to
identify conjunctival leukocytes. B, E The forward and side
scatter profiles for peripheral blood and OSIC, respectively.
Live leukocytes were identified by gating for CD45+ cells that
were negative for the dead cell exclusion dye Sytox blue (lower
right box in C and F) and back-gated to show the forward and
side scatter profiles of the CD45+ live cells (D and G).
Percentages are shown for the representative subject (n=30)
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Membranes were removed and placed in 1.5 ml of
RPMI 1640 (Sigma-Aldrich, Dorset, UK) supplemented
with 1% GPS (1.64 mML-glutamine, 40 U/ml benzyl-
penicillin, 0.4 mg/ml streptomycin) (Sigma-Aldrich),
1% HEPES buffer (Sigma-Aldrich) and 10% heat-
inactivated fetal calf serum (HIFCS–Biosera Ltd.,
Ringmer, UK) in a sterile 5-ml universal container
and processed within 6 h after OSIC. In order to
expedite cellular recovery, the cells were recovered by
gentle agitation with a pipette tip for 1 min. Cell
suspensions were transferred to a 1.5-ml Eppendorf
tube and centrifuged (400×g for 5 min).
The majority of the supernatant was discarded, which
was re-suspended in RPMI/10% HIFCS to a total
volume of 200 μl (cohort 1) or 100 μl (cohort 2). One
hundred microliters of cells were placed into each well
of a 96-well plate for flow cytometric analysis.
Preparation of lysed peripheral blood
Peripheral blood was collected in EDTA tubes, centri-
fuged and re-suspended in 1:10 dilution of filter-sterilized
red cell lysis buffer (8.29 g NH4Cl, 1 g KHCO3 and
37.2 mg of EDTA per liter of dH20). After 5 min at
room temperature, the suspension was diluted with up to
15 ml of RPMI to block further lysis. Following
centrifugation, the pellet was re-suspended in PBS at a
concentration of 1×107 cells per milliliter and aliquoted
at a volume of 100 μl in to individual wells.
Flow cytometry
Flow cytometry was undertaken with a Dako Cyan ADP
high performance flow cytometer (Beckman Coulter,
High Wycombe, UK). Multi-color cytometry compensa-
tion was performed using cells or compensation beads
individually stained with each fluorochrome conjugated-
antibody in order to circumvent spectral overlap by
adjusting for false positives from other fluorochromes.
An analysis was undertaken with Summit 4.3 for
Windows (Dako, CO 2007). Non-parametric compari-
sons were undertaken with the Mann–Whitney U test,
Wilcoxon signed rank test and correlations by Spear-
man’s correlation using Prism version 5.0 for Macintosh
(GraphPad Software, CA 2008).
To characterize the cellular profile of the conjunc-
tival ocular surface, nine color flow cytometry panels
were developed. Commercially available antibodies to
cell surface markers were employed in two panels;
panel 1 mouse anti-human CD45RO (FITC), γδTCR
(phycoerythrin), CD4 (PerCP Cy5.5), CD45 (allophy-
cocyanin), CD3 (AlexaFluor 780) (Ebioscience, Hat-
field, UK); CD8α (Pacific Orange) (Invitrogen,
Paisley, UK); CD8β (PE Texas Red) (Beckman
Coulter); CD56 (PE Cy7) (Biolegend, Cambridge,
UK) and panel 2 mouse anti-human CD16 (FITC),
CD45 (Allophycocyanin), CD14 (AlexaFluor 780)
(Ebioscience); CD20 (Pacific Orange), CD19 (PE
Texas Red) (Invitrogen); CD138 (PerCP Cy5.5) (BD,
Oxford, UK) and CD11b (PE Cy7) (Biolegend).
These were titrated to determine the optimal concen-
trations. Each panel was applied to cells recovered
from conjunctival OSIC or peripheral blood.
One hundred microliters of cells were placed into
96-well plates (with a cell count per well ranging
from 2×105–1×106 for PBMCs) or 20 μl of positive
and negative compensation beads. Cells were centri-
fuged for 4 min at 1,200 rpm at 4°C, the supernatant
removed and the 96-well plate gently vortexed. Cells
were stained with surface marker antibodies (made up
in 50 μl at appropriate dilutions) and incubated on ice
in the dark for 20 min. One hundred microliters of
PBS/0.5% BSA was added to each well prior to
further centrifugation and removal of supernatant.
Cells were re-suspended in 295 μl of FACS and 5 μl
counting beads (1,002 beads per microliter) buffer
prior to analysis. For dead cell exclusion, 30 μl Sytox
blue (Invitrogen) was added at a concentration of
1/800 to the FACS tubes and incubated for 5 min prior
to running on the flow cytometer.
Intracellular cytokine staining
For cytokine assays, conjunctival and lysed peripheral
blood cells were stimulated with phorbol 12-
Fig. 2 TCRαβ+CD8αβ+T cells are the dominant population
of lymphocytes in the conjunctival epithelium. Representative
scatter profile of leukocyte populations derived from matched
peripheral blood and conjunctival OSIC from a healthy subject.
Data are shown for a representative subject, gated on CD45+
live cells for peripheral blood (A) and conjunctival OSIC (B).
CD45RO staining is shown for CD3+CD56−TCRγδ−gated
CD4+CD8β−(top panel) and CD8αβ+(bottom panel) cells.
Percentages of CD3+CD56- lymphocytes are shown for the
representative subject (n=30). Statistical comparisons between
peripheral blood and conjunctival impression populations of
CD8αβ+, CD4+, CD8αα+ and TCRαβ+CD4−CD8αβ−
(double negative; DN) T cells (C–F) were undertaken by the
Mann–Whitney U test (NS not significant [P>0.05], **P<0.01,
***P<0.001)

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mysristate 13-acetate (PMA) (Sigma-Aldrich) and
ionomycin (Sigma-Aldrich). Briefly, cells were incu-
bated in 200 μl containing PMA (250 ng/ml),
ionomycin (250 ng/ml) and Brefeldin A (Sigma-
Aldrich) 2 ug/ml for 3 h at 37°C, 5% CO2.
A Live/Dead fixable yellow dye (Invitrogen) was
used to discriminate dead cells. Cells were suspended
in 100 μl of 1:1,000 Dye/DMSO for 30 min on ice in
the dark.
An additional panel was utilized to determine
cytokine expression by T cell subsets: mouse anti-
human IFNγ (eFluor 450) (Ebioscience), IL-17
(FITC) (Ebioscience), CD4 (PerCP Cy5.5), CD45
(Allophycocyanin), CD3 (AlexaFluor 780) (Ebio-
science), CD8β (PE Texas Red) (Beckman Coul-
ter), CD56 (PE Cy7) (Biolegend) and rat anti-
human IL-10 (Phycoerythrin) (Biolegend). For
cytokine assays, surface marker antibodies in this
panel were suspended in Fixation Medium A (Fix
& Perm, Invitrogen) under the same conditions as
described for “Flow cytometry.” Intracellular anti-
bodies were suspended in Permeabilization Medium
B (Fix & Perm, Invitrogen) on ice in the dark for
20 min before centrifugation and re-suspension as
described.
Results
Defining resident conjunctival leukocyte populations
Conjunctival OSIC (Fig. 1a) and matched peripheral
blood samples were taken from healthy subjects and
recovered cells analyzed by flow cytometry. Whilst
the light scatter profile for peripheral blood clearly
delineated each leukocyte population (Fig. 1b), it was
not possible to make this discrimination from OSIC
(Fig. 1e). This was overcome by gating on CD45+
live cells, which permitted demonstration of lympho-
cytes as the dominant leukocyte population in the
conjunctival epithelium (Fig. 1f, g). This approach
also clarified the identity of the leukocyte populations
found in peripheral blood (Fig. 1c, d).
There were no differences in the number of
leukocytes between the right and left eyes (p=0.23;
Wilcoxon signed rank test) and right and left eye
leukocyte numbers highly correlated (r=0.72; p<
0.0001). Therefore, the mean of the right and left
eyes for each subject was calculated (i.e. the right and
left eyes per individual subject were considered to be
experimental duplicates). CD45+ live leukocytes
accounted for a median 834 [range, 6017,635] of
total events. Of the cohort of 30 subjects (median age,
61 years [21–83 years]), the dominant conjunctival
leukocyte population was lymphocytes (median, 89%
[32–99%]) as defined by their forward and side
scatter profiles; 9% [0–34] were monocytes and 1%
[0–66] were neutrophils. This compared to 52%
[18–75], 5% [3–28] and 42% [19–76], respectively
in matched peripheral blood.
T and NK cell subsets were defined by the
expression of CD3 and CD56 (Fig. 2). T cells (CD3
+CD56−) dominated in both conjunctival OSIC (69%
[47–90]) and in matched peripheral blood (74%
[57–84]), and these were >98% TCRγδ-(TCRαβ+)
in both (Fig. 2a, b). T cells were further characterized
by the expression of the CD4, CD8α and CD8β cell
surface co-receptors (Fig. 2a, b). Unlike in the
peripheral blood where the dominant T cell population
was CD4+ (Fig. 2d; 69% [45–91]), the dominant
population from the conjunctival impression was
CD8αβ+ (Fig. 2c, 80% [37–100]). The majority of
CD4+ and CD8αβ+ T cells were CD45RO+ in the
conjunctival epithelium (100% [0–100] and 94%
[55–100], respectively), higher than the proportion
of antigen experienced populations in blood (61%
[0–90] and 56% [20–86], respectively). CD4−CD8αβ−
(DN) Tcells accounted for only 7.3% [0.7–22] and 3.5%
[0.4–26] of conjunctival and peripheral blood
T cells, respectively (Fig. 2e). Whilst CD8αα+ cells
formed the minority of T cells, these were significantly
higher in the conjunctiva than in peripheral blood
(Fig. 2f; 2.6% [0–12.5] versus 1.4% [0.1–4.4]
(p<0.001)).
NK cells represented 7% [0–20] of conjunctival
epithelial lymphocytes compared with 9% [0–22] in
the peripheral blood. There was also a greater
proportion of NKT (CD3+CD56+) cells (conjunctiva
6% [0–17] versus peripheral blood 2% [0–6] (p>
0.05)) but fewer CD19+CD20+ B cells (3% [1–45]
versus 9% [3–23], respectively, (p<0.0001)).
Fig. 3 Changes in T cell subsets and memory populations in
peripheral blood and conjunctiva with age. Changes in the T cell
populations in peripheral blood and conjunctival OSIC for CD3+
CD56− lymphocytes (A), as well as CD8αβ+ and CD4+ subsets
(B/C, E/F) with their respective CD45RO frequencies (D, G).
Statistical analysis was undertaken by Spearman’s correlation
(NS not significant [p>0.05], *P<0.05, **P<0.01) (n=30)

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Fig. 4 TCRαβ+CD4+ T cells increase with age but do not
alter their cytokine production. Expression of IFNγ, IL-17 and
IL-10 in the T cell populations in stimulated peripheral blood
(PB) and conjunctival OSIC for CD45+CD3+CD56−CD4+
live lymphocytes (A). Representative figures from a subjects
aged <35 and >65 years are shown. The number and percentage
of CD4+ T cells are shown for this cohort (B), as well as the
number and percentages of cytokine-secreting cells (C).
Statistical comparisons were undertaken by the Mann–Whitney
U test (NS not significant [p>0.05], *P<0.05)
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Age-related changes in leukocyte populations
in the healthy human conjunctival epithelium
Changes in leukocyte populations with age were
determined in this cohort (Table 1). Analysis of
peripheral blood monocyte, neutrophil and lympho-
cyte frequencies showed that the only change was a
decrease with age in lymphocytes calculated as a
percentage of total leukocytes (Table 1). This was not
observed in cells recovered from the conjunctival
epithelium. By contrast, conjunctival cells showed an
increase in the absolute numbers of lymphocytes and
monocytes (but not neutrophils), resulting in a
significant increase in the total number of leukocytes
(Table 1).
Within the conjunctival epithelial lymphocyte
population there was an age-related decrease in the
proportion of T cells (Fig. 3a; Table 2), compensated
for by an increase in the percentage of NK cells
(Table 2). The dominant CD8αβ+cell population
remained unchanged in the conjunctival epithelium
with age but decreased in peripheral blood (Fig. 3b;
Table 2). Conversely, the absolute number of CD4+
cells significantly increased in the conjunctiva but
remained unchanged in peripheral blood (Fig. 3e;
Table 2). This resulted in proportional changes in
CD8αβ+and CD4+ lymphocytes (Fig. 3c and f;
Table 2) with a consequent increase in the CD4/CD8
ratio with age (Table 2). In addition, the CD45RO+
memory population increased in the peripheral blood
with age, a change that was not seen in conjunctival
OSIC (Fig. 3d and g; Table 2), reflecting the high
proportion of antigen experienced CD8+ (93%) and
CD4+ cells (100%) present in the conjunctival
epithelium from a young age.
The conjunctival CD4+ T cell populations of the
cohort of five additional healthy younger (<35 years)
and five older subjects (>65 years) were characterized
for the expression of IFNγ, IL-17 and IL-10 follow-
ing stimulation with PMA/ionomycin (Fig. 4a). The
CD4+ population was significantly elevated in the
older age group (19% [11–52) vs. those <35 years]
(4% [2–13]; p=0.02) (Fig. 4b).
Eighteen percent [14–48] of conjunctival CD4+ T
cells were capable of expressing IFNγ, 3.5% [0–22]
IL-17 and 0% [0–4] IL-10. The absolute number of
CD4+ T cells able to secrete IFNγ was significantly
elevated with age (<35 years, 7[4–39] vs. >65 years,
43 [20–145]; p=0.03) while the percentage of IFNγ+
CD4+ remained unchanged (17% [14–35] vs. 18%
[16–48], p=NS, respectively) (Fig. 4c). Changes in
IL-17 and IL-10 producing CD4+ T cells were not
observed with age (Fig. 4c).
Discussion
OSIC offers a non-invasive sampling technique which
when combined with multicolor flow cytometric
analysis of the recovered cells enables a comprehen-
sive characterization of the conjunctival epithelial
leukocytes superficial to the basement membrane
zone. In this study, we have utilized this methodology
to describe a detailed phenotyping of conjunctival
Table 1 Changes in leukocyte populations in peripheral blood and conjunctiva with age
Cell population Age correlation r value (p valuea)
Peripheral blood Conjunctival OSIC Peripheral blood Conjunctival OSIC
Leukocytes numbers No change Increase 0.05 (NS) 0.43 (0.02)
Lymphocytes numbers No change Increase −0.23 (0.03) 0.38 (0.04)
Lymphocytes (% of leukocytes) Decrease No change −0.4 (0.03) −0.08 (NS)
Monocyte numbers No change Increase 0.01 (NS) 0.45 (0.01)
Monocytes (% of leukocytes) No change No change −0.01 (NS) 0.34 (NS)
Neutrophil numbers No change No change 0.20 (NS) 0.33 (NS)
Neutrophils (% of leukocytes) No change No change 0.34 (NS) −0.09 (NS)
NS not significant
p>0.05, NS
a Spearman’s correlation
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leukocytes in a cohort of healthy individuals and how
these change with age. We have identified that the
dominant conjunctival epithelial leukocyte population
is CD3+CD56−TCRαβ+CD8αβ+ lymphocytes. In-
terestingly, although this population remained un-
changed with age, there was an increase in the
conjunctival epithelial CD4+ population resulting in
an alteration in the CD4/CD8 ratio. We have
demonstrated that 14–48% of conjunctival epithelial
CD4+ cells were capable of producing IFNγ and 0–22%
were capable of producing IL-17. This was maintained in
older subjects and given the increase in absolute numbers
of CD4+ cells with age, this resulted in a substantial
increase in the number of pro-inflammatory conjunctival
CD4+ T cells.
The role of conjunctival IELs is unresolved. In
other mucosal tissues, two subtypes of IEL have been
defined: type a (TCRαβ+CD8αβ+) ‘conventional’
and type b (TCRαβ+ CD8αα+, TCRγδ+ CD8αα+
and TCRγδ+ double negative (DN)) IELs, with
differing roles in effector function and regulation
(Hayday et al. 2001). Type b IELs are thought to
represent an interface between the innate and adaptive
immune response and are also implicated in the repair
of damaged mucosa. Function is dependent on
additional activation, and in their resting state a
number of anti-proliferative genes are expressed e.g.
Btg1 and 2. This has given rise to the concept of
being ‘activated but resting’ (Hayday et al. 2001). Our
study suggests that the dominant IEL population in
the human conjunctiva is ‘conventional’ (type a)
TCRαβ+CD8αβ+ with less than 1% TCRγδ+.
Whether TCRγδ+ cells have a relatively minor role
to play in conjunctival epithelial biology, or are
confined to below the basement membrane zone
within the substantia propria (which we were unable
to sample using OSIC) remains unknown.
Tissue-based immunohistochemical analyses iden-
tified CD45RO+cells (75–100%) in the bulbar con-
junctiva (Hingorani et al. 1997), but those studies
were limited as precise T cell subsets were not
quantified. Our data showed that antigen experience
(defined by the expression of CD45RO) was evident
in all CD4+ and almost al (median 94%) of CD8αβ+
conjunctival epithelial T cells, whereas a significant
increase in the CD8αβ+ and CD4+ CD45RO+T cell
population was observed in peripheral blood, in
keeping with the findings of others (Saule et al.
2006; Utsuyama et al. 2009). The predominance of
CD45RO+lymphocytes in the conjunctival epitheli-
um is expected and consistent with the preferential
recruitment of memory cells into mucosal tissues.
The major alteration in IELs was an increase in the
number and percentage of CD4+ cells with age. This
resulted in a reduction in the percentage of the
dominant conjunctival CD8αβ+ population and an
Table 2 Changes in lymphocyte populations in peripheral blood and conjunctiva with age
Cell population Age correlation r value (p valuea)
Peripheral blood Conjunctival OSIC Peripheral blood Conjunctival OSIC
T cells (% of lymphocytes) No change Decrease −0.18 (NS) −0.45 (0.01)
CD8αβ+ numbers Decrease No change −0.5 (<0.01) 0.3 (NS)
CD8αβ+ (% of T cells) No change Decrease 0.31 (NS) −0.49 (<0.01)
CD45RO+cells (% of CD8αβ+ cells) Increase No change 0.53 (<0.01) 0.13 (NS)
CD4+ numbers No change Increase −0.1 (NS) 0.61 (<0.001)
CD4+ (% of T cells) Increase Increase 0.52 (<0.01) 0.52 (<0.01)
CD45RO+cells (% of CD4+ cells) Increase No change 0.53 (<0.01) 0.27 (NS)
CD4:CD8 ratio Increase Increase 0.41 (0.03) 0.49 (<0.01)
B cells (% of lymphocytes) No change No change 0.18 (NS) −0.08 (NS)
NK cells (% lymphocytes) No change Increase 0.24 (NS) 0.4 (0.03)
NKT cells (% lymphocytes) No change No change −0.05 (NS) 0.15 (NS)
NS not significant
p>0.05, NS
a Spearman’s correlation
AGE
increase in the CD4/CD8 ratio. By contrast, there
was a decrease in the number of CD8αβ+T cells in
blood, although this too resulted in an increase in
the CD4/CD8 ratio, as previously reported by
Utsuyama et al (Utsuyama et al. 2009).
As the proportion of T cells decreased in the
conjunctival epithelium with increasing age, both the
proportion and number of NK cells, increased.
Although this observation has been previously de-
scribed in peripheral blood (Borrego et al. 1999) (and
there was an observed trend in our cohort) this is the
first time those changes have been defined in the
conjunctiva. Whether this represents an accumulation
of NK cells in the ocular surface reflecting immune
senescence, or a direct response to a specific change
in ocular surface antigen exposure, remains unknown.
It is clear that the changes in IEL populations seen in
our cohort, in particular the increased TCRαβ+CD4+ T
cell population, have implications for age matching
when undertaking comparisons with disease popula-
tions, specifically in relation to infective or immune-
mediated processes affecting the ocular surface. Dry-
eye problems increase with age (Draper et al. 1999)
including dry eye disease (McCarty et al. 1998; Moss
et al. 2000). Although changes to the lacrimal acinar
gland have been attributed to age-related ocular surface
dryness (Draper et al. 1999), dry eye syndromes
(including Sjögren’s syndrome and non-Sjögren’s
syndrome-related dry eye) are thought to have an
underlying inflammatory and autoimmune component.
Intriguingly, elevations of CD4+ T cells in both
humans and in animal models of dry eye have been
identified (De Paiva et al. 2010; Stern et al. 2010), but
the contribution of elevated conjunctival intraepithelial
CD4+ cells to a pro-inflammatory state is not known
and may offer clues to dry eye vulnerability amongst
older subjects. The absolute number of CD4+ T cells
able to secrete interferon-γ was significantly elevated
with age and IL-17 producers were maintained with
age in this study. An elevation of IFNγ and IL-17
producing cells has been identified in the conjunctiva
in murine models of dry eye (De Paiva et al. 2009).
Furthermore, an increase in these cytokines is seen in
tears of human subjects with dry eye disease (De Paiva
et al. 2009). Whether age-associated accumulation of
CD4+ cells predisposes to dry eye problems by an
increased number of IFNγ and IL-17 secreting cells or
whether an alteration in function occurs under dry eye
conditions in humans, remains to be defined.
In murine models, there appears to be a defective
suppressor function by T regulatory cells on Th17
cells (Chauhan et al. 2009). Few conjunctival CD4+ T
cells were capable of producing IL-10 in this study,
and no changes were observed with age. The
expression of the transcription factor FoxP3 was seen
in approximately 2% of CD3+ conjunctival T cells
(data not shown). This suggests that in the healthy
conjunctival epithelium, there is not a significant
population of CD4+ T cells with an IL-10+ or FoxP3+
regulatory phenotype. An increase in the stromal CD4
+ population has also been identified from histolog-
ical conjunctival sections (Bernauer et al. 1993) taken
from patients with Mucous Membrane Pemphigoid, a
disease characterized histologically by antibody de-
position in the basement membrane zone with
subsequent conjunctival inflammation, scarring, cor-
neal limbal epithelial stem cell failure and ocular
surface keratinization (Foster 1986; Chan et al. 2002;
Liesegang 2008), that typically affects older patient
populations (although disease activity and progression
is worse in younger patients) (Rauz et al. 2005).
The possibility of utilizing a non-invasive sam-
pling technique such as OSIC to characterize changes
in supra-basement membrane structures of the ocular
mucosa in the context of infectious and non-infectious
disease affords an attractive method for both cross-
sectional and longitudinal research into human ocular
surface inflammatory disease. The importance of
aging on conjunctival leukocyte profiles in disease
states is yet to be elucidated, but has implications in
forming comparative healthy control cohorts, indicat-
ing that age-matching is essential.
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